Methods for treating exacerbation of inflammatory respiratory diseases

By measuring specific LPAs in patient samples, the method accurately predicts exacerbation risk and tailors treatment for inflammatory respiratory diseases, effectively reducing exacerbation frequency and severity.

JP2024160261AActive Publication Date: 2024-11-13GENENTECH INC +1

Patent Information

Application Number
JP2024122651
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-07-31
Filing Date
2024-07-29
Publication Date
2024-11-13
Estimated Expiration
2041-07-30

AI Technical Summary

Technical Problem

Current methods fail to consistently identify patients at risk for exacerbations of inflammatory respiratory diseases like COPD and IPF, lacking reliable blood biomarkers for predicting exacerbations and effective treatment strategies.

Method used

Measuring specific lysophosphatidic acid (LPA) species, such as LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4, in patient samples to identify patients at high risk for exacerbations and tailor treatment with agents that reduce exacerbations.

Benefits of technology

This approach allows for accurate prediction of exacerbation risk and effective treatment by identifying patients who benefit from specific agents, reducing exacerbation frequency and severity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160261000033
    Figure 2024160261000033
  • Figure 2024160261000034
    Figure 2024160261000034
  • Figure 2024160261000035
    Figure 2024160261000035
Patent Text Reader

Abstract

To provide: therapeutic methods for the treatment of exacerbation of inflammatory respiratory diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and asthma; in particular, methods for patient selection, diagnosis and treatment; and methods for preparing and analyzing lysophosphatidic acid (LPA) samples.SOLUTION: The level of one or more of lysophosphatidic acid (LPA) 16:0, LPA18:0, LPA18:1, LPA18:2 and LPA20:4 in a sample from a patient is measured.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Provided herein are therapeutic methods for treating exacerbations of inflammatory respiratory diseases, including chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and asthma. In particular, the present invention provides methods for patient selection, diagnosis, and treatment. Also provided herein are methods for preparing and analyzing lysophosphatidic acid (LPA) samples. [Background technology]

[0002] Exacerbations of inflammatory respiratory diseases such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and asthma have a significant impact on disease progression. In COPD, the frequency and severity of exacerbations are associated with an increased rate of lung function decline and worse health-related quality of life, and fewer than half of patients survive an additional five years after a severe exacerbation.

[0003] Exacerbations are heterogeneous events due to the complex interplay between exacerbation triggers and the host inflammatory response, and as such, studies have not been able to identify consistent blood biomarkers associated with COPD exacerbations.

[0004] Thus, there is an unmet need for methods to predict whether a patient with an inflammatory respiratory disease is likely to experience an exacerbation, and for methods to treat such patients. Summary of the Invention

[0005] In one aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with chronic obstructive pulmonary disease (COPD) may be at high risk for an exacerbation, the method comprising measuring a level of one or more of lysophosphatidic acid (LPA) 16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for an exacerbation.

[0006] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with COPD would benefit from a treatment including an agent that reduces exacerbations, comprising measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as one who may benefit from a treatment including an agent that reduces exacerbations.

[0007] In another aspect, the disclosure features a method of selecting a therapy for a patient with COPD, comprising measuring levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as one who may benefit from a treatment including an agent that reduces exacerbations.

[0008] In some embodiments, the patient has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces an exacerbation.

[0009] In another aspect, the disclosure features a method of treating a patient with COPD, the method including: (a) measuring the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is less than a reference level; and (b) administering to the patient an effective amount of an agent that reduces an exacerbation.

[0010] The disclosure features a method of treating a patient who has COPD and has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is below a reference level, the method comprising administering to the patient an effective amount of an agent that reduces an exacerbation.

[0011] In another aspect, the disclosure features a method of treating a patient with COPD, comprising administering to the patient an effective amount of an agent that reduces an exacerbation, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be less than a reference level.

[0012] In another aspect, the disclosure features a method of reducing exacerbations in a patient with COPD, the method including: (a) measuring the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is less than a reference level; and (b) administering to the patient an effective amount of an agent that reduces an exacerbation.

[0013] The disclosure features a method for reducing exacerbations in a patient who has COPD and has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is below a reference level, the method comprising administering to the patient an effective amount of an agent that reduces an exacerbation.

[0014] In another aspect, the disclosure features a method of reducing exacerbations in a patient with COPD, the method including administering to the patient an exacerbation-reducing effective amount of an agent, wherein levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient have been determined to be less than a reference level.

[0015] In another aspect, the disclosure features a method for identifying a patient suitable for administration with a drug that treats COPD or reduces COPD exacerbations, the method including measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as suitable for administration with a drug that treats COPD or reduces COPD exacerbations.

[0016] In another aspect, the disclosure features a method for monitoring a patient's response to a treatment that includes an exacerbation-reducing agent in a patient with COPD, the method including: (a) measuring levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient at a time point after administration of a first dose of the treatment that includes an exacerbation-reducing agent; and (b) comparing the levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample to reference levels, thereby monitoring the patient's response to the treatment that includes the exacerbation-reducing agent.

[0017] In some embodiments, levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that are greater than the reference level indicate that the patient is responding to an agent that reduces exacerbations.

[0018] In another aspect, the method further includes administering at least a second dose of an agent that reduces exacerbations to a patient whose sample has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 above a reference level.

[0019] In another aspect, the disclosure features a method of enrolling a patient suitable for a clinical study, the method including measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as suitable for the clinical study. In some aspects, the method further includes enrolling the patient identified as suitable for the clinical study in the clinical study.

[0020] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0021] In some embodiments, the sample is a bronchoalveolar lavage fluid (BALF) sample.

[0022] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0023] In some embodiments, the sample is a serum sample.

[0024] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0025] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0026] In some embodiments, the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM, hi some embodiments, the reference level of LPA16:0 is about 0.14 μM.

[0027] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0028] In some embodiments, the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM, hi some embodiments, the reference level of LPA18:1 is about 0.12 μM.

[0029] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0030] In some embodiments, the reference level of LPA20:4 is between about 9 μM and about 13 μM, hi some embodiments, the reference level of LPA20:4 is about 10.9 μM.

[0031] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population.

[0032] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, and LPA18:2 in the sample is less than or equal to the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0033] In some embodiments, the level of LPA20:4 in the sample is less than or equal to the 67th percentile of the level of LPA20:4 in a reference population.

[0034] In some embodiments, the reference population is a population of patients with COPD. In some embodiments, the COPD is stage II, stage III, or stage IV COPD.

[0035] In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0036] In some embodiments, the benefit comprises an increase in the patient's time to exacerbation compared to treatment without the agent that reduces exacerbations.

[0037] In some embodiments, the exacerbation is an increase in one or more of dyspnea, cough, sputum volume, sputum purulence, fatigue, sleep disturbances, morning headache, confusion, and hypoxemia.

[0038] In some embodiments, the exacerbation is a severe exacerbation.

[0039] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0040] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0041] In some embodiments, the exacerbation-reducing agent is a member of the Global Initiative for Chronic Obstructive Lung Disease. TM This is a drug disclosed in the (GOLD) Pocket Guide to COPD Diagnosis, Management, and Prevention (2020 edition).

[0042] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority for reducing, controlling, or maintaining an exacerbation. In some embodiments, the regulatory health authority is the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the National Medical Products Administration (NMPA).

[0043] In some embodiments, the patient is male.

[0044] In another aspect, the disclosure features the use of an agent that reduces exacerbations in patients having levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that are below reference levels in the manufacture of a medicament for the treatment of COPD.

[0045] In another aspect, the disclosure features the use of an agent that reduces exacerbations in patients having levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that are less than reference levels in the manufacture of a medicament for reducing COPD exacerbations.

[0046] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0047] In some embodiments, the sample is a BALF sample.

[0048] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0049] In some embodiments, the sample is a serum sample.

[0050] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0051] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0052] In some embodiments, the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM, hi some embodiments, the reference level of LPA16:0 is about 0.14 μM.

[0053] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0054] In some embodiments, the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM, hi some embodiments, the reference level of LPA18:1 is about 0.12 μM.

[0055] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0056] In some embodiments, the reference level of LPA20:4 is between about 9 μM and about 13 μM, hi some embodiments, the reference level of LPA20:4 is about 10.9 μM.

[0057] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population.

[0058] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, and LPA18:2 in the sample is less than or equal to the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0059] In some embodiments, the level of LPA20:4 in the sample is less than or equal to the 67th percentile of the level of LPA20:4 in a reference population.

[0060] In some embodiments, the reference population is a population of patients with COPD.

[0061] In some embodiments, the patient has COPD. In some embodiments, the COPD is stage II, stage III, or stage IV COPD.

[0062] In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0063] In some embodiments, the exacerbation is an increase in one or more of dyspnea, cough, sputum volume, sputum purulence, fatigue, sleep disturbances, morning headache, confusion, and hypoxemia.

[0064] In some embodiments, the exacerbation is a severe exacerbation.

[0065] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0066] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0067] In some embodiments, the exacerbation-reducing agent is a member of the Global Initiative for Chronic Obstructive Lung Disease. TMThis is a drug disclosed in the (GOLD) Pocket Guide to COPD Diagnosis, Management, and Prevention (2020 edition).

[0068] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority for reducing, controlling, or maintaining an exacerbation. In some embodiments, the regulatory health authority is the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the National Medical Products Administration (NMPA).

[0069] In some embodiments, the patient is male.

[0070] In another aspect, the disclosure features an exacerbation-reducing agent for use in treating a patient who has COPD and has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is below a reference level.

[0071] In another aspect, the disclosure features an exacerbation-reducing agent for use in treating a patient with COPD, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be less than a reference level.

[0072] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0073] In some embodiments, the sample is a BALF sample.

[0074] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0075] In some embodiments, the sample is a serum sample.

[0076] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0077] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0078] In some embodiments, the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM, hi some embodiments, the reference level of LPA16:0 is about 0.14 μM.

[0079] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0080] In some embodiments, the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM, hi some embodiments, the reference level of LPA18:1 is about 0.12 μM.

[0081] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0082] In some embodiments, the reference level of LPA20:4 is between about 9 μM and about 13 μM, hi some embodiments, the reference level of LPA20:4 is about 10.9 μM.

[0083] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population.

[0084] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, and LPA18:2 in the sample is less than or equal to the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0085] In some embodiments, the level of LPA20:4 in the sample is less than or equal to the 67th percentile of the level of LPA20:4 in a reference population.

[0086] In some embodiments, the reference population is a population of patients with COPD.

[0087] In some embodiments, the patient has COPD. In some embodiments, the COPD is stage II, stage III, or stage IV COPD.

[0088] In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0089] In some embodiments, the exacerbation is an increase in one or more of dyspnea, cough, sputum volume, sputum purulence, fatigue, sleep disturbances, morning headache, confusion, and hypoxemia.

[0090] In some embodiments, the exacerbation is a severe exacerbation.

[0091] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0092] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0093] In some embodiments, the exacerbation-reducing agent is a member of the Global Initiative for Chronic Obstructive Lung Disease. TM This is a drug disclosed in the (GOLD) Pocket Guide to COPD Diagnosis, Management, and Prevention (2020 edition).

[0094] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority for reducing, controlling, or maintaining an exacerbation. In some embodiments, the regulatory health authority is the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the National Medical Products Administration (NMPA).

[0095] In some embodiments, the patient is male.

[0096] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with COPD may be at high risk for an exacerbation, comprising measuring levels of one or more of LPC, sphingomyelin, and ceramide in a sample from the patient, wherein a level of LPC in the sample that is less than a reference level and / or a level of one or both of sphingomyelin and ceramide in the sample that is greater than the reference level identifies, diagnoses, and / or predicts the patient as being at high risk for an exacerbation.

[0097] In some embodiments, the LPC is LPC(16:0) or LPC(18:2).

[0098] In some embodiments, the patient has a level of LPC in the sample that is below a reference level and / or a level of one or both of sphingomyelin and ceramide in the sample that is above a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces exacerbation.

[0099] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0100] In some embodiments, the sample is a BALF sample.

[0101] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0102] In some embodiments, the sample is a serum sample.

[0103] In some embodiments, the level of one or more of LPC, sphingomyelin, and ceramide is a baseline level of one or more of LPC, sphingomyelin, and ceramide.

[0104] In some embodiments, the reference level is a pre-assigned level of one or more of LPC, sphingomyelin, and ceramide.

[0105] In some embodiments, the reference level of LPC is between about 227 nmol / mL and about 277 nmol / mL, hi some embodiments, the reference level of LPC is about 252 nmol / mL.

[0106] In some embodiments, the reference level of sphingomyelin is between about 448 nmol / mL and about 548 nmol / mL, hi some embodiments, the reference level of sphingomyelin is about 498 nmol / mL.

[0107] In some embodiments, the ceramide is hexosylceramide (HCER).

[0108] In some embodiments, the reference level of HCER is between about 6.1 nmol / mL and about 7.5 nmol / mL, hi some embodiments, the reference level of HCER is about 6.8 nmol / mL.

[0109] In some embodiments, the ceramide is lactosylceramide (LCER).

[0110] In some embodiments, the reference level for LCER is between about 4.3 nmol / mL and about 5.3 nmol / mL, hi some embodiments, the reference level for LCER is about 4.8 nmol / mL.

[0111] In some embodiments, the reference level is the level of one or more of LPC, sphingomyelin, and ceramide in a reference population.

[0112] In some embodiments, the ceramide is LCER or HCER.

[0113] In some embodiments, the level of LPC in the sample is less than or equal to the 33rd percentile of the levels of LPC in a reference population, and / or the level of sphingomyelin, LCER, and / or HCER is greater than or equal to the 67th percentile of the levels of sphingomyelin, LCER, or HCER, respectively, in a reference population.

[0114] In some embodiments, the reference population is a population of patients with COPD.

[0115] In another aspect, the disclosure features a method for predicting time to next exacerbation in a patient with COPD who has experienced at least one exacerbation in the past 12 months, the method including measuring levels of one or both of LPA18:0 and LPA18:2 in a sample from the patient, wherein levels of one or both of LPA18:0 and LPA18:2 in the sample that are greater than a reference level identify the patient as one who is likely to have an increased time to next exacerbation.

[0116] In some embodiments, the patient has levels of one or both of LPA18:0 and LPA18:2 in the sample that are above the reference level, and the method further includes maintaining the patient's treatment regimen and / or reducing patient monitoring.

[0117] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0118] In some embodiments, the sample is a BALF sample.

[0119] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0120] In some embodiments, the sample is a serum sample.

[0121] In some embodiments, the level of one or both of LPA18:0 and LPA18:2 is a baseline level of one or both of LPA18:0 and LPA18:2.

[0122] In some embodiments, the reference level is a pre-assigned level of one or both of LPA18:0 and LPA18:2.

[0123] In some embodiments, the reference level of LPA18:0 is between about 0.03 μM and about 0.05 μM, hi some embodiments, the reference level of LPA18:0 is about 0.04 μM.

[0124] In some embodiments, the reference level of LPA18:2 is between about 0.68 μM and about 0.84 μM, hi some embodiments, the reference level of LPA18:2 is about 0.76 μM.

[0125] In some embodiments, the reference level is the level of one or both of LPA18:0 and LPA18:2 in a reference population.

[0126] In some embodiments, the level of one or both of LPA18:0 and LPA18:2 in the sample is greater than or equal to the 67th percentile of the levels of LPA18:0 or LPA18:2, respectively, in a reference population.

[0127] In some embodiments, the increase in time to next exacerbation is an increase of at least 100 days.

[0128] In some embodiments, the COPD is stage II, stage III, or stage IV COPD.

[0129] In some embodiments, the exacerbation is an increase in one or more of dyspnea, cough, sputum volume, sputum purulence, fatigue, sleep disturbances, morning headache, confusion, and hypoxemia.

[0130] In some embodiments, the patient is male.

[0131] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient may be at high risk for COPD, comprising measuring levels of one or both of LPA18:0 and LPA18:1 in a sample from the patient, wherein levels of one or both of LPA18:0 and LPA18:1 in the sample that are greater than a reference level identify, diagnose, and / or predict the patient as being at high risk for inflammatory respiratory disease.

[0132] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0133] In some embodiments, the sample is a BALF sample.

[0134] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0135] In some embodiments, the sample is a serum sample.

[0136] In some embodiments, the level of one or both of LPA18:0 and LPA18:1 is a baseline level of one or both of LPA18:0 and LPA18:1.

[0137] In some embodiments, the reference level is a pre-assigned level of one or both of LPA18:0 and LPA18:1.

[0138] In some embodiments, the reference level is the level of one or both of LPA18:0 and LPA18:1 in a reference population.

[0139] In some embodiments, the reference population is a population of patients without an inflammatory respiratory disease.

[0140] In some embodiments, the level of one or both of LPA18:0 and LPA18:1 in the sample is at least 4.6 times the average level of one or both of LPA18:0 and LPA18:1, respectively, in a reference population.

[0141] In some embodiments, the reference level for LPA18:0 is between about 0.01 nmol / mL and about 0.035 nmol / mL.

[0142] In some embodiments, the reference level for LPA18:0 is 0.025 nmol / mL.

[0143] In some embodiments, the reference level for LPA18:1 is between about 0.05 nmol / mL and about 0.017 nmol / mL.

[0144] In some embodiments, the reference level for LPA18:1 is 0.11 nmol / mL.

[0145] In some embodiments, the COPD is stage II, stage III, or stage IV COPD.

[0146] In some embodiments, the sample is from a fasting patient.

[0147] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with idiopathic pulmonary fibrosis (IPF) may be at high risk for exacerbation or respiratory hospitalization, the method comprising measuring a level of one or more of lysophosphatidic acid (LPA) 16:0, LPA 18:1, LPA 18:2, and LPA 20:4 in a sample from the patient, wherein a level of one or more of LPA 16:0, LPA 18:1, LPA 18:2, and LPA 20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for exacerbation or respiratory hospitalization.

[0148] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with IPF could benefit from a treatment including an agent that reduces exacerbations, the method comprising measuring a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as one that may benefit from a treatment including an agent that reduces exacerbations.

[0149] In another aspect, the disclosure features a method of selecting a therapy for a patient with IPF, the method including measuring a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies the patient as one who is likely to benefit from a treatment including an agent that reduces exacerbations.

[0150] In some embodiments, the patient has a level of one or more of LPA16:0, LPA18:0, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces an exacerbation.

[0151] In another aspect, the disclosure features a method of treating a patient with IPF, the method including: (a) measuring the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is equal to or greater than a reference level; and (b) administering to the patient an effective amount of an agent that reduces exacerbations.

[0152] The disclosure features a method of treating a patient who has IPF and has a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is equal to or greater than a reference level, the method comprising administering to the patient an effective amount of an agent that reduces an exacerbation.

[0153] In another aspect, the disclosure features a method of treating a patient having IPF, comprising administering to the patient an exacerbation-reducing effective amount of an agent, wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be equal to or greater than a reference level.

[0154] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some aspects, the sample is a stored sample, a fresh sample, or a frozen sample. In some aspects, the sample is a serum sample.

[0155] In some embodiments, the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4.

[0156] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4.

[0157] In some embodiments, (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM. In some embodiments, (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

[0158] In some embodiments, (a) the patient is female and the reference level of LPA18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA18:1 is between about 0.078 μM and about 0.118 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

[0159] In some embodiments, (a) the patient is female and the reference level of LPA18:2 is between about 0.388 μM and about 0.428 μM; or (b) the patient is male and the reference level of LPA18:2 is between about 0.339 μM and about 0.379 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:2 is about 0.408 μM; or (b) the patient is male and the reference level of LPA18:2 is about 0.359 μM.

[0160] In some embodiments, (a) the patient is female and the reference level of LPA20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA20:4 is between about 0.110 μM and about 0.150 μM. In some embodiments, (a) the patient is female and the reference level of LPA20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA20:4 is about 0.130 μM.

[0161] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population.

[0162] In some embodiments, the level of one or more of LPA16:0, LPA18:1, and LPA18:2 in the sample is equal to or greater than the median level of LPA16:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0163] In some embodiments, the reference population is a population of patients with IPF.

[0164] In some embodiments, the reference population is a population of patients without IPF.

[0165] In some embodiments, the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is at least twice the reference level.

[0166] In some embodiments, the benefit comprises an increase in the patient's time to exacerbation compared to treatment without the agent that reduces exacerbations.

[0167] In some embodiments, the exacerbation is an acute respiratory exacerbation. In some embodiments, the acute respiratory exacerbation is dyspnea. In some embodiments, the acute respiratory exacerbation is not caused by pneumothorax, cancer, heart failure, fluid overload, or pulmonary embolism.

[0168] In some embodiments, the acute respiratory deterioration is associated with a new radiological abnormality, hi some embodiments, the radiological abnormality is bilateral ground-glass opacities / consolidations.

[0169] In some embodiments, the exacerbation is a severe exacerbation.

[0170] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0171] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0172] In some embodiments, the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, acid-reducing therapy, corticosteroids, cyclophosphamide, or a combination thereof.

[0173] In some embodiments, the exacerbation-reducing agent is nintedanib or pirfenidone.

[0174] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority for reducing, controlling, or maintaining an exacerbation. In some embodiments, the regulatory health authority is the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the National Medical Products Administration (NMPA).

[0175] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with idiopathic pulmonary fibrosis (IPF) may be at increased risk of death, comprising measuring a level of one or both of triglycerides (TG) 48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as being at increased risk of death.

[0176] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with IPF will benefit from a treatment including an agent that reduces exacerbations, comprising measuring a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as one that may benefit from a treatment including an agent that reduces exacerbations.

[0177] In another aspect, the disclosure features a method of selecting a therapy for a patient with IPF, the method including measuring a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies the patient as one that is likely to benefit from a therapy including an agent that reduces exacerbations.

[0178] In some embodiments, the patient has a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level, and the method further includes administering to the patient an effective amount of an agent that reduces exacerbation.

[0179] In another aspect, the disclosure features a method of treating a patient with IPF, the method including: (a) measuring the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample is less than a reference level; and (b) administering to the patient an effective amount of an agent that reduces exacerbations.

[0180] In another aspect, the disclosure features a method of treating a patient with IPF and having a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient that is below a reference level, the method comprising administering to the patient an effective amount of an agent that reduces exacerbations.

[0181] In another aspect, the disclosure features a method of treating a patient having IPF, comprising administering to the patient an effective amount of an agent that reduces an exacerbation, wherein the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient has been determined to be below a reference level.

[0182] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0183] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0184] In some embodiments, the sample is a serum sample.

[0185] In some embodiments, the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 is a baseline level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2.

[0186] In some embodiments, the reference level is a pre-assigned level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2.

[0187] In some embodiments, (a) the patient is female and the reference level for TG48:4-FA12:0 is between about 0.800 μM and about 0.840 μM; or (b) the patient is male and the reference level for TG48:4-FA12:0 is between about 1.166 μM and about 1.206 μM. In some embodiments, (a) the patient is female and the reference level for TG48:4-FA12:0 is about 0.820 μM; or (b) the patient is male and the reference level for TG48:4-FA12:0 is about 1.186 μM.

[0188] In some embodiments, (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is between about 1.587 μM and about 1.627 μM; or (b) the patient is male and the reference level (μM) of TG48:4-FA18:2 is between about 2.153 μM and about 2.193 μM. In some embodiments, (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is about 1.607 μM; or (b) the patient is male and the reference level of TG48:4-FA18:2 is about 2.173 μM.

[0189] In some embodiments, the reference level is the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a reference population.

[0190] In some embodiments, the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample is less than the median level of TG48:4-FA12:0 and TG48:4-FA18:2, respectively, in a reference population.

[0191] In some embodiments, the reference population is a population of patients with IPF.

[0192] In some embodiments, the reference population is a population of patients without IPF.

[0193] In some embodiments, the level of one or both of TG48:4-FA12:0 or TG48:4-FA18:2 in the sample is at least half the reference level.

[0194] In some embodiments, the benefit includes an increase in the time to death of the patient compared to treatment without the agent that reduces progression.

[0195] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0196] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0197] In some embodiments, the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, acid-reducing therapy, corticosteroids, cyclophosphamide, or a combination thereof.

[0198] In some embodiments, the exacerbation-reducing agent is nintedanib or pirfenidone.

[0199] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority to reduce, control, or maintain an exacerbation.

[0200] In some embodiments, the regulatory health authority is the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

[0201] In another aspect, the disclosure features a method for predicting time to exacerbation or respiratory hospitalization in a patient with IPF, the method including measuring a level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 in a sample from the patient, wherein (a) a level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample that is equal to or greater than a reference level, or (b) a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than the reference level, identifies the patient as one who is likely to have a shorter time to exacerbation or respiratory hospitalization.

[0202] In some embodiments, the patient has (a) a level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample that is equal to or greater than a reference level, or (b) a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces exacerbation.

[0203] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0204] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0205] In some embodiments, the sample is a serum sample.

[0206] In some embodiments, the level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 is a baseline level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2. In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2.

[0207] In some embodiments, (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM. In some embodiments, (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

[0208] In some embodiments, (a) the patient is female and the reference level of LPA18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA18:1 is between about 0.078 μM and about 0.118 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

[0209] In some embodiments, (a) the patient is female and the reference level of LPA20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA20:4 is between about 0.110 μM and about 0.150 μM. In some embodiments, (a) the patient is female and the reference level of LPA20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA20:4 is about 0.130 μM.

[0210] In some embodiments, (a) the patient is female and the reference level of LPA22:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA22:4 is between about 0.110 μM and about 0.150 μM. In some embodiments, (a) the patient is female and the reference level of LPA22:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA22:4 is about 0.130 μM.

[0211] In some embodiments, (a) the patient is female and the reference level for TG48:4-FA12:0 is between about 0.800 μM and about 0.840 μM; or (b) the patient is male and the reference level for TG48:4-FA12:0 is between about 1.166 μM and about 1.206 μM. In some embodiments, (a) the patient is female and the reference level for TG48:4-FA12:0 is about 0.820 μM; or (b) the patient is male and the reference level for TG48:4-FA12:0 is about 1.186 μM.

[0212] In some embodiments, (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is between about 1.587 μM and about 1.627 μM; or (b) the patient is male and the reference level (μM) of TG48:4-FA18:2 is between about 2.153 μM and about 2.193 μM. In some embodiments, (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is about 1.607 μM; or (b) the patient is male and the reference level of TG48:4-FA18:2 is about 2.173 μM.

[0213] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 in a reference population.

[0214] In some embodiments, (a) the level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample is greater than or equal to the median level of LPA16:0, LPA18:1, LPA20:4, or LPA22:4, respectively, in a reference population; or (b) the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample is less than or equal to the median level of TG48:4-FA12:0 or TG48:4-FA18:2, respectively, in a reference population.

[0215] In some embodiments, the reference population is a population of patients with IPF.

[0216] In some embodiments, the reference population is a population of patients without IPF.

[0217] In some embodiments, (a) the level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample is at least twice the reference level, or (b) the level of one or both of TG48:4-FA12:0 or TG48:4-FA18:2 in the sample is at least half the reference level.

[0218] In some embodiments, the exacerbation is an acute respiratory exacerbation.

[0219] In some embodiments, the acute respiratory deterioration is dyspnea.

[0220] In some embodiments, the acute respiratory deterioration is not caused by pneumothorax, cancer, heart failure, fluid overload, or pulmonary embolism.

[0221] In some embodiments, the acute respiratory deterioration is associated with new radiological abnormalities.

[0222] In some embodiments, the radiological abnormality is bilateral ground-glass opacities / consolidations.

[0223] In some embodiments, the exacerbation is a severe exacerbation.

[0224] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0225] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0226] In some embodiments, the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, acid-reducing therapy, corticosteroids, cyclophosphamide, or a combination thereof.

[0227] In some embodiments, the exacerbation-reducing agent is nintedanib or pirfenidone.

[0228] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority to reduce, control, or maintain an exacerbation.

[0229] In some embodiments, the regulatory health authority is the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

[0230] In another aspect, the disclosure provides a method for identifying, diagnosing, and / or predicting whether a patient with idiopathic pulmonary fibrosis (IPF) may be at increased risk for a deterioration in a measure of lung health, comprising: (a) measuring a level of one or more of LPA16:0, LPA16:1, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the measure of lung health is diffusing capacity for carbon monoxide (DLCO), and wherein a level of one or more of LPA16:0, LPA16:1, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as being at increased risk for a deterioration in DLCO; and (b) measuring a level of LPA22:4 in the sample from the patient, wherein the measure of lung health is diffusing capacity for carbon monoxide (DLCO). and (c) measuring a level of one or more of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the measure of lung health is lower-zone lung fibrosis and a level of one or more of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for increased lower-zone lung fibrosis.

[0231] In some embodiments, (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM. In some embodiments, (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

[0232] In some embodiments, (a) the patient is female and the reference level of LPA 16:1 is between about 0.101 ratio to normal (rts) and about 0.141 rts; or (b) the patient is male and the reference level of LPA 16:1 is between about 0.058 rts and about 0.098 rts. In some embodiments, (a) the patient is female and the reference level of LPA 16:1 is about 0.121 rts; or (b) the patient is male and the reference level of LPA 16:1 is about 0.078 rts.

[0233] In some embodiments, (a) the patient is female and the reference level of LPA18:0 is between about 0.007 μM and about 0.047 μM; or (b) the patient is male and the reference level of LPA18:0 is between about 0.003 μM and about 0.043 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:0 is about 0.027 μM; or (b) the patient is male and the reference level of LPA18:0 is about 0.023 μM.

[0234] In some embodiments, (a) the patient is female and the reference level of LPA18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA18:1 is between about 0.078 μM and about 0.118 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

[0235] In some embodiments, (a) the patient is female and the reference level of LPA18:2 is between about 0.388 μM and about 0.428 μM; or (b) the patient is male and the reference level of LPA18:2 is between about 0.339 μM and about 0.379 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:2 is about 0.408 μM; or (b) the patient is male and the reference level of LPA18:2 is about 0.359 μM.

[0236] In some embodiments, (a) the patient is female and the reference level of LPA20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA20:4 is between about 0.110 μM and about 0.150 μM. In some embodiments, (a) the patient is female and the reference level of LPA20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA20:4 is about 0.130 μM.

[0237] In some embodiments, (a) the patient is female and the reference level of LPA22:4 is between about 0.009 rts and about 0.049 rts; or (b) the patient is male and the reference level of LPA22:4 is between about 0.011 rts and about 0.051 rts. In some embodiments, (a) the patient is female and the reference level of LPA22:4 is about 0.029 rts; or (b) the patient is male and the reference level of LPA22:4 is about 0.031 rts.

[0238] In another aspect, the disclosure features a method for preparing an LPA fraction from a patient, useful for analyzing LPA species involved in inflammatory respiratory diseases, the method including: (a) providing a serum sample or a BALF sample from the patient, wherein the serum sample has a volume of between about 5 μL and about 20 μL; and (b) extracting LPA from the serum sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, wherein the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample.

[0239] In some embodiments, the method further comprises (c) separating LPA species from the fraction of LPA extracted in (b).

[0240] In some embodiments, the extraction buffer comprises between about 27-33 mM citric acid and between about 36-44 mM disodium phosphate. In some embodiments, the extraction buffer comprises about 30 mM citric acid and 40 mM disodium phosphate. In some embodiments, the extraction buffer does not contain hydrochloric acid.

[0241] In some embodiments, the separation in (c) is by liquid chromatography. In some embodiments, the liquid chromatography is high performance liquid chromatography (HPLC). In some embodiments, the HPLC is performed using a reverse phase column. In some embodiments, the reverse phase column is a C18 column.

[0242] In another aspect, the disclosure features an LPA fraction from a patient produced by a method including: (a) providing a serum sample from the patient, wherein the serum sample has a volume of between about 5 μL and about 20 μL; and (b) extracting LPA from the serum sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, wherein the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample.

[0243] In another aspect, the disclosure features purified LPA species produced by a method including: (a) providing a serum sample from a patient, wherein the serum sample has a volume of between about 5 μL and about 20 μL; (b) extracting LPA from the serum sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, wherein the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample; and (c) separating the LPA species from the fraction of LPA extracted in (b).

[0244] In another aspect, the disclosure features: (a) a method for analyzing an LPA fraction according to claim 175, the method including separating LPA species from the LPA fraction. In some aspects, the method further includes analyzing the separated LPA species.

[0245] In another aspect, the disclosure features a method for analyzing LPA species in a serum sample from a patient, the method including: (a) providing a serum sample from the patient, where the serum sample has a volume of between about 5 μL and about 20 μL; (b) extracting LPA from the serum sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, where the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample; (c) separating LPA species from the fraction of LPA extracted in (b); and (d) analyzing the separated LPA species produced in (c).

[0246] In some embodiments, the analysis is by mass spectrometry. In some embodiments, the mass spectrometry is performed using negative ionization mode. In some embodiments, the limit of detection (LOD) of the LPA species is less than 0.008 pmol / μL serum. In some embodiments, the LOD of the LPA species is between 0.002 pmol / μL serum and 0.008 pmol / μL serum. In some embodiments, the LOD of the LPA species is less than 0.002 pmol / μL serum. In some embodiments, the absolute recovery of the LPA species from the sample is between 82% and 110%.

[0247] In some embodiments, the LPA species is one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4. In some embodiments, the LPA species is one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4. [Brief explanation of the drawings]

[0248] [Figures 1A-1E] Figure 1A is a scatter plot showing the levels of LPA 16:0 detected by LC-MS / MS after extraction with two different sample preparation buffers. LPA: lysophosphatidic acid. Sodium buffer: 40 mM Na2HP4, 20 mM citrate. LPA was extracted from serum of a healthy donor. The indicated P values ​​were calculated by Student's t-test. Figure 1B is a scatter plot showing the levels of LPA 18:0 detected by LC-MS / MS after extraction with two different sample preparation buffers. The indicated P values ​​were calculated by Student's t-test. Figure 1C is a scatter plot showing the levels of LPA 18:1 detected by LC-MS / MS after extraction with two different sample preparation buffers. The indicated P values ​​were calculated by Student's t-test. Figure 1D is a scatter plot showing the levels of LPA 18:2 detected by LC-MS / MS after extraction with two different sample preparation buffers. The indicated P values ​​were calculated by Student's t-test. Figure 1E is a scatter plot showing the levels of LPA 20:4 detected by LC-MS / MS after extraction with two different sample preparation buffers. The indicated p-values ​​were calculated by Student's t-test. [Figure 1F-1K]Figure 1F is a scatter plot showing the levels of LPA 16:0 detected by LC-MS / MS after extraction with two different sample preparation buffers: disodium buffer: 40 mM Na2HPO4, 30 mM citric acid. Figure 1G is a scatter plot showing the levels of LPA 18:0 detected by LC-MS / MS after extraction with two different sample preparation buffers: disodium buffer: 40 mM Na2HPO4, 30 mM citric acid. P values ​​were calculated using the nonparametric Mann-Whitney U test. Figure 1H is a scatter plot showing the levels of LPA 18:1 detected by LC-MS / MS after extraction with two different sample preparation buffers: disodium buffer: 40 mM Na2HPO4, 30 mM citric acid. P values ​​were calculated using the nonparametric Mann-Whitney U test. Figure 1I is a scatter plot showing the levels of LPA 18:2 detected by LC-MS / MS after extraction with two different sample preparation buffers. Disodium buffer: 40 mM Na2HPO4, 30 mM citric acid. P values ​​were calculated using the nonparametric Mann-Whitney U test. Figure 1J is a scatter plot showing the levels of LPA 20:4 detected by LC-MS / MS after extraction with two different sample preparation buffers. Disodium buffer: 40 mM Na2HPO4, 30 mM citric acid. P values ​​were calculated using the nonparametric Mann-Whitney U test. Figure 1K is a scatter plot showing the levels of LPA 17:0 detected by LC-MS / MS after extraction with two different sample preparation buffers. Disodium buffer: 40 mM Na2HPO4, 30 mM citric acid. P values ​​were calculated using the nonparametric Mann-Whitney U test. [Figure 2A] 2A is a line graph showing the stability of LPA species in a −80° C. freezer as concentration (μM) of LPA species at time points over 35 days. LPA species were extracted from quality control (QC) samples. [Figure 2B] Figure 2B is a line graph showing the stability of LPA species in extraction buffer in an autosampler at 15°C as measured peak areas of LPA species at time points over a 55-hour period. LPA species were extracted from quality control (QC) samples. [Figures 3A-3E] Figure 3A is a boxplot showing the concentration (log2 [μM]) of LPA16:0 in serum samples from healthy subjects and patients with chronic obstructive pulmonary disease (COPD). The indicated P values ​​were calculated by Student's t-test. Figure 3B is a boxplot showing the concentration (log2 [μM]) of LPA18:0 in serum samples from healthy subjects and patients with COPD. The indicated P values ​​were calculated by Student's t-test. Figure 3C is a boxplot showing the concentration (log2 [μM]) of LPA18:1 in serum samples from healthy subjects and patients with COPD. The indicated P values ​​were calculated by Student's t-test. Figure 3D is a boxplot showing the concentration (log2 [μM]) of LPA18:2 in serum samples from healthy subjects and patients with COPD. The indicated P values ​​were calculated by Student's t-test. Figure 3E is a boxplot showing the concentration (log2 [μM]) of LPA20:4 in serum samples from healthy subjects and patients with COPD. The indicated P values ​​were calculated by Student's t-test. [Figures 4A-4E]Figure 4A shows boxplots depicting the concentrations (log2 [µM]) of LPA16:0 in serum samples from female (F) and male (M) patients with COPD. The univariate p-values ​​shown were calculated using a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. The p-values ​​from multivariate analysis and the FDR-adjusted q-values ​​are shown in Table 5. Figure 4B shows boxplots depicting the concentrations (log2 [µM]) of LPA18:0 in serum samples from female (F) and male (M) patients with COPD. The p-values ​​shown were calculated using a Student's t-test. The univariate p-values ​​shown were calculated using a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. The p-values ​​from multivariate analysis and the FDR-adjusted q-values ​​are shown in Table 5. Figure 4C shows boxplots depicting the concentrations (log2 [µM]) of LPA18:1 in serum samples from female (F) and male (M) patients with COPD. The p-values ​​shown were calculated by Student's t-test. The univariate p-values ​​shown were calculated from a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. The p-values ​​and FDR-adjusted q-values ​​from multivariate analysis are shown in Table 5. Figure 4D shows boxplots depicting the concentrations (log2 [µM]) of LPA18:2 in serum samples from female (F) and male (M) patients with COPD. The p-values ​​shown were calculated by Student's t-test. The univariate p-values ​​shown were calculated from a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. The p-values ​​and FDR-adjusted q-values ​​from multivariate analysis are shown in Table 5. Figure 4E shows the concentration (log2 [µM]) of LPA 20:4 in serum samples from female (F) and male (M) patients with COPD. The p-values ​​shown were calculated by Student's t-test. The univariate p-values ​​shown were calculated from a nonparametric Mann-Whitney U-test on the logarithmic scale of LPA concentrations. The p-values ​​from multivariate analysis and the FDR-adjusted q-values ​​are shown in Table 5. [Figures 5A-5E]Figure 5A is a box-and-whisker plot showing LPA16:0 levels in serum samples from female and male patients with and without chronic bronchitis (CB). No: patients without CB; Yes: patients with CB. Univariate analysis p-values ​​shown were calculated from a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. P-values ​​from multivariate analysis and FDR-adjusted q-values ​​are shown in Table 5. Figure 5B is a box-and-whisker plot showing LPA18:0 levels in serum samples from female and male patients with and without CB. No: patients without CB; Yes: patients with CB. Univariate analysis p-values ​​shown were calculated from a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. P-values ​​from multivariate analysis and FDR-adjusted q-values ​​are shown in Table 5. Figure 5C is a box-and-whisker plot showing LPA18:1 levels in serum samples from female and male patients with and without CB. No: patients without CB; Yes: patients with CB. Univariate analysis p-values ​​shown were calculated from a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. P-values ​​from multivariate analysis and FDR-adjusted q-values ​​are shown in Table 5. No: patients without CB; Yes: patients with CB. Univariate analysis p-values ​​shown were calculated from a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. P-values ​​from multivariate analysis and FDR-adjusted q-values ​​are shown in Table 5. Figure 5D is a boxplot showing LPA18:2 levels in serum samples from female and male patients with and without CB. No: patients without CB; Yes: patients with CB. Univariate analysis p-values ​​shown were calculated from a nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. P-values ​​from multivariate analysis and FDR-adjusted q-values ​​are shown in Table 5. Figure 5E is a boxplot showing LPA20:4 levels in serum samples from female and male patients with and without CB. No: patients without CB; Yes: patients with CB. Univariate analysis p-values ​​shown were calculated from the nonparametric Mann-Whitney U test on the logarithmic scale of LPA concentrations. Multivariate analysis p-values ​​and FDR-adjusted q-values ​​are shown in Table 5. [Figures 6A-6E]Figure 6A is a box-and-whisker plot showing LPA16:0 levels in serum samples from female and male COPD patients in the Americas or other regions of the world. NSA: Americas; Other: Other regions of the world. The p-values ​​shown were calculated by Student's t-test. Figure 6B is a box-and-whisker plot showing LPA18:0 levels in serum samples from female and male COPD patients in the Americas or other regions of the world. NSA: Americas; Other: Other regions of the world. The p-values ​​shown were calculated by Student's t-test. Figure 6C is a box-and-whisker plot showing LPA18:1 levels in serum samples from female and male COPD patients in the Americas or other regions of the world. NSA: Americas; Other: Other regions of the world. The p-values ​​shown were calculated by Student's t-test. Figure 6D is a box-and-whisker plot showing LPA18:2 levels in serum samples from female and male COPD patients in the Americas or other regions of the world. NSA: Americas; Other: Other regions of the world. The indicated P values ​​were calculated by Student's t-test. Figure 6E is a box-and-whisker plot showing LPA20:4 levels in serum samples from female and male COPD patients from the Americas or other parts of the world. NSA: Americas; Other: other parts of the world. The indicated P values ​​were calculated by Student's t-test. [Figures 7A-7E] Figure 7A is a box plot showing LPA16:0 levels in serum samples from healthy subjects from a small cohort study who were smokers (S) or non-smokers (NS). Figure 7B is a box plot showing LPA18:0 levels in serum samples from healthy subjects from a small cohort study who were smokers or non-smokers. Figure 7C is a box plot showing LPA18:1 levels in serum samples from healthy subjects from a small cohort study who were smokers or non-smokers. Figure 7D is a box plot showing LPA18:2 levels in serum samples from healthy subjects from a small cohort study who were smokers or non-smokers. Figure 7E is a box plot showing LPA20:4 levels in serum samples from healthy subjects from a small cohort study who were smokers or non-smokers. [Figures 8A-8E]Figure 8A is a box-and-whisker plot showing LPA 16:0 levels in baseline serum samples from female and male COPD patients who are current or former smokers. Figure 8B is a box-and-whisker plot showing LPA 18:0 levels in baseline serum samples from female and male COPD patients who are current or former smokers. Figure 8C is a box-and-whisker plot showing LPA 18:1 levels in baseline serum samples from female and male COPD patients who are current or former smokers. Figure 8D is a box-and-whisker plot showing LPA 18:2 levels in baseline serum samples from female and male COPD patients who are current or former smokers. Figure 8E is a box-and-whisker plot showing LPA 20:4 levels in baseline serum samples from female and male COPD patients who are current or former smokers. [Figures 9A-9E] Figure 9A is a box-and-whisker plot showing LPA 16:0 levels in baseline serum samples from female and male COPD patients with low weight or normal weight (15 < BMI < 25), overweight (OV) (25 < BMI < 30), or obesity (BMI > 30). Figure 9B is a box-and-whisker plot showing LPA 18:0 levels in baseline serum samples from female and male COPD patients with low weight or normal weight (15 < BMI < 25), overweight (OV) (25 < BMI < 30), or obesity (BMI > 30). Figure 9C is a box-and-whisker plot showing LPA 18:1 levels in baseline serum samples from female and male COPD patients with low weight or normal weight (15 < BMI < 25), overweight (OV) (25 < BMI < 30), or obesity (BMI > 30). Figure 9D is a box-and-whisker plot showing LPA 18:2 levels in baseline serum samples from female and male COPD patients with low weight or normal weight (15 < BMI < 25), overweight (OV) (25 < BMI < 30), or obesity (BMI > 30). Figure 9E is a box-and-whisker plot showing LPA 20:4 levels in baseline serum samples from female and male COPD patients with low weight or normal weight (15 < BMI < 25), overweight (OV) (25 < BMI < 30), or obesity (BMI > 30). [Figures 10A-10E]Figure 10A is a scatter plot showing the correlation (Pearson) of LPA16:0 levels with age in female (F) patients. Figure 10B is a scatter plot showing the correlation (Pearson) of LPA18:0 levels with age in female (F) patients. Figure 10C is a scatter plot showing the correlation (Pearson) of LPA18:1 levels with age in female (F) patients. Figure 10D is a scatter plot showing the correlation (Pearson) of LPA18:2 levels with age in female (F) patients. Figure 10E is a scatter plot showing the correlation (Pearson) of LPA20:4 levels with age in female (F) patients. [Figure 10F-10J] Figure 10F is a scatter plot showing the correlation (Pearson) of LPA16:0 levels with age in male (M) patients. Figure 10G is a scatter plot showing the correlation (Pearson) of LPA18:0 levels with age in male (M) patients. Figure 10H is a scatter plot showing the correlation (Pearson) of LPA18:1 levels with age in male (M) patients. Figure 10I is a scatter plot showing the correlation (Pearson) of LPA18:2 levels with age in male (M) patients. Figure 10J is a scatter plot showing the correlation (Pearson) of LPA20:4 levels with age in male (M) patients. [Figure 11] Figure 11 is a set of scatter plots showing the correlation between levels of the LPA species LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 and measures of lung function (FEV1, FVC, and FEV1 / FVC). Pearson's r and p values ​​are shown. [Figure 12] FIG. 12 is a chart showing correlation values ​​(Spearman's rho) of the levels of the LPA species LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 with each other and with the levels of the biomarkers monocytes, neutrophils, eosinophils, platelets, fibrinogen, and immunoglobulin E (IgE) at baseline in serum samples from placebo patients in clinical trial NCT02546700. [Figure 13]Figure 13 is a graph showing the risk of exacerbations by baseline biomarkers in male COPD patients. Each baseline biomarker profile was fitted to a multivariate logistic regression model adjusted for the following covariates: number of exacerbations in the past 12 months, smoking status, geographic region, bronchodilator response, and baseline COPD medication. Odds ratios greater than 1 indicate a higher risk of exacerbation in patients with blood eosinophils ≥ 200 cells / μL compared with patients with < 200 cells / μL; patients with chronic bronchitis compared with patients without chronic bronchitis (as identified using the St. George's Respiratory Questionnaire for COPD; CB_SGRQ; fibrinogen ≥ 3.5 g / L compared with patients with < 3.5 g / L); or patients with levels of the LPA species LPA20:4, LPA18:1, LPA16:0, LPA18:2, or LPA18:0 in the lowest tertile of LPA species values ​​compared with the highest tertile of LPA species values. Q values ​​are false discovery rate-adjusted p-values. Line arrows indicate censored confidence intervals. [Figure 14] Figure 14 is a set of graphs showing adjusted exacerbation rates (per patient per year) over 24 weeks by baseline biomarker profile and gender. L = lowest, M = median, and H = highest tertile of LPA levels for each LPA type. Adjusted exacerbation rates are estimates from a quasi-Poisson regression model adjusted for the following covariates, in addition to log(patient-years) as an offset: number of exacerbations in the past 12 months, smoking status, geographic region, bronchodilator response, and baseline COPD medication. P values ​​compare L with M or H subgroups. *p<0.05; **p<0.01. N=number of patients. [Figures 15A-15C]Figure 15A is a set of Kaplan-Meier curves showing the percentage of male patients who were exacerbation-free over time, stratified by L = lowest; M = median; H = highest tertile of baseline LPA16:0 concentrations. Baseline biomarker profiles were fit to Cox proportional hazards regression models adjusted for the following covariates: number of exacerbations within the past 12 months, smoking status, geographic region, bronchodilator response, and baseline COPD medication. P values ​​indicate comparisons between the three LPA16:0 subgroups. Figure 15B is a set of Kaplan-Meier curves showing the percentage of male patients who were exacerbation-free over time, stratified by L = lowest; M = median; H = highest tertile of baseline LPA18:0 concentrations. Baseline biomarker profiles were fit to Cox proportional hazards regression models as described for Figure 15A. Figure 15C is a set of Kaplan-Meier curves showing the percentage of male patients who remained progression-free over time, stratified by L = lowest; M = median; H = highest tertile of baseline LPA18:1 concentrations. Baseline biomarker profiles were fitted to Cox proportional hazards regression models as described for Figure 15A. [Figure 15D-15E] Figure 15D is a set of Kaplan-Meier curves showing the percentage of male patients who remained exacerbation-free over time, stratified by L=lowest; M=median; H=highest tertile of baseline LPA18:2 concentrations. Baseline biomarker profiles were fit to a Cox proportional hazards regression model as described for Figure 15A. Figure 15E is a set of Kaplan-Meier curves showing the percentage of male patients who remained exacerbation-free over time, stratified by L=lowest; M=median; H=highest tertile of baseline LPA20:4 concentrations. Baseline biomarker profiles were fit to a Cox proportional hazards regression model as described for Figure 15A. [Figure 16] FIG. 16 is a Venn diagram showing lipid species overlap with unadjusted p-values ​​<0.05 when comparing between the LPA-low and LPA-high subgroups for each lipid species in men. [Figure 17] FIG. 17 is a Venn diagram showing lipid species overlap with unadjusted p-values ​​<0.05 when comparing between the LPA-low and LPA-high subgroups for each lipid species in women. [Figures 18A-18C] Figure 18A is a set of boxplots showing the baseline concentration (μM) of each LPA species stratified by gender. **p<0.005; ***p<0.001 Student's t-test. Figure 18B is a set of boxplots showing the baseline concentration (μM) of each LPA species stratified by statin use. **p<0.005; ***p<0.001 Student's t-test. Figure 18C is a set of boxplots showing the baseline concentration (μM) of each LPA species stratified by whether the patient had chronic bronchitis (chronic bronchitis identified using the CB_SGRQ: St. George's Respiratory Questionnaire for COPD). **p<0.005; ***p<0.001 Student's t-test. [Figures 19A-19B] Figure 19A is a heatmap showing the overlap of low, median, and high LPA species levels in men. Rows indicate LPA species and are coded by the tertile cutoff (μM) used to classify patients into low (blue), middle (gray), and high (red) tertiles for LPA species levels. Each column represents a patient. Patients who were in the low or high tertile for all LPA species are indicated in brackets. Figure 19B is a heatmap showing the overlap of low, median, and high LPA species levels in men. Rows indicate LPA species and are coded by the tertile cutoff (μM) used to classify patients into low (blue), middle (gray), and high (red) tertiles for LPA species levels. Each column represents a patient. Patients who were in the low or high tertile for all LPA species are indicated in brackets. [Figure 20]Figure 20 shows the risk of exacerbations by baseline biomarkers in female COPD patients. Each baseline biomarker profile was fitted to a multivariate logistic regression model adjusted for the following covariates: number of exacerbations in the past 12 months, smoking status, geographic region, bronchodilator response, and baseline COPD medication. Odds ratios greater than 1 indicate a higher risk of exacerbation in patients with blood eosinophils ≥ 200 cells / μl compared with patients with < 200 cells / μl, patients with chronic bronchitis compared with patients without chronic bronchitis (chronic bronchitis identified using the St. George's Respiratory Questionnaire for COPD (CB_SGRQ)), patients with fibrinogen ≥ 3.5 g / L compared with patients with < 3.5 g / L, or patients with levels of the LPA species LPA20:4, LPA18:1, LPA16:0, LPA18:2, or LPA18:0 in the lowest tertile of LPA species values ​​compared with the highest tertile of LPA species values. Q values ​​are false discovery rate-adjusted p-values. [Figures 21A-21E]Figure 21A is a set of Kaplan-Meier curves showing the percentage of female patients who did not experience an exacerbation over time, stratified by L=lowest; M=median; H=highest tertile of baseline LPA16:0 concentrations. Baseline biomarker profiles were fit to a Cox proportional hazards regression model as described for Figure 15A. Figure 21B is a set of Kaplan-Meier curves showing the percentage of female patients who did not experience an exacerbation over time, stratified by L=lowest; M=median; H=highest tertile of baseline LPA18:0 concentrations. Baseline biomarker profiles were fit to a Cox proportional hazards regression model as described for Figure 15A. Figure 21C is a set of Kaplan-Meier curves showing the percentage of female patients who did not experience an exacerbation over time, stratified by L=lowest; M=median; H=highest tertile of baseline LPA18:1 concentrations. Baseline biomarker profiles were fit to Cox proportional hazards regression models as described for Figure 15A. Figure 21D is a set of Kaplan-Meier curves showing the percentage of female patients who did not experience an exacerbation over time, stratified by L=lowest; M=median; H=highest tertile of baseline LPA18:2 concentrations. Baseline biomarker profiles were fit to Cox proportional hazards regression models as described for Figure 15A. Figure 21E is a set of Kaplan-Meier curves showing the percentage of female patients who did not experience an exacerbation over time, stratified by L=lowest; M=median; H=highest tertile of baseline LPA20:4 concentrations. Baseline biomarker profiles were fit to Cox proportional hazards regression models as described for Figure 15A. [Figure 22] Figure 22 is a set of boxplots showing exacerbation duration (in days) stratified by L=lowest; M=median; H=highest tertile of baseline LPA levels for LPA16;0, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and gender. Kruskal-Wallis p-values ​​are shown. N=number of exacerbation events. [Figures 23A-23B]Figure 23A is a set of bar graphs showing the differential expression of 12 lipid classes between men in the low and high baseline LPA species subgroups. The x-axis shows the mean log2 (low analyte / high analyte), with values ​​less than 0 indicating a decrease and values ​​greater than 0 indicating an increase in patients in the low and high subgroups. Green bars indicate unadjusted p-values ​​<0.05. CE: cholesteryl ester; CER: ceramide; DAG: diacylglycerol; DCER: dihydroceramide; HCER: hexosylceramide; LCER: lactosylceramide; LPC: lysophosphatidylcholine; LPE: lysophosphatidylethanolamine; PC: phosphatidylcholine; PE: phosphatidylethanolamine; SM: sphingomyelin; TAG: triacylglycerol. Figure 23B is a set of volcano plots showing lipid species in men in the low and high baseline LPA species subgroups. The X-axis shows the mean log2 (low analyte abundance / high analyte abundance). The Y-axis shows -log10 (unadjusted p-value). Colored circles indicate unadjusted p-values ​​<0.05; red circles indicate lipid species that are more abundant in the LPA-low subgroup compared to the LPA-high subgroup, and blue circles indicate lipid species that are less abundant in the LPA-low subgroup compared to the LPA-high subgroup. Colored labels highlight species with large fold changes. [Figures 24A-24B]Figure 24A is a set of bar graphs showing the differential expression of 12 lipid classes between women in the low- and high-baseline LPA species subgroups. The x-axis represents the mean log2 (low analyte abundance / high analyte abundance), with values ​​less than 0 indicating a decrease and values ​​greater than 0 indicating an increase in patients in the low and high LPA subgroups. Green bars indicate unadjusted p-values ​​<0.05; orange bars indicate a false discovery rate <0.1. CE: cholesteryl ester; CER: ceramide; DAG: diacylglycerol; DCER: dihydroceramide; HCER: hexosylceramide; LCER: lactosylceramide; LPC: lysophosphatidylcholine; LPE: lysophosphatidylethanolamine; PC: phosphatidylcholine; PE: phosphatidylethanolamine; SM: sphingomyelin; TAG: triacylglycerol. Figure 24B is a set of volcano plots showing lipid species in women from the low and high baseline LPA species subgroups. The X-axis shows the mean log2 (low analyte abundance / high analyte abundance). The Y-axis shows -log10 (unadjusted p-value). Colored circles indicate an unadjusted p-value < 0.05; red circles indicate lipid species that are more abundant in the LPA-low subgroup compared to the LPA-high subgroup, and blue circles indicate lipid species that are less abundant in the LPA-low subgroup compared to the LPA-high subgroup. Colored labels highlight species with large fold changes or small p-values. [Figures 25A-25B] Figure 25A is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline ceramide (CER) levels in female COPD patients. Figure 25B is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline CER levels in male COPD patients. [Figures 26A-26B]Figure 26A is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline hydroxyceramide (HCER) levels in female COPD patients. Figure 26B is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline HCER levels in male COPD patients. [Figures 27A-27B] Figure 27A is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline lactosylceramide (LCER) levels in female COPD patients. Figure 27B is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline LCER levels in male COPD patients. [Figures 28A-28B] Figure 28A is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline lysophosphatidylcholine (LPC) levels in female COPD patients. Figure 28B is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline LPC levels in male COPD patients. [Figures 29A-29B] Figure 29A is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline sphingomyelin (SM) levels in female COPD patients. Figure 29B is a plot showing adjusted exacerbation rates (per patient per year) stratified by L=lowest; M=median; H=highest tertile of baseline SM levels in male COPD patients. [Figure 30]Figure 30 is a plot showing the multivariate linear regression model adjusted for age and sex used to assess differences in lipid levels between healthy controls and IPF patients. The x-axis represents log2 (analyte amount in IPF / analyte amount in healthy controls) and the y-axis represents -log10 (adjusted p-value or false discovery rate for multivariate regression). Yellow circles represent lipid species with a false discovery rate <0.05, and red circles represent lipid species with a fold change >2 with a false discovery rate <0.05. [Figure 31A] Figure 31A is a set of plots showing the results of univariate and multivariate linear regressions adjusted for age and sex used to assess the association of LPA16:0, LPA16:1, and LPA18:0 with baseline demographic or clinical measures in healthy patients. [Figure 31B] Figure 31B is a set of plots showing the results of univariate and multivariate linear regressions adjusted for age and sex used to assess the association of LPA16:0, LPA16:1, and LPA18:0 with baseline demographic or clinical measures in patients with idiopathic pulmonary fibrosis (IPF). [Figure 31C] FIG. 31C is a chart showing correlation values ​​(Spearman's rho) between LPA and TG species in IPF patients. [Figure 31D] Figure 31D is a chart showing the association between LPA or TG species and protein biomarkers in multivariate linear regression analysis adjusted for age, sex, and geographic region. -ve = negative association; F = female; M = male; 6MWT = 6-minute walk test distance in meters; rts = ratio to normal. [Figure 32]Figure 32 is a set of scatter plots showing the results of a multivariate linear regression model adjusted for the covariates age, sex, baseline FVC%pred, baseline DLCO%pred, and geographic region used to assess the association between baseline levels of the indicated LPA or TG species and decline in DLCO%pred (over 52 weeks), calculated as slope. DLCO%pred = percentage of predicted diffusing capacity for carbon monoxide; FVC%pred = percentage of predicted forced vital capacity; rts = ratio to normal; uM = micromoles. **p<0.01; ***p<0.001. [Figure 33] Figure 33 is a plot showing the risk of exacerbation or respiratory hospitalization over 52 weeks based on baseline lipid profile. Baseline lipid profile was fitted to a multivariate logistic regression model adjusted for the following covariates: age, sex, baseline FVC%pred, baseline DLCO%pred, and geographic region. Odds ratios greater than 1 indicate higher odds of exacerbation or respiratory hospitalization in patients with high LPA levels (≥median) compared with patients with low LPA levels (<median); or in patients with low TG levels (<median) compared with patients with high TG levels (≥median). Line arrows indicate censored confidence intervals. DLCO%pred = percentage of predicted diffusing capacity for carbon monoxide; FVC%pred = percentage of predicted forced vital capacity. [Figure 34] Figure 34 is a set of charts showing the probability of respiratory hospitalization progression or lack thereof over time based on lipid biomarker levels. Baseline LPA and TG profiles were fitted to Cox proportional hazards regression models adjusted for the following covariates: age, sex, baseline FVC%pred, baseline DLCO%pred, and geographic region. Group (gr) 0 = biomarker low (<median); 1 = biomarker high (≥median). DLCO%pred = percentage of predicted diffusing capacity for carbon monoxide; FVC%pred = percentage of predicted forced vital capacity. #p<0.1; *p<0.05. [Figure 35]Figure 35 is a plot showing the risk of death over 52 weeks based on baseline lipid profile. Baseline lipid profile was fitted to a multivariate logistic regression model adjusted for the following covariates: age, sex, baseline FVC%pred, baseline DLCO%pred, and geographic region. Odds ratios greater than 1 indicate higher odds of mortality in patients with high LPA levels (≥median) compared with patients with low LPA levels (<median); or in patients with low TG levels (<median) compared with patients with high TG levels (≥median). Line arrows indicate censored confidence intervals. DLCO%pred = percentage of predicted diffusing capacity for carbon monoxide; FVC%pred = percentage of predicted forced vital capacity. [Figure 36] Figure 36 is a set of charts showing the probability of death over time based on lipid biomarker levels. Baseline TG profiles were fitted to a Cox proportional hazards regression model adjusted for the following covariates: age, sex, baseline FVC%pred, baseline DLCO%pred, and geographic region. Group (gr) 0 = biomarker low (<median), 1 = biomarker high (≥median). DLCO%pred = percentage of predicted diffusing capacity for carbon monoxide; FVC%pred = percentage of predicted forced vital capacity. #p<0.1. [Figure 37] Figure 37 is a set of scatter plots showing the change from baseline in ground-glass opacity in the whole lung over 72 weeks versus baseline lipid levels. Multivariate linear regression models adjusted for the covariates of age, sex, baseline FVC%pred, baseline DLCO%pred, and geographic region were used to assess the association of LPA and TG with the change from baseline in ground-glass opacity. DLCO%pred = percentage of predicted diffusing capacity for carbon monoxide; FVC%pred = percentage of predicted forced vital capacity; rts = ratio to normal; uM = micromoles. *p<0.05. [Figure 38]Figure 38 is a set of plots showing the percentage of radiographic changes (ground-glass opacity (upper left panel), honeycombing (lower left panel), and fibrosis (right panel)) in indicated areas of the lung at the screening visit and at week 72. Medians and interquartile ranges of radiographic metrics are shown as box plots, with individual patients connected by gray lines. GGCAD = ground-glass opacity; HCCAD = honeycombing; QLFCAD = fibrosis; SCRN = screen; wk = week. [Figure 39A-39B] Figure 39A is a set of scatter plots showing the change in fibrosis from baseline in the left lower lung zone versus baseline lipid levels over 72 weeks. Associations of LPA and TG with change in fibrosis from baseline were assessed using multivariate linear regression models adjusted for the covariates of age, sex, baseline FVC%pred, baseline DLCO%pred, and geographic region. DLCO%pred = percentage of predicted diffusing capacity for carbon monoxide; rts = ratio to normal; uM = micromoles. #p<0.1; *p<0.05; **p<0.01. Figure 39B is a set of scatter plots showing the change in fibrosis from baseline in the right lower lung zone versus baseline lipid levels over 72 weeks. Associations of LPA and TG with change in fibrosis from baseline were assessed using multivariate linear regression models adjusted for the covariates of age, sex, baseline FVC%pred, baseline DLCO%pred, and geographic region. DLCO%pred = percentage of predicted diffusing capacity for carbon monoxide; rts = ratio to standard; uM = micromolar. #p<0.1; *p<0.05; **p<0.01. [Figure 40] FIG. 40 is a set of plots showing levels (log2 transformed) of LPA16:0, LPA16:1, LPA18:1, LPA18:2, and LPA20:4 in IPF patients and healthy controls. [Figure 41A-41B]Figure 41A is a set of plots showing the levels of LPA16:0, LPA16:1, and LPA18:0 in female (F) and male (M) IPF patients, as well as a plot showing the negative correlation between LPA18:0 levels (log2 transformed) and diffusing capacity for carbon monoxide (DLCO) at baseline. Figure 41B is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPA species and 6-minute walk distance (6MWD) in IPF patients at baseline in univariate or multivariate regressions adjusted for age and sex. [Figure 42] FIG. 42 is a set of scatter plots showing the correlation between levels of the indicated LPA species (log2 transformed; μm or ratio to normal) and DLCO (slope: DLCO decline over 48 weeks) in male IPF patients. [Figure 43] FIG. 43 is a set of scatter plots showing the correlation between levels of the indicated LPA species (log2 transformed; μm or ratio to normal) and FVC (slope: FVC decline over 48 weeks) in male IPF patients. [Figure 44] Figure 44 is a set of curves showing the probability of survival over time in male IPF patients with levels of the indicated LPA species below the median level (gr=0) or above the median level (gr=1). Median cutoffs: LPA16:0 - 0.173 μM, LPA16:1 - 0.0780 ratio to normal; LPA18:1 - 0.0983 μM; LPA20:4 - 0.130 μM. [Figure 45] FIG. 45 is a set of scatter plots showing the correlation between levels of the indicated LPA species (log2 transformed; μm or ratio to normal) and increase in ground-glass opacity (GGCAD_CHG) at week 72 in male IPF patients. [Figure 46] FIG. 46 is a set of scatter plots showing the correlation between levels of the indicated LPA species (log2 transformed; μm or ratio to normal) and honeycombing increase (HCCAD_CHG) at week 72 in male IPF patients. [Figure 47]FIG. 47 is a set of scatter plots showing the correlation between levels of the indicated LPA species (log2 transformed; μm or ratio to normal) and increased interstitial lung disease (ILD) metrics (QILD_CHG) in male IPF patients. [Figure 48A] FIG. 48A is a set of plots showing the levels (log2 transformed) of the indicated LPC species in IPF patients and healthy controls. [Figure 48B] FIG. 48B is a set of plots showing the levels (log2 transformed) of the indicated LPC species in IPF patients and healthy controls. [Figure 49] FIG. 49 is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPC species and decline in FVC over 48 weeks in IPF patients. [Figure 50] Figure 50 is a set of curves showing the probability of survival over time in IPF patients with levels of the indicated LPC species below the median level (gr=0) or above the median level (gr=1). Median cutoffs: (μM): LPC15:0: 1.2696 (female), 1.3919 (male); LPC20:2: 0.7232 (female), 0.7513 (male); LPC22:0: 0.0854 (female), 0.0906 (male); LPC22:1: 0.0853 (female), 0.0888 (male). [Figure 51A] FIG. 51A is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPC species and increase in ground-glass opacity (GGCAD_CHG) at week 72 in IPF patients. [Figure 51B] FIG. 51B is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPC species and increase in ground-glass opacity (GGCAD_CHG) at week 72 in IPF patients. [Figure 52] FIG. 52 is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPC species and honeycomb increase at week 72 in IPF patients. [Figure 53]FIG. 53 is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPC species and increased fibrosis at 72 weeks in IPF patients. [Figure 54A] FIG. 54A is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPC species and increased ILD metrics at week 72 in IPF patients. [Figure 54B] FIG. 54B is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPC species and increased ILD metrics at week 72 in IPF patients. [Figure 55A] Figure 55A is a set of plots showing the levels (log2 transformed) of the indicated LPE species in IPF patients and healthy controls. [Figure 55B] Figure 55B is a set of plots showing the levels (log2 transformed) of the indicated LPE species in IPF patients and healthy controls. [Figure 56] FIG. 56 is a scatter plot showing the correlation between levels (log2 transformed) of the indicated LPE species and reduced DLCO at week 48 in IPF patients. [Figure 57] FIG. 57 is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPE species and decline in FVC over 48 weeks in patients with IPF. [Figure 58] Figure 58 is a set of curves showing the probability of survival over time in IPF patients with levels of the indicated LPE species below the median level (gr=0) or above the median level (gr=1). Median cutoff values: (μM): 0.0435 (female), 0.0422 (male). [Figure 59] FIG. 59 is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPE species and increase in ground-glass opacity (GGCAD_CHG) at week 72 in IPF patients. [Figure 60] FIG. 60 is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPE species and honeycombing increase (HCCAD_CHG) at week 72 in IPF patients. [Figure 61] FIG. 61 is a scatter plot showing the correlation between levels (log2 transformed) of the indicated LPE species and increased fibrosis at week 72 (QLFCAD_CHG) in IPF patients. [Figure 62] FIG. 62 is a set of scatter plots showing the correlation between levels (log2 transformed) of the indicated LPE species and increase in ILD metrics at week 72 (QILD_CHG) in IPF patients. [Figure 63A-63B] Figure 63A is a pair of bar graphs showing the gender (female (F) or male (M)) and status (alive or deceased) of patients for whom lipid analysis was performed. Figure 63B is a chart showing the lipid classes assessed in comprehensive lipid profiling. [Figure 64] Figure 64 is a set of box plots showing the levels of the indicated lipid species in patients with IPF and healthy control patients. [Figure 65] Figure 65 shows a set of diagrams showing the structures of LPA18:1, LPE18:1, and LPC18:1, as well as charts showing the results of lipid profiling analysis in patients with IPF compared to healthy control patients. Lipid species that were significantly higher in IPF patient samples (p<0.05, <0.01, <0.001, <0.0001) are shown shaded. [Figure 66] FIG. 66 is a set of box plots showing the levels of the indicated ceramide (CE) species in patients with IPF and healthy control patients. [Figure 67A-67B] Figure 67A is a plot showing the levels of phosphatidylcholine (PC) species in patient samples compared to healthy donors, and Figure 67B is a set of box plots showing the levels of PC species in patients with IPF and healthy control patients. [Figure 68] Figure 68 is a set of box plots showing the levels of the indicated LPC species in IPF patients who are disease progressors (FP) or non-progressors (0). [Figure 69] FIG. 69 is a set of box plots showing the levels of the indicated lipid species in IPF patients with (1) or without (0) fibrosis. [Figure 70] Figure 70 is a set of charts showing correlations between the indicated LPA, LPE, and LPC species and the indicated biomarkers. The direction of correlation is indicated by color. [Figure 71] Figure 71 is a set of box plots showing levels of the indicated dihydroceramide (DCER) species in IPF patients with fibrosis (1), no fibrosis (0), or a mixture of (1) and (0). [Figure 72] Figure 72 is a set of box plots showing the levels of the indicated phosphatidylcholine (PC) species in IPF patients who are disease progressors (1), non-disease progressors (0), or a mixture of (1) and (0). [Figure 73] Figure 73 is a pie chart and stacked bar graph showing the correlation between PC species and the indicated biomarkers. [Figure 74] Figure 74 is a set of box plots showing levels of the indicated phosphatidylethanolamine (PE) species in IPF patients who are disease progressors (1), non-disease progressors (0), or a mixture of (1) and (0). [Figure 75] Figure 75 is a pie chart and pair of stacked bar graphs showing the correlation between PE or PC species and the indicated biomarkers. [Figure 76A] Figure 76A is a chromatogram showing the separation of the indicated LPA standards. [Figure 76B] Figure 76B is a pair of chromatograms showing the levels of LPA14:0, LPA16:1, and LPA22:4 detected in healthy and COPD serum using theoretical multiple reaction monitoring (MRM) transitions. [Figure 76C] Figure 76C is a chromatogram showing the levels and separation of LPG18:0, LPI18:0, LPS18:0, LPC18:0 and LPE18:0, including LPA18:0, in serum. [Figure 76D] Figure 76D is a pair of extracted ion chromatograms showing the levels of LPA18:0 and LPC18:0 from healthy and COPD serum. [Figure 77A] Figure 77A shows boxplots depicting the concentrations of the indicated LPA species in serum samples from healthy subjects and patients with chronic obstructive pulmonary disease (COPD). The Q values ​​shown are from age- and sex-adjusted, false discovery rate-adjusted logistic regression analyses on the logarithmic scale of LPA concentrations. [Figure 77B] Figure 77B shows the PLS-DA score plot of LPA species (healthy controls vs. COPD patients). The PLS-DA model was validated using 7-fold internal cross-validation. Permutation testing confirmed the robustness of the model (100 permutations). DETAILED DESCRIPTION OF THE INVENTION

[0249] I. Definition As used herein, the singular forms "a," "an," and "the" include plural referents unless otherwise indicated.

[0250] The term "about" as used herein refers to a normal error range for each value, as would be readily understood by one of ordinary skill in the art. As used herein, a reference to "about" a value or parameter includes (and describes) the aspect directed to that value or parameter itself. For example, a reference to "about X" includes a reference to "X." In some embodiments, "about" may refer to ±15%, ±10%, ±5%, or ±1%, as would be understood by a person of ordinary skill in the art.

[0251] Aspects of the invention described herein include "comprising," "consisting of," and / or "consisting essentially of" aspects.

[0252] As used herein, the term "inflammatory respiratory disease" refers to a disease, disorder, or condition associated with inflammation in the airways, such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), asthma, interstitial lung disease (ILD), or cystic fibrosis.

[0253] As used herein, the term "exacerbation" refers to a worsening of one or more symptoms of an inflammatory respiratory disease (e.g., COPD, IPF, or asthma), e.g., a significant worsening on a clinical scale that requires medical treatment. A COPD exacerbation can be one or more new or increased symptoms of COPD, e.g., shortness of breath (dyspnea), cough, sputum production, sputum purulence, fatigue, sleep disturbances, morning headache, confusion, or increased low oxygen levels (hypoxemia), e.g., a new or increased symptom that lasts for at least two consecutive days and / or leads to hospitalization and / or treatment with systemic corticosteroids and / or antibiotics. An IPF exacerbation can be one or more new or increased symptoms of IPF, e.g., acute respiratory exacerbation (e.g., dyspnea), where the acute respiratory exacerbation is not caused by pneumothorax, cancer, heart failure, fluid overload, or pulmonary embolism. An IPF exacerbation may be associated with new radiological abnormalities, such as bilateral ground-glass opacities / consolidations. An asthma exacerbation may be one or more episodes of gradually worsening shortness of breath, cough, wheezing, and chest tightness. Episodes may be acute or subacute. The duration of an exacerbation may be defined, for example, as the period during which the patient experiences symptoms and / or the number of days the patient is taking systemic corticosteroids and / or antibiotics to treat the exacerbation. An exacerbation may be a severe exacerbation, for example, an exacerbation requiring hospitalization.

[0254] As used herein, the term "exacerbation-reducing agent" refers to an agent that slows the rate of exacerbations, increases the time to exacerbation (e.g., increases the time to the first exacerbation or increases the time between exacerbations, e.g., increases the time to the next exacerbation), shortens the duration of an exacerbation, and / or reduces the severity of an exacerbation in a patient with an inflammatory respiratory disease. Such agents include agents used in the treatment of inflammatory respiratory diseases (e.g., maintenance therapy agents), such as agents used in the treatment of COPD, IPF, and / or asthma, as well as agents used to treat exacerbations of inflammatory respiratory diseases. Agents that reduce exacerbations include agents approved by regulatory health authorities (e.g., the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA)) to reduce, control, or maintain exacerbations.Exemplary agents that reduce exacerbations include influenza vaccination, pneumococcal vaccination, supplemental oxygen, short-acting bronchodilators (SABDs), long-acting bronchodilators, dual-acting bronchodilators, short-acting anticholinergics, long-acting anticholinergics, short-acting antimuscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), short-acting beta-2 agonists (SABAs), long-acting beta-2 agonists (LABAs), PDE4 inhibitors, methylxanthines, phosphodiesterase-4 inhibitors, mucolytics, mucomodulators, antioxidants, anti-inflammatory agents, corticosteroids, antibiotics, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof; GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE™ (GOLD) Pocket Guide to COPD Diagnosis, Management, and These include, but are not limited to, agents disclosed in Preventio (2020 edition); nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, acid-blocking therapy, corticosteroids, cyclophosphamide, or combinations thereof; inhaled short-acting beta-2 agonists (SABAs), albuterol, bitolterol, levalbuterol, pirbuterol, systemic SABAs (e.g., epinephrine or terbutaline), anticholinergics (such as ipratropium bromide), or systemic corticosteroids (such as prednisone, methylprednisolone, or prednisolone).

[0255] As used herein, the term "efficacy" refers to the effectiveness of a therapy (e.g., a therapy comprising an agent that reduces exacerbations) in treating a disease (e.g., an inflammatory respiratory disease, e.g., chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or asthma). Efficacy can be assessed using, for example, exacerbation rate, time to exacerbation (e.g., time to first or subsequent exacerbation), exacerbation severity, or exacerbation duration. In some embodiments, efficacy can be assessed using overall survival (OS). In some embodiments, efficacy can be assessed using a measure of pulmonary function, such as spirometry, e.g., FEV1 (forced expiratory volume in 1 second) or FVC (forced vital capacity). In some embodiments, the patient has asthma or COPD, and efficacy is assessed using FEV1. In other embodiments, the patient has IPF, and efficacy is assessed using FVC.

[0256] "Individual response" or "response" can be assessed using any endpoint that indicates benefit to an individual, including, but not limited to, (1) inhibition to some extent of disease progression (e.g., exacerbations or progression of an inflammatory respiratory disease), including slowing or completely halting; (2) alleviation to some extent of one or more symptoms associated with the disease or disorder (e.g., alleviation of symptoms of an inflammatory respiratory disease exacerbation); (3) increase or prolongation of survival, including overall survival and progression-free survival (e.g., increase or prolongation of time to exacerbation); (4) reduction in the duration and / or severity of exacerbations, (5) reduction in mortality at a given time point after treatment, and / or (6) improvement in one or more measures of pulmonary function (e.g., FEV1 or FVC).

[0257] A patient's "effective response" or patient "responsiveness" to treatment with a pharmaceutical agent, and similar terms, refer to a clinical or therapeutic benefit conferred on a patient at risk for or suffering from a disease or disorder, such as an inflammatory respiratory disease. In some embodiments, such benefit includes one or more of an increase in survival (including overall survival and / or progression-free survival (e.g., an increase or increase in time to exacerbation)), a decrease in the rate, duration, and / or severity of exacerbations, or an improvement in signs or symptoms of an inflammatory respiratory disease (e.g., an improvement in one or more measures of lung function, e.g., FEV1 or FVC).

[0258] An "effective amount" of a compound, e.g., an exacerbation-reducing agent or composition thereof (e.g., a pharmaceutical composition), is at least the minimum amount necessary to achieve a desired therapeutic or prophylactic result, such as a measurable improvement or prevention of a particular disorder (e.g., an inflammatory respiratory disease (e.g., COPD, IPF, or asthma), or an exacerbation thereof). The effective amount herein may vary depending on factors such as the patient's disease state, age, sex, and weight, and the ability of the compound to elicit a desired response in the patient. An effective amount is also one in which any toxic or adverse effects of the treatment are outweighed by the therapeutic beneficial effects. Beneficial or desired results for prophylactic use include results such as elimination or reduction of the risk, reduction in severity, or delay in the onset of disease, including biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes manifest during the development of the disease. For therapeutic use, beneficial or desired results include clinical results such as a reduction in one or more symptoms attributable to the disease, an improvement in the quality of life of the disease sufferer, a reduction in the dose of other drugs required to treat the disease, an enhancement of the effect of another drug, e.g., by targeting, a delay in disease progression, and / or an increase in survival time. An effective amount can be administered in one or more administrations. For purposes of the present invention, an effective amount of a drug, compound, or pharmaceutical composition is an amount sufficient to achieve prophylactic or therapeutic treatment, directly or indirectly. As understood in a clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved in conjunction with another drug, compound, or pharmaceutical composition. Thus, an "effective amount" may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if a desired result can be or is achieved in combination with one or more other agents.

[0259] A "disorder" is any condition that would benefit from treatment, including, but not limited to, chronic and acute disorders or diseases, including pathological conditions that predispose a mammal to the disorder in question. In one aspect, the disorder is an inflammatory respiratory disease, such as COPD, IPF, or asthma.

[0260] The term "pharmaceutical formulation" refers to a preparation that is in a form such that the biological activity of the active ingredient contained in the preparation is effective and that does not contain additional components that are unacceptably toxic to the subject to which the formulation is administered.

[0261] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation other than the active ingredient that is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, additives, stabilizers, or preservatives.

[0262] As used herein, "treatment" (and grammatical variations thereof, such as "treat" or "treating") refers to a clinical intervention that attempts to alter the natural course of the patient being treated, and can be performed prophylactically or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, preventing exacerbations of disease, reducing the rate of exacerbations, shortening the duration of exacerbations, reducing the severity of exacerbations, reducing the risk of exacerbations (e.g., subsequent exacerbations), alleviating symptoms, diminishing any direct or indirect pathological consequences of the disease, slowing the rate of disease progression, ameliorating or alleviating the disease state, and achieving remission or improved prognosis. In some embodiments, an exacerbation-reducing agent is used to reduce the frequency, duration, or severity of exacerbations of an inflammatory respiratory disease, such as COPD, IPF, or asthma.

[0263] A "patient," "subject," or "individual" is a human. In a particular embodiment, the patient is male.

[0264] As used herein, "administering" refers to a method of administering a dose of a compound (e.g., a drug that reduces progression) to a subject. The compositions used in the methods described herein can be administered, for example, intramuscularly, intravenously, intradermally, transdermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intraperitoneally, subcutaneously, subconjunctivally, intravesicularly, intramucosally, intrapericardially, intraumbilically, intraocularly, orally, topically, by inhalation, by injection, by infusion, by continuous infusion, by local perfusion that directly bathes target cells, by catheter, by perfusion, in a cream, or in a lipid composition. The administration method can vary depending on various factors (e.g., the compound or composition to be administered and the severity of the condition, disease, or disorder to be treated).

[0265] The terms "in combination" or "concurrently" are used herein to refer to the administration of two or more therapeutic agents where at least some of the administration overlaps in time. Thus, concurrent administration includes dosing regimens where administration of one or more agents continues after administration of one or more other agents is discontinued.

[0266] "Reducing or inhibiting" refers to the ability to cause an overall decrease of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or more. "Reducing" or "inhibiting" can refer, for example, to the frequency, duration, or severity of symptoms of the disorder being treated, e.g., exacerbations of inflammatory respiratory disease.

[0267] ii. Methods for preparing and analyzing LPA fractions Lysophosphatidic acid (LPA) is a phospholipid derivative that can function as a signaling mediator. LPA species (e.g., LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA8:1, LPA18:2, LPA20:4, LPA22:5, and LPA22:6) differ in length and degree of fatty acid saturation.

[0268] LPA is produced by multiple enzymes, including phospholipase C, phospholipase A1 (PLA1), phospholipase A2 (PLA2), and lysophospholipase D (lysoPLD). Autotaxin (ATX), a lysoPLD family member, has been detected in various tissues and biological fluids, including plasma, serum, follicular fluid, saliva, and malignant pleural effusion. The majority of bioactive LPA detected in blood and at sites of inflammation is produced via the autotaxin-lysophosphatidic acid (ATX-LPA) pathway. ATX, a secreted glycoprotein, primarily functions as lysophospholipase D, removing the choline moiety from lysophosphatidylcholine (LPC), thereby generating LPA.

[0269] LPA, produced via the ATX pathway, is an extracellular signaling molecule that binds to the G protein-coupled receptors LPAR1-6, regulates fibrosis, lymphocyte homing, platelet aggregation, promotes proliferation of vascular smooth muscle cells and fibroblasts, and activates vascular endothelial cells, monocytes, and macrophages.

[0270] Previously used methods to extract LPA species have used HCl in the extraction process; however, such methods have been shown to overestimate the levels of LPA species in samples. In the presence of strong acid, lysophospholipids such as lysophosphatidylcholine (LPC) are converted to LPA by hydrolysis of the choline group from the lysophospholipid (e.g., LPC species), thereby artificially increasing LPA levels in samples. Onorato et al. (J. Lipid Res., 55:1784-1796, 2014) showed that acidifying samples using 6N HCl can overestimate LPA levels by approximately 10-fold.

[0271] LPA is known to have important functions in many pathophysiological conditions. The autotaxin-lysophosphatidic acid (ATX-LPA) pathway is involved in inflammatory lung diseases, including COPD (Shea et al., Proc Am Thorac Soc, 9:102-110, 2012; Magkrioti, World J Respirol, 3:77, 2013). Therefore, accurate measurement of LPA as a potential biomarker is crucial for the diagnosis and prognosis of inflammatory respiratory diseases such as COPD, IPF, and asthma.

[0272] A. Preparation of LPA fraction i. LPA fraction and its preparation method In some aspects, the disclosure features a method for preparing an LPA fraction from a patient, useful for analyzing LPA species involved in inflammatory respiratory diseases, comprising: (a) providing a sample from the patient (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a bronchoalveolar lavage fluid (BALF) sample; or a urine sample), e.g., a sample having a volume of between about 5 μL and about 20 μL; and (b) extracting LPA from the sample of (a) using an extraction buffer containing citric acid and disodium phosphate, where the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the sample. The sample can be a preserved sample, a fresh sample, or a frozen sample. In some aspects, the sample is a serum sample.

[0273] In some aspects, the disclosure features an LPA fraction from a patient produced by a method including: (a) providing a sample from the patient (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a bronchoalveolar lavage fluid (BALF) sample; or a urine sample), e.g., a sample having a volume of between about 5 μL and about 20 μL; and (b) extracting LPA from the sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, where the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample. The sample can be a preserved sample, a fresh sample, or a frozen sample. In some aspects, the sample is a serum sample.

[0274] In some embodiments, the LPA species is one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4, e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0275] ii. Sample In some embodiments, the sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a BALF sample; or a urine sample) has a volume of between about 0.5 μL and about 3 mL, e.g., a volume of 3 mL or less, 2 mL or less, 1 mL or less, 600 μL or less, 500 μL or less, 100 μL or less, 50 μL or less, 20 μL or less, 19 μL or less, 18 μL or less, 17 μL or less, 16 μL or less, 15 μL or less, 14 μL or less, 13 μL or less, 12 μL or less, 11 μL or less, 10 μL or less, 9 μL or less, 8 μL or less, 7 μL or less, 6 μL or less, 5 μL or less, 4 μL or less, 3 μL or less, 2 μL or less, 1 μL or less, or 0.5 μL or less. In some embodiments, the sample has a volume of about 0.5 μL to about 100 μL, for example, about 1 μL to about 80 μL, about 1 μL to about 50 μL, about 5 μL to about 30 μL, or about 5 μL to about 20 μL. In some embodiments, the sample has a volume of about 5 μL to about 100 μL, for example, about 10 μL to about 80 μL, about 10 μL to about 50 μL, about 15 μL to about 30 μL, or about 15 μL to about 25 μL. In some embodiments, the sample has a volume of about 5 μL to about 600 μL, for example, about 10 μL to about 500 μL, about 20 μL to about 400 μL, about 50 μL to about 300 μL, or about 100 μL to about 200 μL. In some embodiments, the sample has a volume of 20 μL.

[0276] In some embodiments, the sample is a serum sample having a volume of between about 0.5 μL and about 3 mL, e.g., a volume of 3 mL or less, 2 mL or less, 1 mL or less, 500 μL or less, 100 μL or less, 50 μL or less, 20 μL or less, 19 μL or less, 18 μL or less, 17 μL or less, 16 μL or less, 15 μL or less, 14 μL or less, 13 μL or less, 12 μL or less, 11 μL or less, 10 μL or less, 9 μL or less, 8 μL or less, 7 μL or less, 6 μL or less, 5 μL or less, 4 μL or less, 3 μL or less, 2 μL or less, 1 μL or less, or 0.5 μL or less. In some embodiments, the serum sample has a volume of about 0.5 μL to about 100 μL, for example, about 1 μL to about 80 μL, about 1 μL to about 50 μL, about 5 μL to about 30 μL, or about 5 μL to about 20 μL. In some embodiments, the serum sample has a volume of about 5 μL to about 100 μL, for example, about 10 μL to about 80 μL, about 10 μL to about 50 μL, about 15 μL to about 30 μL, or about 15 μL to about 25 μL. In some embodiments, the serum sample has a volume of about 5 μL to about 600 μL, for example, about 10 μL to about 500 μL, about 20 μL to about 400 μL, about 50 μL to about 300 μL, or about 100 μL to about 200 μL. In some embodiments, the serum sample has a volume of 20 μL.

[0277] In some embodiments, the sample is taken from a fasted patient, for example, a patient who has fasted for at least 4 hours, at least 6 hours, at least 8 hours, at least 10 hours, at least 12 hours, or more than 12 hours prior to sample collection.

[0278] iii.Extraction buffer In some embodiments, the extraction buffer in step (b) contains about 25 mM to about 35 mM citric acid, e.g., about 26 mM to 34 mM, 27 mM to 33 mM, 28 mM to 32 mM, 29 mM to 31 mM, 29.5 mM to 30.5 mM, or 29.9 mM to 30.1 mM citric acid, e.g., about 25 mM, 26 mM, 27 mM, 28 mM, 29 mM, 29.1 mM, 29 In some embodiments, the extraction buffer of step (b) comprises about 27 mM to about 33 mM citric acid.

[0279] In some embodiments, the extraction buffer contains about 35 mM to about 45 mM disodium phosphate, e.g., about 36 mM to 44 mM, 37 mM to 43 mM, 38 mM to 42 mM, 39 mM to 41 mM, 39.5 mM to 40.5 mM, or 39.9 mM to 40.1 mM disodium phosphate, e.g., 35 mM, 36 mM, 37 mM, 38 mM, 39 mM, 39.1 mM, In some embodiments, the extraction buffer of step (b) comprises about 30 mM citric acid and 40 mM disodium phosphate.

[0280] In some embodiments, the extraction buffer does not contain hydrochloric acid.

[0281] B. Method for separating LPA species from the LPA fraction In some embodiments, the methods described herein further comprise step (c) of separating LPA species from the fraction of LPA extracted in step (b), e.g., separating one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4) from the fraction of LPA extracted in step (b). In some embodiments, the separation in (c) is by liquid chromatography, e.g., high-performance liquid chromatography (HPLC). HPLC can be performed using a reverse-phase column, e.g., a C18 column.

[0282] In some aspects, the disclosure features a method of analyzing an LPA fraction produced using a method described herein, the method including separating LPA species (e.g., separating one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4) from the LPA fraction, e.g., separating the species using liquid chromatography, e.g., HPLC (e.g., HPLC performed using a reverse-phase column, e.g., a C18 column).

[0283] In some aspects, the disclosure features purified LPA species produced by a method including: (a) providing a sample from a patient (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a bronchoalveolar lavage fluid (BALF) sample; or a urine sample), wherein the sample has a volume of between about 5 μL and about 20 μL; (b) extracting LPA from the sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, wherein the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample; and (c) separating the species using liquid chromatography, e.g., HPLC (e.g., HPLC performed using a reverse-phase column, e.g., a C18 column). The isolated LPA species may be one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4), such as one, two, three, four, five, six, seven, or all eight of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4, or one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4). In some embodiments, the sample is a serum sample.

[0284] C. Methods for Analyzing LPA Species In some aspects of the methods described herein, the method analyzes, e.g., the identity, amount, and / or level of LPA species in the sample, e.g., analyzes the identity, amount, and / or level of one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4). The method further includes a step (d) of analyzing the separated LPA species produced in step (c), for example, analyzing one, two, three, four, five, six, seven, or all eight of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4, or analyzing one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0285] The disclosure features a method for analyzing LPA species in a serum sample from a patient, the method including: (a) providing a sample from the patient (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a bronchoalveolar lavage fluid (BALF) sample; or a urine sample; e.g., a serum sample described in Section IIA(ii)); (b) extracting LPA from the sample of (a) using an extraction buffer comprising citric acid and disodium phosphate (e.g., an extraction buffer described in Section IIA(iii)), where the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the sample; (c) separating the LPA species from the fraction of LPA extracted in (b) (e.g., separating the LPA species as described in Section IIB); and (d) analyzing the separated LPA species produced in (c).

[0286] In some embodiments, the analysis is by mass spectrometry, for example, mass spectrometry performed using negative ionization mode.

[0287] In some embodiments, the limit of detection (LOD) of the LPA species is less than 0.05 pmol / μL serum, e.g., less than 0.01 pmol / μL serum, less than 0.009 pmol / μL serum, less than 0.008 pmol / μL serum, less than 0.007 pmol / μL serum, less than 0.006 pmol / μL serum, less than 0.005 pmol / μL serum, less than 0.004 pmol / μL serum, less than 0.003 pmol / μL serum, less than 0.002 pmol / μL serum, less than 0.001 pmol / μL serum, or less than 0.0001 pmol / μL serum. In some embodiments, the LOD of the LPA species is less than 0.008 pmol / μL serum. In some embodiments, the LOD of the LPA species is less than 0.002 pmol / μL serum. In some embodiments, the LOD of the LPA species is between 0.0001 pmol / μL serum and 0.05 pmol / μL serum, e.g., between 0.001 pmol / μL serum and 0.01 pmol / μL serum, between 0.001 pmol / μL serum and 0.009 pmol / μL serum, or between 0.002 pmol / μL serum and 0.008 pmol / μL serum.

[0288] In some embodiments, the absolute recovery of LPA species from a sample is between 75% and 125%, e.g., about 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1100%, 1111%, 1120%, 1122%, 1123%, 1124%, 1125%, 1126%, 1127%, 1128%, 1129%, 1130%, 1131%, 1132%, 1133%, 1134%, 1135%, 1136%, 1137%, 1138%, 1139%, 1140%, 1141%, 1142%, 1143%, 1144%, 1145%, 1146%, 1147%, 1148%, 1149%, 1150%, 1151%, 1152%, 1153%, 1154%, 1155%, 1156%, 1157%, 1158%, 1159%, 1160%, 1161%, 1162%, 1163%, 1164%, 1165%, 1166%, 1167%, 1168%, 1169%, 1170%, 1171%, 1172%, 1173 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, or 125%, e.g., between 80% and 110%, between 82% and 110%, or between 82% and 102%. In some embodiments, the absolute recovery of LPA species from the sample is between 82% and 110%.

[0289] III. Diagnostic and Therapeutic Methods A. Methods for diagnosing COPD and asthma i. LPA biomarkers for increased risk of exacerbation In some aspects, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) may be at high risk for an exacerbation (e.g., an exacerbation of a respiratory disease described in Section IIIE herein), comprising measuring a level of one or more of lysophosphatidic acid (LPA) 16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 (e.g., a baseline level of one or more LPA species) in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as a patient at high risk for an exacerbation; diagnoses the patient as a patient at high risk for an exacerbation; or predicts that the patient is a patient at high risk for an exacerbation. In some aspects, the inflammatory respiratory disease is COPD. In some embodiments, the inflammatory respiratory disease is asthma, and the method includes measuring levels of one or more of LPA16:0, LPA18:0, and LPA18:2, for example, one, two, or all three of LPA16:0, LPA18:0, and LPA18:2 (e.g., baseline levels of one or more of LPA16:0, LPA18:0, and LPA18:2) in a sample from the patient.

[0290] In some aspects, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient having an inflammatory respiratory disease will benefit from a treatment comprising an exacerbation-reducing agent (e.g., an agent described in Section IIIG herein), comprising measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as a patient who may benefit from a treatment comprising an exacerbation-reducing agent. In some aspects, the inflammatory respiratory disease is COPD. In some embodiments, the inflammatory respiratory disease is asthma, and the method includes measuring levels of one or more of LPA16:0, LPA18:0, and LPA18:2, for example, one, two, or all three of LPA16:0, LPA18:0, and LPA18:2 (e.g., baseline levels of one or more of LPA16:0, LPA18:0, and LPA18:2) in a sample from the patient.

[0291] In some aspects, the disclosure features a method of selecting a therapy for a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), comprising measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as one who may benefit from a therapy comprising an agent that reduces exacerbations. In some aspects, the inflammatory respiratory disease is COPD. In some embodiments, the inflammatory respiratory disease is asthma, and the method includes measuring levels of one or more of LPA16:0, LPA18:0, and LPA18:2, for example, one, two, or all three of LPA16:0, LPA18:0, and LPA18:2 (e.g., baseline levels of one or more of LPA16:0, LPA18:0, and LPA18:2) in a sample from the patient.

[0292] In some embodiments, the benefit includes an increase in the patient's time to exacerbation compared to treatment without the exacerbation-reducing agent, for example, an increase of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, or more than 1 year in the patient's time to first exacerbation or time to next exacerbation.

[0293] In some embodiments, benefit includes a reduction in the duration of a patient's exacerbation compared to treatment without the exacerbation-reducing agent, including, for example, a reduction in the duration of an exacerbation by at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, or more than 1 year. In some embodiments, a reduction in the duration of an exacerbation is a reduction in the duration of an exacerbation by at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months.

[0294] In some embodiments, the benefit includes a reduction in the frequency and / or duration of hospitalizations, hi some embodiments, the benefit includes a reduction in the use of therapeutic agents, such as systemic corticosteroids or antibiotics.

[0295] In some aspects, the disclosure features a method for identifying a patient suitable for administration of an agent that treats an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) or reduces an exacerbation of an inflammatory respiratory disease (e.g., an agent described in Section IIIG herein), the method comprising measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as suitable for administration of an agent that treats an inflammatory respiratory disease or reduces an exacerbation of an inflammatory respiratory disease. In some aspects, the inflammatory respiratory disease is COPD. In some embodiments, the inflammatory respiratory disease is asthma, and the method includes measuring levels of one or more of LPA16:0, LPA18:0, and LPA18:2, for example, one, two, or all three of LPA16:0, LPA18:0, and LPA18:2 (e.g., baseline levels of one or more of LPA16:0, LPA18:0, and LPA18:2) in a sample from the patient.

[0296] In some embodiments, the patient has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level (e.g., a level of one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4), and the method further includes administering to the patient an effective amount of an agent that reduces an exacerbation (e.g., an agent described in Section IIIG herein). In some embodiments, the patient has a level of one or more of LPA16:0, LPA18:0, and LPA18:2 in the sample that is less than a reference level (e.g., a level of one, two, or all three of LPA16:0, LPA18:0, and LPA18:2), and the method further includes administering to the patient an effective amount of an agent that reduces exacerbations (e.g., an agent described in Section IIIG of the present specification).

[0297] The sample can be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a bronchoalveolar lavage fluid (BALF) sample; or a urine sample. The sample can be, for example, a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0298] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4, e.g., a level measured when the patient is not experiencing an exacerbation, e.g., when recovered from an exacerbation, or when the patient has never experienced an exacerbation.

[0299] In some embodiments, one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4), such as LPA14:0, LPA16: The levels of one, two, three, four, five, six, seven, or all eight of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4, or one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4) are less than the reference levels.

[0300] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0301] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0302] In some embodiments, the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM, hi some embodiments, the reference level of LPA16:0 is about 0.14 μM.

[0303] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0304] In some embodiments, the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM, hi some embodiments, the reference level of LPA18:1 is about 0.12 μM.

[0305] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0306] In some embodiments, the reference level of LPA20:4 is between about 9 μM and about 13 μM, hi some embodiments, the reference level of LPA20:4 is about 10.9 μM.

[0307] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, or 50th percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population. ile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0308] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0309] In some embodiments, the level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 in the sample from the patient (e.g., the baseline level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 in the patient) is at or below the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 in a reference population, e.g., at or below the 32nd percentile, at or below the 31st percentile, at or below the 30th percentile, at or below the 29th percentile, at or below the 28th percentile, at or below the 27th percentile of the levels of LPA16:0, LPA18:0, LPA18:1, LPA18:2, or LPA20:4, respectively, in a reference population. The 26th percentile or less, the 25th percentile or less, the 24th percentile or less, the 23rd percentile or less, the 22nd percentile or less, the 21st percentile or less, the 20th percentile or less, the 19th percentile or less, the 18th percentile or less, the 17th percentile or less, the 16th percentile or less, the 15th percentile or less, the 14th percentile or less, the 13th percentile or less, the 12th percentile or less, the 11th percentile or less, the 10th percentile or less, the 9th percentile or less, the 8th percentile or less, the 7th percentile or less, the 6th percentile or less, the 5th percentile or less, the 4th percentile or less, the 3rd percentile or less, the 2nd percentile or less, or the 1st percentile or less.

[0310] In some embodiments, the reference level of LPA20:4 is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile of the level of LPA20:4 in a reference population. percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0311] In some embodiments, the reference level of LPA20:4 is the 67th percentile of LPA20:4 levels in a reference population.

[0312] In some embodiments, the level of LPA20:4 in the sample from the patient (e.g., the baseline level of LPA20:4 in the patient) is less than or equal to the 67th percentile of the level of LPA20:4 in a reference population, e.g., less than or equal to the 66th percentile, less than or equal to the 65th percentile, less than or equal to the 64th percentile, less than or equal to the 63rd percentile, less than or equal to the 62nd percentile, less than or equal to the 61st percentile, less than or equal to the 60th percentile, less than or equal to the 59th percentile, or less than or equal to the 58th percentile of the level of LPA20:4 in a reference population. , 57th percentile or less, 56th percentile or less, 55th percentile or less, 54th percentile or less, 53rd percentile or less, 52nd percentile or less, 51st percentile or less, 50th percentile or less, 49th percentile or less, 48th percentile or less, 47th percentile or less, 46th percentile or less, 45th percentile or less, 44th percentile or less, 43rd percentile or less, 42nd percentile or less, 41st percentile or less, 40th percentile or less, 39th percentile or less Below, 38th percentile or below, 37th percentile or below, 36th percentile or below, 35th percentile or below, 34th percentile or below, 33rd percentile or below, 32nd percentile or below, 31st percentile or below, 30th percentile or below, 29th percentile or below, 28th percentile or below, 27th percentile or below, 26th percentile or below, 25th percentile or below, 24th percentile or below, 23rd percentile or below, 22nd percentile or below, 21st percentile or below, 20th percentile or below, 19th percentile or below, 18th percentile or below, 17th percentile or below, 16th percentile or below, 15th percentile or below, 14th percentile or below, 13th percentile or below, 12th percentile or below, 11th percentile or below, 10th percentile or below, 9th percentile or below, 8th percentile or below, 7th percentile or below, 6th percentile or below, 5th percentile or below, 4th percentile or below, 3rd percentile or below, 2nd percentile or below, or 1st percentile or below.

[0313] ii. LPA biomarker for reducing the risk of COPD and asthma exacerbations In some aspects, the disclosure features a method for predicting the time to next exacerbation in a patient with an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) who has experienced at least one exacerbation in the past 12 months, comprising measuring levels of one or both of LPA18:0 and LPA18:2 in a sample from the patient, wherein levels of one or both of LPA18:0 and LPA18:2 in the sample that are greater than a reference level identify the patient as one who is likely to experience an increased time to next exacerbation. In some aspects, the inflammatory respiratory disease is COPD.

[0314] In some embodiments, the patient has levels of one or both of LPA18:0 and LPA18:2 in the sample that are above the reference level, and the method further includes maintaining the patient's treatment regimen and / or reducing patient monitoring.

[0315] In some embodiments, the increase in time to next exacerbation is at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 15 days, at least 20 days, at least 25 days, at least 30 days, at least 35 days, at least 40 days, at least 45 days, at least 50 days, at least 55 days, at least 60 days, at least 65 days, at least 70 days, at least 75 days, at least 80 days, at least 85 days, at least 90 days, at least 100 days, at least 110 days, at least 120 days, at least 130 days, at least 140 days, at least 150 days, at least 160 days, at least 170 days, at least 180 days, at least 190 days, at least 200 days, at least 210 days , at least 220 days, at least 230 days, at least 240 days, at least 250 days, at least 260 days, at least 270 days, at least 280 days, at least 290 days, at least 300 days, at least 1 year, or more than 1 year, for example, 1 to 20 days, 20 to 40 days, 40 to 60 days, 60 to 80 days, 80 to 100 days, 100 to 120 days, 120 to 140 days, 140 to 180 days, 180 to 200 days, 200 The increase in time to next exacerbation is an increase of at least 220 days, 220 to 240 days, 240 to 260 days, 260 to 280 days, 280 to 300 days, 300 to 320 days, 320 to 340 days, 340 to 360 days, 360 to 380 days, 380 to 400 days, 400 to 420 days, 420 to 440 days, 440 to 460 days, 460 to 480 days, 480 to 500 days, 500 to 520 days, 520 to 540 days, 540 to 560 days, 560 to 580 days, or 580 to 600 days. In some embodiments, the increase in time to next exacerbation is an increase of at least 100 days.

[0316] The sample can be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a bronchoalveolar lavage fluid (BALF) sample; or a urine sample. The sample can be, for example, a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0317] In some embodiments, the levels of one or both of LPA18:0 and LPA18:2 are baseline levels of one or both of LPA18:0 and LPA18:2, e.g., levels measured when the patient is not experiencing an exacerbation.

[0318] In some embodiments, the reference level is a pre-assigned level of one or both of LPA18:0 and LPA18:2.

[0319] In some embodiments, the reference level is the level of one or more of LPA18:0 and LPA18:2 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0320] In some embodiments, the reference level of LPA18:0 is between about 0.03 μM and about 0.05 μM, hi some embodiments, the reference level of LPA18:0 is about 0.04 μM.

[0321] In some embodiments, the reference level of LPA18:2 is between about 0.68 μM and about 0.84 μM, hi some embodiments, the reference level of LPA18:2 is about 0.76 μM.

[0322] In some embodiments, the reference level of LPA18:0 or LPA18:2 is the 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile of the level of LPA18:0 or LPA18:2, respectively, in a reference population. , 72nd percentile, 73rd percentile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0323] In some embodiments, the reference level of LPA18:0 or LPA18:2 is the 67th percentile of the levels of LPA16:0, LPA18:0 or LPA18:2, respectively, in a reference population.

[0324] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0325] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0326] In some embodiments, the reference level of LPA18:0 or LPA18:2 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, 46th percentile, 47th percentile, or the 28th percentile of the level of LPA18:0 or LPA18:2, respectively, in a reference population. percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0327] In some embodiments, the reference level of LPA18:0 or LPA18:2 is the 33rd percentile of the levels of LPA16:0, LPA18:0 or LPA18:2, respectively, in a reference population.

[0328] In some embodiments, the level of LPA18:0 or LPA18:2 in the sample from the patient (e.g., the baseline level of LPA18:0 or LPA18:2 in the sample from the patient) is greater than or equal to the 67th percentile of the levels of LPA18:0 or LPA18:2 in a reference population, e.g., greater than or equal to the 68th percentile, greater than or equal to the 69th percentile, greater than or equal to the 70th percentile, greater than or equal to the 71st percentile, greater than or equal to the 72nd percentile, greater than or equal to the 73rd percentile, greater than or equal to the 74th percentile, greater than or equal to the 75th percentile, greater than or equal to the 76th percentile, greater than or equal to the 77th percentile of the levels of LPA18:0 or LPA18:2, respectively, in a reference population. or above the 78th percentile, or above the 79th percentile, or above the 80th percentile, or above the 81st percentile, or above the 82nd percentile, or above the 83rd percentile, or above the 84th percentile, or above the 85th percentile, or above the 86th percentile, or above the 87th percentile, or above the 88th percentile, or above the 89th percentile, or above the 90th percentile, or above the 91st percentile, or above the 92nd percentile, or above the 93rd percentile, or above the 94th percentile, or above the 95th percentile, or above the 96th percentile, or above the 97th percentile, or above the 98th percentile, or above the 99th percentile.

[0329] iii. LPC, sphingomyelin, and ceramide biomarkers for COPD and asthma In some aspects, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) may be at high risk for an exacerbation, comprising measuring levels of one or more of LPC, sphingomyelin, and ceramide (e.g., hexosylceramide (HCER) or lactosylceramide (LCER)) in a sample from the patient, wherein a level of LPC in the sample that is less than a reference level and / or a level of one or both of sphingomyelin and ceramide (e.g., HCER or LCER) in the sample that is greater than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for an exacerbation. In some aspects, the inflammatory respiratory disease is COPD.

[0330] In some embodiments, the LPC is LPC(16:0) or LPC(18:2).

[0331] In some aspects, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient having an inflammatory respiratory disease is likely to benefit from a treatment comprising an exacerbation-reducing agent (e.g., an agent described in Section IIIG herein), comprising measuring levels of one or more of LPC, sphingomyelin, and ceramide (e.g., HCER or LCER) in a sample from the patient, wherein a level of LPC in the sample that is less than a reference level and / or a level of one or both of sphingomyelin and ceramide (e.g., HCER or LCER) in the sample that is greater than a reference level identifies, diagnoses, and / or predicts the patient as a patient that is likely to benefit from a treatment comprising an exacerbation-reducing agent. In some aspects, the inflammatory respiratory disease is COPD.

[0332] In some aspects, the disclosure features a method of selecting a therapy for a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), comprising measuring levels of one or more of LPC, sphingomyelin, and ceramide in a sample from the patient, wherein a level of LPC in the sample that is less than a reference level and / or a level of one or both of sphingomyelin and ceramide (e.g., HCER or LCER) in the sample that is greater than a reference level identifies the patient as one that is likely to benefit from a therapy comprising an agent that reduces exacerbations. In some aspects, the inflammatory respiratory disease is COPD.

[0333] In some embodiments, the benefit includes an increase in the patient's time to exacerbation compared to treatment without the exacerbation-reducing agent, for example, an increase of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, or more than 1 year in the patient's time to first exacerbation or time to next exacerbation.

[0334] In some embodiments, the benefit includes a reduction in the duration of a patient's exacerbation compared to treatment without the exacerbation-reducing agent, for example, a reduction in the duration of an exacerbation by at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, or more than 1 year.

[0335] In some aspects, the disclosure features a method for identifying a patient suitable for administration of an agent that treats an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) or an agent that reduces an exacerbation of an inflammatory respiratory disease (e.g., an agent described in Section IIIG herein), the method comprising measuring levels of one or more of LPC, sphingomyelin, and ceramide (e.g., HCER or LCER) in a sample from the patient, wherein a level of LPC in the sample that is less than a reference level and / or a level of one or both of sphingomyelin and ceramide in the sample that is greater than a reference level identifies the patient as suitable for administration of an agent that treats an inflammatory respiratory disease or an agent that reduces an exacerbation of an inflammatory respiratory disease. In some aspects, the inflammatory respiratory disease is COPD.

[0336] In some embodiments, the patient has a level of LPC (e.g., LPC(16:0) or LPC(18:2)) in the sample that is less than a reference level, and / or a level of one or both of sphingomyelin and ceramide (e.g., HCER or LCER) in the sample that is greater than a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces an exacerbation.

[0337] In some embodiments, the benefit includes a reduction in the duration of a patient's exacerbation compared to treatment without the exacerbation-reducing agent, for example, a reduction in the duration of an exacerbation by at least 10 minutes, at least 20 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 6 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, or more than 1 year.

[0338] The sample can be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some embodiments, the sample is a BALF sample or a urine sample. The sample can be a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0339] In some aspects, the levels of one or more of LPC, sphingomyelin, and ceramide (e.g., HCER or LCER) are baseline levels of one or more of LPC (e.g., LPC(16:0) or LPC(18:2)), sphingomyelin, and ceramide, e.g., levels measured when the patient is not experiencing an exacerbation.

[0340] In some aspects, the reference level is a pre-assigned level of one or more of LPC (eg, LPC(16:0) or LPC(18:2)), sphingomyelin, and ceramide.

[0341] In some embodiments, the reference level is the level of one or more of LPC (e.g., LPC(16:0) or LPC(18:2)), sphingomyelin, and ceramide (e.g., HCER or LCER) in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0342] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is between about 227 nmol / mL and about 277 nmol / mL. In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is about 252 nmol / mL.

[0343] In some embodiments, the reference level of sphingomyelin is between about 448 nmol / mL and about 548 nmol / mL, hi some embodiments, the reference level of sphingomyelin is about 498 nmol / mL.

[0344] In some embodiments, the ceramide is hexosylceramide (HCER). In some embodiments, the reference level of HCER is between about 6.1 nmol / mL and about 7.5 nmol / mL. In some embodiments, the reference level of HCER is about 6.8 nmol / mL.

[0345] In some embodiments, the ceramide is lactosylceramide (LCER). In some embodiments, the reference level of LCER is between about 4.3 nmol / mL and about 5.3 nmol / mL. In some embodiments, the reference level of LCER is about 4.8 nmol / mL. In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0346] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 33rd percentile of LPC (e.g., LPC(16:0) or LPC(18:2)) levels in a reference population.

[0347] In some embodiments, the reference level of sphingomyelin or ceramide (e.g., HCER or LCER) is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, or 74th percentile of the level of sphingomyelin or ceramide, respectively, in a reference population. ile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0348] In some embodiments, the reference level of sphingomyelin or ceramide (eg, HCER and / or LCER) is the 67th percentile of the levels of sphingomyelin or ceramide, respectively, in a reference population.

[0349] In some embodiments, the level of LPC (e.g., LPC(16:0) or LPC(18:2)) (e.g., the baseline level of LPC (e.g., LPC(16:0) or LPC(18:2)) in the patient) is less than or equal to the 33rd percentile of the levels of LPC (e.g., LPC(16:0) or LPC(18:2)) in a reference population, e.g., less than or equal to the 32nd percentile, less than or equal to the 31st percentile, less than or equal to the 30th percentile, less than or equal to the 29th percentile, less than or equal to the 28th percentile, less than or equal to the 27th percentile, less than or equal to the 26th percentile, less than or equal to the 25th percentile of the levels of LPC (e.g., LPC(16:0) or LPC(18:2)) in a reference population. percentile or less, 24th percentile or less, 23rd percentile or less, 22nd percentile or less, 21st percentile or less, 20th percentile or less, 19th percentile or less, 18th percentile or less, 17th percentile or less, 16th percentile or less, 15th percentile or less, 14th percentile or less, 13th percentile or less, 12th percentile or less, 11th percentile or less, 10th percentile or less, 9th percentile or less, 8th percentile or less, 7th percentile or less, 6th percentile or less, 5th percentile or less, 4th percentile or less, 3rd percentile or less, 2nd percentile or less, or 1st percentile or less.

[0350] In some embodiments, the level of sphingomyelin or ceramide (e.g., HCER and / or LCER) (e.g., the patient's baseline level of sphingomyelin or ceramide) is greater than or equal to the 67th percentile of sphingomyelin or ceramide levels in a reference population, e.g., greater than or equal to the 68th percentile, greater than or equal to the 69th percentile, greater than or equal to the 70th percentile, greater than or equal to the 71st percentile, greater than or equal to the 72nd percentile, greater than or equal to the 73rd percentile, greater than or equal to the 74th percentile, greater than or equal to the 76th percentile, greater than or equal to the 77th percentile, greater than or equal to the 78th percentile, greater than or equal to the 79th percentile, greater than or equal to the 80th percentile, greater than or equal to the 81st percentile, greater than or equal to the 82nd percentile, greater than or equal to the 83rd percentile, greater than or equal to the 84th percentile, greater than or equal to the 85th percentile, greater than or equal to the 86th percentile, greater than or equal to the 87th percentile, greater than or equal to the 88th percentile, greater than or equal to the 89th percentile, greater than or equal to the 90th percentile, greater than or equal to the 91st percentile, greater than or equal to the 92nd percentile, greater than or equal to the 93rd percentile, greater than or equal to the 94th percentile, greater than or equal to the 95th percentile, greater than or equal to the 96th percentile, greater than or equal to the 97th percentile, greater than or equal to the 98th percentile, greater than or equal to the 99th percentile, greater than or equal to the 99th percentile, or above the 8th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0351] B. Methods for Treating COPD and Asthma i. LPA biomarker for COPD and asthma In some aspects, the disclosure features a method of treating a patient with an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), the method including: (a) measuring the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is less than a reference level; and (b) administering to the patient an effective amount of an agent that reduces an exacerbation. In some aspects, the inflammatory respiratory disease is COPD or IPF. In some embodiments, the inflammatory respiratory disease is asthma, and the level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient, for example, one, two, or all three of LPA16:0, LPA18:0, and LPA18:2, is below the reference level.

[0352] In some aspects, the disclosure features a method of treating a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) and having a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is below a reference level, the method comprising administering to the patient an effective amount of an exacerbation-reducing agent. In some aspects, the inflammatory respiratory disease is asthma, and the level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient, e.g., one, two, or all three of LPA16:0, LPA18:0, and LPA18:2, is below a reference level.

[0353] In some aspects, the disclosure features a method of treating a patient with an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), comprising administering to the patient an effective amount of an agent that reduces an exacerbation, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be below a reference level. In some aspects, the inflammatory respiratory disease is asthma, and the level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient, e.g., one, two, or all three of LPA16:0, LPA18:0, and LPA18:2, has been determined to be below a reference level.

[0354] In some aspects, the disclosure features a method of reducing exacerbations in a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), the method including: (a) measuring the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is less than a reference level; and (b) administering to the patient an effective amount of an agent that reduces the exacerbation. In some embodiments, the inflammatory respiratory disease is asthma, and the level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient, for example, one, two, or all three of LPA16:0, LPA18:0, and LPA18:2, is below the reference level.

[0355] In some aspects, the disclosure features a method of reducing exacerbations in a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) and having levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that are below reference levels, the method comprising administering to the patient an exacerbation-reducing effective amount of an agent. In some aspects, the inflammatory respiratory disease is asthma, and the patient has levels of one or more of LPA16:0, LPA18:0, and LPA18:2, e.g., one, two, or all three of LPA16:0, LPA18:0, and LPA18:2, in a sample from the patient that are below reference levels.

[0356] In some aspects, the disclosure features a method of reducing an exacerbation in a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), comprising administering to the patient an exacerbation-reducing effective amount of an agent, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be below a reference level. In some aspects, the inflammatory respiratory disease is asthma, and the level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient, e.g., one, two, or all three of LPA16:0, LPA18:0, and LPA18:2, has been determined to be below a reference level.

[0357] In some embodiments, the patient has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level (e.g., a level of one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4).

[0358] The sample can be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a bronchoalveolar lavage fluid (BALF) sample; or a urine sample. The sample can be, for example, a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0359] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4, e.g., a level measured when the patient is not experiencing an exacerbation.

[0360] In some embodiments, one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4), such as LPA14:0, LPA16: The levels of one, two, three, four, five, six, seven, or all eight of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4, or one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4) are less than the reference levels.

[0361] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0362] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD), IPF, or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0363] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD), IPF, or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0364] In some embodiments, the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM, hi some embodiments, the reference level of LPA16:0 is about 0.14 μM.

[0365] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0366] In some embodiments, the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM, hi some embodiments, the reference level of LPA18:1 is about 0.12 μM.

[0367] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0368] In some embodiments, the reference level of LPA20:4 is between about 9 μM and about 13 μM, hi some embodiments, the reference level of LPA20:4 is about 10.9 μM.

[0369] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, or 50th percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population. ile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0370] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0371] In some embodiments, the reference level of LPA20:4 is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile of the level of LPA20:4 in a reference population. percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0372] In some embodiments, the reference level of LPA20:4 is the 67th percentile of LPA20:4 levels in a reference population.

[0373] ii. Lipid biomarkers for COPD and asthma In some aspects, the disclosure features a method of treating a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), the method including: (a) measuring the level of one or more of LPC, sphingomyelin, and ceramide (e.g., HCER and / or LCER) in a sample from the patient, wherein the level of LPC in the sample is below a reference level and / or the level of one or both of sphingomyelin and ceramide in the sample is above a reference level; and (b) administering to the patient an effective amount of an agent that reduces an exacerbation. In some aspects, the inflammatory respiratory disease is COPD or IPF.

[0374] In some aspects, the disclosure features a method of treating a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) and having a level of LPC in the sample that is below a reference level and / or a level of one or both of sphingomyelin and ceramide (e.g., HCER or LCER) in the sample that is above a reference level, the method comprising administering to the patient an effective amount of an agent that reduces an exacerbation.

[0375] In some aspects, the disclosure features a method of treating a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), comprising administering to the patient an effective amount of an agent that reduces an exacerbation, wherein the level of LPC in the sample has been determined to be below a reference level, and / or the level of one or both of sphingomyelin and ceramide (e.g., HCER or LCER) in the sample has been determined to be above the reference level.

[0376] In some aspects, the disclosure features a method of reducing an exacerbation in a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), the method including: (a) measuring the level of one or more of LPC, sphingomyelin, and ceramide (e.g., HCER or LCER) in a sample from the patient, wherein the level of LPC in the sample is less than a reference level and / or the level of one or both of sphingomyelin and ceramide in the sample is greater than a reference level; and (b) administering to the patient an effective amount of an agent that reduces an exacerbation.

[0377] In some aspects, the disclosure features a method of reducing an exacerbation in a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) and having a level of LPC in a sample from the patient that is below a reference level and / or a level of one or both of sphingomyelin and ceramide (e.g., HCER or LCER) in a sample from the patient that is above a reference level, the method comprising administering to the patient an effective amount of an agent that reduces an exacerbation.

[0378] In some aspects, the disclosure features a method of reducing an exacerbation in a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), comprising administering to the patient an exacerbation-reducing effective amount of an agent, wherein the level of LPC in a sample from the patient has been determined to be below a reference level, and / or the level of one or both of sphingomyelin and ceramide (e.g., HCER or LCER) in the sample from the patient has been determined to be above a reference level.

[0379] The sample can be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof; a bronchoalveolar lavage fluid (BALF) sample; or a urine sample. The sample can be, for example, a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0380] In some embodiments, the level of one or more of LPC, sphingomyelin, and ceramide is a baseline level of one or more of LPC, sphingomyelin, and ceramide, e.g., a level measured when the patient is not experiencing an exacerbation.

[0381] In some embodiments, the reference level is a pre-assigned level of one or more of LPC, sphingomyelin, and ceramide.

[0382] In some embodiments, the reference level is the level of one or more of LPC, sphingomyelin, and ceramide in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD), IPF, or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0383] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is between about 227 nmol / mL and about 277 nmol / mL. In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is about 252 nmol / mL.

[0384] In some embodiments, the reference level of sphingomyelin is between about 448 nmol / mL and about 548 nmol / mL, hi some embodiments, the reference level of sphingomyelin is about 498 nmol / mL.

[0385] In some embodiments, the ceramide is hexosylceramide (HCER). In some embodiments, the reference level of HCER is between about 6.1 nmol / mL and about 7.5 nmol / mL. In some embodiments, the reference level of HCER is about 6.8 nmol / mL.

[0386] In some embodiments, the ceramide is lactosylceramide (LCER). In some embodiments, the reference level of LCER is between about 4.3 nmol / mL and about 5.3 nmol / mL. In some embodiments, the reference level of LCER is about 4.8 nmol / mL.

[0387] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0388] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 33rd percentile of LPC (e.g., LPC(16:0) or LPC(18:2)) levels in a reference population.

[0389] In some embodiments, the reference level of sphingomyelin or ceramide (e.g., HCER or LCER) is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, or 74th percentile of the level of sphingomyelin or ceramide, respectively, in a reference population. ile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0390] C. Methods for diagnosing and treating IPF i. LPA biomarkers for increased risk of exacerbations or respiratory hospitalization In one aspect, the disclosure provides a method for identifying, diagnosing, and / or predicting whether a patient with idiopathic pulmonary fibrosis (IPF) may be at increased risk for an IPF exacerbation (e.g., an IPF exacerbation as described in Section IIIE herein) or respiratory hospitalization, comprising measuring levels of one or more of lysophosphatidic acid (LPA) 16:0, LPA 18:1, LPA 18:2, and LPA 20:4 in a sample from the patient (e.g., measuring levels of one or more of LPA 16:0, LPA 18:1, LPA 18:2, and LPA 20:4 in a sample from the patient). and measuring the levels of one, two, three, or all four of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample, wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies the patient as being at high risk for exacerbation or respiratory hospitalization; diagnoses the patient as being at high risk for exacerbation or respiratory hospitalization; or predicts that the patient is being at high risk for exacerbation or respiratory hospitalization.

[0391] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with IPF will benefit from a treatment including an agent that reduces exacerbations, the method comprising measuring levels of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient (e.g., measuring levels of one, two, three, or all four of LPA16:0, LPA18:1, LPA18:2, and LPA20:4), wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as one who may benefit from a treatment including an agent that reduces exacerbations.

[0392] In another aspect, the disclosure features a method of selecting a therapy for a patient with IPF, the method including measuring levels of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient (e.g., measuring levels of one, two, three, or all four of LPA16:0, LPA18:1, LPA18:2, and LPA20:4), wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies the patient as one who is likely to benefit from treatment including an agent that reduces exacerbations (e.g., an agent described in Section IIIG herein).

[0393] In some embodiments, the patient has a level of one or more of LPA16:0, LPA18:0, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level (e.g., a level of one, two, three, or all four of LPA16:0, LPA18:1, LPA18:2, and LPA20:4), and the method further includes administering to the patient an effective amount of an agent that reduces an exacerbation.

[0394] In another aspect, the disclosure features a method of treating a patient with IPF, the method including: (a) measuring the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient (e.g., measuring the level of one, two, three, or all four of LPA16:0, LPA18:1, LPA18:2, and LPA20:4), wherein the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is equal to or greater than a reference level; and (b) administering to the patient an effective amount of an agent that reduces an exacerbation.

[0395] The disclosure features a method of treating a patient who has IPF and has a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is equal to or greater than a reference level (e.g., a level of one, two, three, or all four of LPA16:0, LPA18:1, LPA18:2, and LPA20:4), the method comprising administering to the patient an effective amount of an agent that reduces an exacerbation.

[0396] In another aspect, the disclosure features a method of treating a patient with IPF, comprising administering to the patient an effective amount of an agent that reduces an exacerbation, wherein levels of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 (e.g., levels of one, two, three, or all four of LPA16:0, LPA18:1, LPA18:2, and LPA20:4) in a sample from the patient have been determined to be equal to or greater than a reference level.

[0397] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some aspects, the sample is a stored sample, a fresh sample, or a frozen sample. In some aspects, the sample is a serum sample.

[0398] In some embodiments, the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4.

[0399] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4.

[0400] In some embodiments, (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM. In some embodiments, (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

[0401] In some embodiments, (a) the patient is female and the reference level of LPA18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA18:1 is between about 0.078 μM and about 0.118 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

[0402] In some embodiments, (a) the patient is female and the reference level of LPA18:2 is between about 0.388 μM and about 0.428 μM; or (b) the patient is male and the reference level of LPA18:2 is between about 0.339 μM and about 0.379 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:2 is about 0.408 μM; or (b) the patient is male and the reference level of LPA18:2 is about 0.359 μM.

[0403] In some embodiments, (a) the patient is female and the reference level of LPA20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA20:4 is between about 0.110 μM and about 0.150 μM. In some embodiments, (a) the patient is female and the reference level of LPA20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA20:4 is about 0.130 μM.

[0404] In some embodiments, the reference level is the level (eg, median level) of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population.

[0405] In some embodiments, the level of one or more of LPA16:0, LPA18:1, and LPA18:2 in the sample is equal to or greater than the median level of LPA16:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0406] In some embodiments, the reference level of LPA16:0, LPA18:1, LPA18:2, or LPA20:4 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, or 50th percentile of the levels of LPA16:0, LPA18:1, LPA18:2, or LPA20:4, respectively, in a reference population. ile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0407] In some embodiments, the reference population is a population of patients with IPF.

[0408] In some embodiments, the reference population is a population of patients without IPF. In some embodiments, the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is at least twice the reference level, e.g., the reference level in a population of patients without IPF.

[0409] In some embodiments, the benefit includes an increase in the patient's time to exacerbation compared to treatment without the exacerbation-reducing agent, for example, an increase of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, or more than 1 year in the patient's time to first exacerbation or respiratory hospitalization or time to next exacerbation or respiratory hospitalization.

[0410] In some embodiments, the exacerbation is an acute respiratory exacerbation. In some embodiments, the acute respiratory exacerbation is dyspnea. In some embodiments, the acute respiratory exacerbation is not caused by pneumothorax, cancer, heart failure, fluid overload, or pulmonary embolism.

[0411] In some embodiments, the acute respiratory deterioration is associated with a new radiological abnormality, hi some embodiments, the radiological abnormality is bilateral ground-glass opacities / consolidations.

[0412] In some embodiments, the exacerbation is a severe exacerbation.

[0413] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0414] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0415] In some embodiments, the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, acid-reducing therapy, corticosteroids, cyclophosphamide, or a combination thereof.

[0416] In some embodiments, the exacerbation-reducing agent is nintedanib or pirfenidone.

[0417] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority for reducing, controlling, or maintaining an exacerbation. In some embodiments, the regulatory health authority is the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the National Medical Products Administration (NMPA).

[0418] ii. TG biomarkers for increased risk of mortality In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with idiopathic pulmonary fibrosis (IPF) may be at high risk of death, comprising measuring a level of one or both of triglycerides (TG) 48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies the patient as a patient at high risk of death; diagnoses the patient as a patient at high risk of death; or predicts the patient as a patient at high risk of death.

[0419] In another aspect, the disclosure features a method for identifying, diagnosing, and / or predicting whether a patient with IPF will benefit from a treatment including an agent that reduces exacerbations, comprising measuring a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as one that may benefit from a treatment including an agent that reduces exacerbations.

[0420] In another aspect, the disclosure features a method of selecting a therapy for a patient with IPF, comprising measuring a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies the patient as one who is likely to benefit from a treatment including an agent that reduces exacerbations (e.g., an agent described in Section IIIG herein).

[0421] In some embodiments, the patient has a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level, and the method further includes administering to the patient an effective amount of an agent that reduces exacerbation.

[0422] In another aspect, the disclosure features a method of treating a patient with IPF, the method including: (a) measuring the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample is less than a reference level; and (b) administering to the patient an effective amount of an agent that reduces exacerbations.

[0423] The disclosure features a method of treating a patient with IPF and having a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient that is below a reference level, the method comprising administering to the patient an effective amount of an agent that reduces exacerbations.

[0424] In another aspect, the disclosure features a method of treating a patient having IPF, comprising administering to the patient an effective amount of an agent that reduces an exacerbation, wherein the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient has been determined to be below a reference level.

[0425] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0426] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0427] In some embodiments, the sample is a serum sample.

[0428] In some embodiments, the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 is a baseline level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2.

[0429] In some embodiments, the reference level is a pre-assigned level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2.

[0430] In some embodiments, (a) the patient is female and the reference level for TG48:4-FA12:0 is between about 0.800 μM and about 0.840 μM; or (b) the patient is male and the reference level for TG48:4-FA12:0 is between about 1.166 μM and about 1.206 μM. In some embodiments, (a) the patient is female and the reference level for TG48:4-FA12:0 is about 0.820 μM; or (b) the patient is male and the reference level for TG48:4-FA12:0 is about 1.186 μM.

[0431] In some embodiments, (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is between about 1.587 μM and about 1.627 μM; or (b) the patient is male and the reference level (μM) of TG48:4-FA18:2 is between about 2.153 μM and about 2.193 μM. In some embodiments, (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is about 1.607 μM; or (b) the patient is male and the reference level of TG48:4-FA18:2 is about 2.173 μM.

[0432] In some embodiments, the reference level is the level (eg, median level) of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a reference population.

[0433] In some embodiments, the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample is less than the median level of TG48:4-FA12:0 and TG48:4-FA18:2, respectively, in a reference population.

[0434] In some embodiments, the reference level of TG48:4-FA12:0 or TG48:4-FA18:2 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0435] In some embodiments, the reference population is a population of patients with IPF.

[0436] In some embodiments, the reference population is a population of patients without IPF, hi some embodiments, the level of one or both of TG48:4-FA12:0 or TG48:4-FA18:2 in the sample is at least half the reference level, e.g., the reference level in a population of patients without IPF.

[0437] In some embodiments, the benefit includes an increase in the time to death of the patient compared to treatment without the exacerbation-reducing agent, for example, an increase in the time to death of the patient by at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 1 year, or more than 1 year.

[0438] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0439] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0440] In some embodiments, the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, acid-reducing therapy, corticosteroids, cyclophosphamide, or a combination thereof.

[0441] In some embodiments, the exacerbation-reducing agent is nintedanib or pirfenidone.

[0442] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority to reduce, control, or maintain an exacerbation.

[0443] In some embodiments, the regulatory health authority is the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

[0444] iii. LPA and TG biomarkers for shortening the time to exacerbation or respiratory hospitalization In another aspect, the disclosure provides a method for predicting time to exacerbation (e.g., an IPF exacerbation as described in Section IIIE herein) or respiratory hospitalization in a patient with IPF, comprising determining a level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 (e.g., one, two, three, four, five, or all six of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2) in a sample from the patient. and measuring a level of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample that is equal to or greater than a reference level (e.g., one, two, three, or all four of LPA16:0, LPA18:1, LPA20:4, and LPA22:4), or (b) a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level, identifies the patient as one who is likely to have a shorter time to exacerbation or respiratory hospitalization.

[0445] In some embodiments, the patient has (a) a level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample that is equal to or greater than the reference level, or (b) a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than the reference level, and the method further includes administering to the patient an effective amount of an agent that reduces exacerbation (e.g., an agent described in Section IIIG of the present specification).

[0446] In some aspects, the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

[0447] In some aspects, the sample is a preserved sample, a fresh sample, or a frozen sample.

[0448] In some embodiments, the sample is a serum sample.

[0449] In some embodiments, the level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 is a baseline level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2. In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2.

[0450] In some embodiments, (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM. In some embodiments, (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

[0451] In some embodiments, (a) the patient is female and the reference level of LPA18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA18:1 is between about 0.078 μM and about 0.118 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

[0452] In some embodiments, (a) the patient is female and the reference level of LPA20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA20:4 is between about 0.110 μM and about 0.150 μM. In some embodiments, (a) the patient is female and the reference level of LPA20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA20:4 is about 0.130 μM.

[0453] In some embodiments, (a) the patient is female and the reference level of LPA22:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA22:4 is between about 0.110 μM and about 0.150 μM. In some embodiments, (a) the patient is female and the reference level of LPA22:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA22:4 is about 0.130 μM.

[0454] In some embodiments, (a) the patient is female and the reference level for TG48:4-FA12:0 is between about 0.800 μM and about 0.840 μM; or (b) the patient is male and the reference level for TG48:4-FA12:0 is between about 1.166 μM and about 1.206 μM. In some embodiments, (a) the patient is female and the reference level for TG48:4-FA12:0 is about 0.820 μM; or (b) the patient is male and the reference level for TG48:4-FA12:0 is about 1.186 μM.

[0455] In some embodiments, (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is between about 1.587 μM and about 1.627 μM; or (b) the patient is male and the reference level (μM) of TG48:4-FA18:2 is between about 2.153 μM and about 2.193 μM. In some embodiments, (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is about 1.607 μM; or (b) the patient is male and the reference level of TG48:4-FA18:2 is about 2.173 μM.

[0456] In some embodiments, the reference level is the level (e.g., median level) of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 in a reference population.

[0457] In some embodiments, (a) the level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample is greater than or equal to the median level of LPA16:0, LPA18:1, LPA20:4, or LPA22:4, respectively, in a reference population; or (b) the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample is less than or equal to the median level of TG48:4-FA12:0 or TG48:4-FA18:2, respectively, in a reference population.

[0458] In some embodiments, the reference level of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, or TG48:4-FA18:2 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile of the levels of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, or TG48:4-FA18:2, respectively, in a reference population. , 43rd percentile, 44th percentile, 45th percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0459] In some embodiments, the reference population is a population of patients with IPF.

[0460] In some embodiments, the reference population is a population of patients without IPF. In some embodiments, (a) the level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample is at least twice the reference level, or (b) the level of one or both of TG48:4-FA12:0 or TG48:4-FA18:2 in the sample is at least half the reference level, e.g., the reference level in a population of patients without IPF.

[0461] In some embodiments, the exacerbation is an acute respiratory exacerbation.

[0462] In some embodiments, the acute respiratory deterioration is dyspnea.

[0463] In some embodiments, the acute respiratory deterioration is not caused by pneumothorax, cancer, heart failure, fluid overload, or pulmonary embolism.

[0464] In some embodiments, the acute respiratory deterioration is associated with new radiological abnormalities.

[0465] In some embodiments, the radiological abnormality is bilateral ground-glass opacities / consolidations.

[0466] In some embodiments, the exacerbation is a severe exacerbation.

[0467] In some embodiments, the agent that reduces an exacerbation is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta 2 agonist (SABA), a long-acting beta 2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

[0468] In some embodiments, the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

[0469] In some embodiments, the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, acid-reducing therapy, corticosteroids, cyclophosphamide, or a combination thereof.

[0470] In some embodiments, the exacerbation-reducing agent is nintedanib or pirfenidone.

[0471] In some embodiments, the exacerbation-reducing agent is approved by a regulatory health authority to reduce, control, or maintain an exacerbation.

[0472] In some embodiments, the regulatory health authority is the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

[0473] iv. LPA and TG biomarkers related to the risk of worsening lung health indicators In another aspect, the disclosure provides a method for identifying, diagnosing, and / or predicting whether a patient with idiopathic pulmonary fibrosis (IPF) may be at increased risk for a deterioration in a measure of lung health, comprising: (a) measuring a level of one or more of LPA16:0, LPA16:1, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the measure of lung health is diffusing capacity for carbon monoxide (DLCO), and wherein a level of one or more of LPA16:0, LPA16:1, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as being at increased risk for a deterioration in DLCO; and (b) measuring a level of LPA22:4 in the sample from the patient, wherein the measure of lung health is diffusing capacity for carbon monoxide (DLCO). and (c) measuring a level of one or more of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein the measure of lung health is lower-zone lung fibrosis and a level of one or more of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for increased lower-zone lung fibrosis.

[0474] In some embodiments, (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM. In some embodiments, (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

[0475] In some embodiments, (a) the patient is female and the reference level of LPA 16:1 is between about 0.101 ratio to normal (rts) and about 0.141 rts; or (b) the patient is male and the reference level of LPA 16:1 is between about 0.058 rts and about 0.098 rts. In some embodiments, (a) the patient is female and the reference level of LPA 16:1 is about 0.121 rts; or (b) the patient is male and the reference level of LPA 16:1 is about 0.078 rts.

[0476] In some embodiments, (a) the patient is female and the reference level of LPA18:0 is between about 0.007 μM and about 0.047 μM; or (b) the patient is male and the reference level of LPA18:0 is between about 0.003 μM and about 0.043 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:0 is about 0.027 μM; or (b) the patient is male and the reference level of LPA18:0 is about 0.023 μM.

[0477] In some embodiments, (a) the patient is female and the reference level of LPA18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA18:1 is between about 0.078 μM and about 0.118 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

[0478] In some embodiments, (a) the patient is female and the reference level of LPA18:2 is between about 0.388 μM and about 0.428 μM; or (b) the patient is male and the reference level of LPA18:2 is between about 0.339 μM and about 0.379 μM. In some embodiments, (a) the patient is female and the reference level of LPA18:2 is about 0.408 μM; or (b) the patient is male and the reference level of LPA18:2 is about 0.359 μM.

[0479] In some embodiments, (a) the patient is female and the reference level of LPA20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA20:4 is between about 0.110 μM and about 0.150 μM. In some embodiments, (a) the patient is female and the reference level of LPA20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA20:4 is about 0.130 μM.

[0480] In some embodiments, (a) the patient is female and the reference level of LPA22:4 is between about 0.009 rts and about 0.049 rts; or (b) the patient is male and the reference level of LPA22:4 is between about 0.011 rts and about 0.051 rts. In some embodiments, (a) the patient is female and the reference level of LPA22:4 is about 0.029 rts; or (b) the patient is male and the reference level of LPA22:4 is about 0.031 rts.

[0481] D. Methods for Measuring LPA Levels The levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 in a sample from a patient can be assessed using any of the methods described herein, for example, the methods described in Section II of the present specification, including: (a) providing a sample from the patient; and (b) extracting LPA from the sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, wherein the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample.

[0482] In some embodiments, levels of one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 are assessed in a sample from the patient. In some embodiments, levels of one, two, three, four, five, or all six of LPA16:0, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 are assessed in a sample from the patient.

[0483] E. Inflammatory respiratory disease Inflammatory respiratory diseases include any disease, disorder, or condition associated with inflammation of the airways.

[0484] Inflammatory respiratory diseases include respiratory diseases associated with fibrosis (eg, idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD)).

[0485] In some embodiments, the inflammatory respiratory disease is chronic obstructive pulmonary disease (COPD), a progressive, chronic inflammatory lung disease caused by smoking and exposure to other substances that irritate and damage the lungs.

[0486] COPD is a GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE TM According to the (GOLD) staging system, the COPD may be at stage I, stage II, stage III, or stage IV. In some embodiments, the COPD is at stage II, stage III, or stage IV.

[0487] In some embodiments, the inflammatory respiratory disease is idiopathic pulmonary fibrosis (IPF).

[0488] In some embodiments, the inflammatory respiratory disease is asthma.

[0489] In some embodiments, the inflammatory respiratory disease is an interstitial lung disease (ILD).

[0490] In some embodiments, the patient with an inflammatory respiratory disease is male.

[0491] F. Exacerbation An exacerbation of an inflammatory respiratory disease (e.g., COPD, IPF, or asthma) can be any worsening of one or more symptoms of the inflammatory respiratory disease, e.g., an exacerbation of the disease that lasts for at least two consecutive days, requires treatment, and / or leads to hospitalization and / or treatment with systemic corticosteroids or antibiotics.

[0492] The duration of an exacerbation can be defined, for example, as the period of time that the patient experiences symptoms and / or the number of days that the patient is taking systemic corticosteroids and / or antibiotics to treat the exacerbation. An exacerbation can be a severe exacerbation, for example, an exacerbation requiring hospitalization.

[0493] Increased risk of exacerbation may occur, for example, at 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147 It may be a 7%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% increase, for example, an increase in risk that an exacerbation will occur within a period of time, for example, within about 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years.

[0494] i. COPD exacerbation A COPD exacerbation can be one or more new or increased symptoms of COPD, such as shortness of breath (dyspnea), cough, sputum production, purulent sputum, fatigue, sleep disturbances, morning headache, confusion, or increased low oxygen levels (hypoxemia), e.g., lasting for at least two consecutive days and / or leading to hospitalization and / or treatment with systemic corticosteroids and / or antibiotics. A COPD exacerbation is defined as a new or increased symptom of COPD that is associated with the Global Initiative for Chronic Obstructive Lung Disease (GILD). TM (GOLD) Pocket Guide to COPD Diagnosis, Management, and Prevention (2020 Edition) and Lareu et al., Am J Respir Crit Care Med, 198:21-22, 2018, which are incorporated herein by reference in their entireties.

[0495] ii. IPF exacerbation An IPF exacerbation may be one or more new or increased symptoms of IPF, such as acute respiratory deterioration (e.g., dyspnea), which is not caused by pneumothorax, cancer, heart failure, fluid overload, or pulmonary embolism. An IPF exacerbation may be associated with new radiological abnormalities, such as bilateral ground-glass opacities / consolidation. IPF exacerbations are described in Collard et al., Am J Respir Crit Care Med, 194(3):265-275, 2016, which is incorporated herein by reference in its entirety.

[0496] iii. Asthma exacerbation An asthma exacerbation can be one or more episodes of gradually worsening shortness of breath, cough, wheezing, and chest tightness. Episodes can be acute or subacute. Asthma exacerbations are described in Camargo et al., Proc Am Thorac Soc, 6(4):357-366, 2009, which is incorporated herein by reference in its entirety.

[0497] G. Drugs that reduce exacerbations In some embodiments, the methods of the present invention include the use of an agent that reduces exacerbations. An agent that reduces exacerbations can be any agent that slows the rate of exacerbations, increases the time to exacerbation (e.g., increases the time to the first exacerbation or increases the time between exacerbations, e.g., increases the time to the next exacerbation), shortens the duration of an exacerbation, and / or reduces the severity of an exacerbation in a patient with an inflammatory respiratory disease. Such agents include agents used in the treatment of inflammatory respiratory diseases (e.g., maintenance therapy agents), such as agents used in the treatment of COPD, IPF, and / or asthma, and agents used to treat exacerbations of inflammatory respiratory diseases.

[0498] Exacerbation-reducing agents include agents approved by a regulatory health authority (e.g., the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA)) to reduce, control, or maintain exacerbations.

[0499] In some embodiments, the exacerbation-reducing agent is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta2 agonist (SABA), a long-acting beta2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid (e.g., an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS)), an antibiotic, an alpha-1 antitrypsin augmentation therapy, or a combination thereof. In some embodiments, the exacerbation-reducing agent is an agent approved for the treatment of asthma, such as mepolizumab or benralizumab.

[0500] In some embodiments, an exacerbation-reducing agent reduces the rate of exacerbation, e.g., reduces the rate of exacerbation by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, reduce by 7%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%.

[0501] In some embodiments, the agent that reduces an exacerbation extends the time to exacerbation (e.g., increases the time to the first exacerbation, or increases the time between exacerbations, e.g., increases the time to the next exacerbation), for example, extends the time to exacerbation by at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 1 year, at least 2 years, at least 3 years, at least 4 years, at least 5 years, at least 6 years, at least 7 years, at least 8 years, at least 9 years, at least 10 years, or more than 10 years.

[0502] In some embodiments, an agent that reduces an exacerbation reduces the duration of an exacerbation, e.g., reduces the duration of an exacerbation by at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, or more than 1 month.

[0503] In some embodiments, the exacerbation-reducing agent reduces the severity of the exacerbation, e.g., reduces the severity of the exacerbation by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% reduction.

[0504] i. Medications that reduce COPD exacerbations In some embodiments, the patient has COPD and the exacerbation-reducing agent is a member of the Global Initiative for Chronic Obstructive Lung Disease. TM (GOLD) Pocket Guide to COPD Diagnosis, Management, and Prevention (2020 edition). In some embodiments, the exacerbation-reducing agent is influenza vaccination, pneumococcal vaccination, supplemental oxygen, a short-acting bronchodilator (SABD), a long-acting bronchodilator, a dual-acting bronchodilator, a short-acting anticholinergic, a long-acting anticholinergic, a short-acting antimuscarinic antagonist (SAMA), a long-acting muscarinic antagonist (LAMA), a short-acting beta2 agonist (SABA), a long-acting beta2 agonist (LABA), a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid (e.g., an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS)), an antibiotic, an alpha-1 antitrypsin augmentation therapy, or a combination thereof.

[0505] ii. Drugs that reduce IPF exacerbations In some embodiments, the patient has IPF and the exacerbation-reducing agent is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, acid-reducing therapy, corticosteroids, cyclophosphamide, or a combination thereof. In some embodiments, the exacerbation-reducing agent is nintedanib or pirfenidone. In some embodiments, the exacerbation-reducing agent is nintedanib. In some embodiments, the exacerbation-reducing agent is pirfenidone.

[0506] iii. Drugs that reduce asthma exacerbations In some embodiments, the patient has asthma and the exacerbation-reducing agent is an inhaled short-acting beta-agonist (SABA), albuterol, bitolterol, levalbuterol, pirbuterol, a systemic SABA (e.g., epinephrine or terbutaline), an anticholinergic (e.g., ipratropium bromide), a systemic corticosteroid (e.g., prednisone, methylprednisolone, prednisolone), mepolizumab, or benralizumab. In some embodiments, the exacerbation-reducing agent is mepolizumab or benralizumab. In some embodiments, the exacerbation-reducing agent is mepolizumab. In some embodiments, the exacerbation-reducing agent is benralizumab.

[0507] H. Delivery method The compositions (e.g., agents that reduce progression) used in the methods described herein can be administered in any suitable manner, for example, intravenously, intramuscularly, subcutaneously, intradermally, transdermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostatically, intrapleurally, intratracheally, intrathecally, intranasally, intravaginally, intrarectally, topically, intratumorally, intraperitoneally, subconjunctivally, intravesicularly, intramucosally, intrapericardially, intraumbilically, intraocularly, intraorbitally, orally, topically, transdermally, intravitreally (e.g., by intravitreal injection), by eye drops, by inhalation, by injection, by implantation, by infusion, by continuous infusion, by local perfusion directly bathing target cells, by catheter, by perfusion, in a cream, or in a lipid composition. The compositions used in the methods described herein can also be administered systemically or locally. The method of administration can vary depending on various factors, such as the compound or composition being administered and the severity of the condition, disease, or disorder being treated.

[0508] In some aspects, the exacerbation-reducing agent is administered by inhalation, intravenously, intramuscularly, subcutaneously, topically, orally, transdermally, intraperitoneally, intraorbitally, by implant, intrathecally, intracerebroventricularly, or intranasally. Dosing can be by any suitable route, for example, injection, such as intravenous or subcutaneous injection, depending in part on whether administration is short-term or long-term. Various dosing schedules are contemplated herein, including, but not limited to, single or multiple doses over various time points, bolus administration, and pulse infusion.

[0509] The exacerbation-reducing agents described herein (and any additional therapeutic agents) may be formulated, dosed, and administered in a manner consistent with good medical practice. Factors to consider in this regard include the particular disorder being treated, the particular mammal being treated, the patient's clinical condition, the cause of the disorder, the site of drug delivery, the method of administration, the administration schedule, and other factors known to medical professionals. The exacerbation-reducing agents may optionally, but need not, be formulated with and / or co-administered with one or more agents currently used to prevent or treat inflammatory respiratory disorders (e.g., COPD, IPF, or asthma). The effective amount of such other agents will depend on the amount of exacerbation-reducing agent present in the formulation, the type of disorder or treatment, and other factors discussed above. These will generally be used in the same dosages and by any route of administration as described herein, or about 1-99% of the dosages described herein, or at any dosage and by any route empirically / clinically determined to be appropriate.

[0510] The appropriate dose of an exacerbation-reducing agent described herein (e.g., an agent described in Section IIIG herein) for the treatment of an inflammatory respiratory disease, e.g., a respiratory disease described in Section IIIE herein, e.g., COPD, IPF, or asthma (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease being treated, the severity and course of the disease, whether the exacerbation-reducing agent is being administered prophylactically or therapeutically, previous treatments, the patient's medical history and response to the exacerbation-reducing agent, and the discretion of the attending physician. The exacerbation-reducing agent is suitably administered to the patient at one time or over a series of treatments. Typical daily dosages may range from about 1 μg / kg to 100 mg / kg, depending on the factors discussed above. For repeated administration over several days or longer, treatment will generally be continued until a desired suppression of disease symptoms occurs, depending on the condition. Such doses can be administered intermittently, e.g., daily, weekly, or monthly. An initial high loading dose may be administered, followed by one or more lower doses. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

[0511] IV. Methods of Monitoring Response to Treatment A. LPA Biomarkers for COPD and Asthma In some aspects, the disclosure features a method for monitoring a patient's response to a treatment comprising an exacerbation-reducing agent in a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), the treatment comprising an exacerbation-reducing agent, the method including: (a) measuring the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample obtained from the patient at a time point after administration of a first dose of the treatment comprising the exacerbation-reducing agent; and (b) comparing the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample to a reference level, thereby monitoring the patient's response to the treatment comprising the exacerbation-reducing agent. In some embodiments, the inflammatory respiratory disease is asthma, and the method includes: (a) measuring the level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample obtained from the patient at a time point after administration of a first dose of a treatment comprising an agent that reduces exacerbations; and (b) comparing the level of one or more of LPA16:0, LPA18:0, and LPA18:2 in the sample with a reference level, thereby monitoring the patient's response to the treatment comprising the agent that reduces exacerbations.

[0512] In some embodiments, a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is greater than the reference level indicates that the patient is responding to an exacerbation-reducing agent. In some embodiments, the inflammatory respiratory disease is asthma, and a level of one or more of LPA16:0, LPA18:0, and LPA18:2 in the sample that is greater than the reference level indicates that the patient is responding to an exacerbation-reducing agent.

[0513] In some embodiments, the method further comprises administering at least a second dose (e.g., the second dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 additional doses) of an exacerbation-reducing agent to a patient whose sample has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 above the reference level. In some embodiments, the inflammatory respiratory disease is asthma, and the method further comprises administering at least a second dose (e.g., the second dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 additional doses) of an exacerbation-reducing agent to a patient whose sample has a level of one or more of LPA16:0, LPA18:0, and LPA18:2 above the reference level.

[0514] In some embodiments, the time point after administration of the first dose of the treatment comprising the exacerbation-reducing agent is about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, or more than 1 month after administration of the first dose of the treatment.

[0515] The sample may be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some embodiments, the sample is a bronchoalveolar lavage fluid (BALF) sample or a urine sample. The sample may be a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0516] The exacerbation may be an exacerbation as described in Section IIIF herein, e.g., any worsening of one or more symptoms of an inflammatory respiratory disease, e.g., an exacerbation of a disease that lasts for at least two consecutive days, requires treatment, and / or leads to hospitalization and / or treatment with systemic corticosteroids or antibiotics, e.g., an exacerbation of COPD or asthma.

[0517] An agent that reduces exacerbations, e.g., a worsening of one or more symptoms of an inflammatory respiratory disease, can be an agent described in Section IIIG herein, e.g., any agent that reduces the rate of exacerbations, increases the time to exacerbation (e.g., increases the time to the first exacerbation, or increases the time between exacerbations, e.g., increases the time to the next exacerbation), shortens the duration of an exacerbation, and / or reduces the severity of an exacerbation in a patient with an inflammatory respiratory disease, e.g., an agent that reduces COPD or asthma exacerbations.

[0518] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4, e.g., a level measured when the patient is not experiencing an exacerbation.

[0519] In some embodiments, one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4), such as LPA14:0, LPA16: The levels of one, two, three, four, five, six, seven, or all eight of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4, or one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4) are less than the reference levels.

[0520] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0521] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0522] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0523] In some embodiments, the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM, hi some embodiments, the reference level of LPA16:0 is about 0.14 μM.

[0524] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0525] In some embodiments, the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM, hi some embodiments, the reference level of LPA18:1 is about 0.12 μM.

[0526] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0527] In some embodiments, the reference level of LPA20:4 is between about 9 μM and about 13 μM, hi some embodiments, the reference level of LPA20:4 is about 10.9 μM.

[0528] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, or 50th percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population. ile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0529] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0530] In some embodiments, the reference level of LPA20:4 is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile of the level of LPA20:4 in a reference population. percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0531] In some embodiments, the reference level of LPA20:4 is the 67th percentile of LPA20:4 levels in a reference population.

[0532] B. Lipid Biomarkers for COPD and Asthma In some aspects, the disclosure features a method of monitoring the response of a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) to a treatment comprising an agent that reduces exacerbations, the method comprising: (a) measuring the level of one or more of LPC, sphingomyelin, and ceramide in a sample obtained from the patient at a time point after administration of a first dose of the treatment comprising the agent that reduces exacerbations; and (b) comparing the level of one or more of LPC, sphingomyelin, and ceramide in the sample to a reference level, thereby monitoring the patient's response to the treatment comprising the agent that reduces exacerbations. In some aspects, the ceramide is hexosylceramide (HCER), lactosylceramide (LCER), or dihydroceramide (DCER). In some aspects, the patient is female and the ceramide is DCER.

[0533] In some embodiments, a level of LPC in the sample that is above the reference level and / or a level of one or both of sphingomyelin and ceramide in the sample that is below the reference level indicates that the patient is responding to the agent that reduces exacerbations.

[0534] In some embodiments, the method further includes administering at least a second dose (e.g., the second dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more than 10 additional doses) of an agent that reduces exacerbation to a patient whose sample has a level of LPC above the reference level and / or whose sample has a level of one or both of sphingomyelin and ceramide below the reference level.

[0535] In some embodiments, the time point after administration of the first dose of the treatment comprising the exacerbation-reducing agent is about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 12 hours, about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 1 month, or more than 1 month after administration of the first dose of the treatment.

[0536] The sample may be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some embodiments, the sample is a bronchoalveolar lavage fluid (BALF) sample or a urine sample. The sample may be a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0537] The exacerbation may be an exacerbation as described in Section IIIF herein, e.g., any worsening of one or more symptoms of an inflammatory respiratory disease, e.g., an exacerbation of a disease that lasts for at least two consecutive days, requires treatment, and / or leads to hospitalization and / or treatment with systemic corticosteroids or antibiotics, e.g., an exacerbation of COPD or asthma.

[0538] An agent that reduces exacerbations, e.g., a worsening of one or more symptoms of an inflammatory respiratory disease, can be an agent described in Section IIIG herein, e.g., any agent that reduces the rate of exacerbations, increases the time to exacerbation (e.g., increases the time to the first exacerbation, or increases the time between exacerbations, e.g., increases the time to the next exacerbation), shortens the duration of an exacerbation, and / or reduces the severity of an exacerbation in a patient with an inflammatory respiratory disease, e.g., an agent that reduces COPD or asthma exacerbations.

[0539] In some embodiments, the level of one or more of LPC, sphingomyelin, and ceramide is a baseline level of one or more of LPC, sphingomyelin, and ceramide, e.g., a level measured when the patient is not experiencing an exacerbation.

[0540] In some embodiments, the reference level is a pre-assigned level of one or more of LPC, sphingomyelin, and ceramide.

[0541] In some embodiments, the reference level is the level of one or more of LPC, sphingomyelin, and ceramide in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0542] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is between about 227 nmol / mL and about 277 nmol / mL. In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is about 252 nmol / mL.

[0543] In some embodiments, the reference level of sphingomyelin is between about 448 nmol / mL and about 548 nmol / mL, hi some embodiments, the reference level of sphingomyelin is about 498 nmol / mL.

[0544] In some embodiments, the ceramide is hexosylceramide (HCER). In some embodiments, the reference level of HCER is between about 6.1 nmol / mL and about 7.5 nmol / mL. In some embodiments, the reference level of HCER is about 6.8 nmol / mL.

[0545] In some embodiments, the ceramide is lactosylceramide (LCER). In some embodiments, the reference level of LCER is between about 4.3 nmol / mL and about 5.3 nmol / mL. In some embodiments, the reference level of LCER is about 4.8 nmol / mL.

[0546] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0547] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 33rd percentile of LPC (e.g., LPC(16:0) or LPC(18:2)) levels in a reference population.

[0548] In some embodiments, the reference level of sphingomyelin or ceramide (e.g., HCER or LCER) is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, or 74th percentile of the level of sphingomyelin or ceramide, respectively, in a reference population. ile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0549] In some embodiments, the reference level of sphingomyelin or ceramide (eg, HCER and / or LCER) is the 67th percentile of the levels of sphingomyelin or ceramide, respectively, in a reference population.

[0550] V. Agents for Use in the Treatment of Inflammatory Respiratory Diseases A. LPA Biomarkers for COPD and Asthma In some aspects, the disclosure features an exacerbation-reducing agent for use in treating a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) and having a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is below a reference level. In some aspects, the inflammatory respiratory disease is asthma, and the patient has a level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient that is below a reference level.

[0551] In some aspects, the disclosure features an exacerbation-reducing agent for use in treating a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma), wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be below a reference level. In some aspects, the inflammatory respiratory disease is asthma, and the level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient has been determined to be below a reference level.

[0552] The sample may be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some embodiments, the sample is a bronchoalveolar lavage fluid (BALF) sample or a urine sample. The sample may be a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0553] The exacerbation may be an exacerbation as described in Section IIIF herein, e.g., any worsening of one or more symptoms of an inflammatory respiratory disease, e.g., an exacerbation of a disease that lasts for at least two consecutive days, requires treatment, and / or leads to hospitalization and / or treatment with systemic corticosteroids or antibiotics, e.g., an exacerbation of COPD or asthma.

[0554] An agent that reduces exacerbations, e.g., a worsening of one or more symptoms of an inflammatory respiratory disease, can be an agent described in Section IIIG herein, e.g., any agent that reduces the rate of exacerbations, increases the time to exacerbation (e.g., increases the time to the first exacerbation, or increases the time between exacerbations, e.g., increases the time to the next exacerbation), shortens the duration of an exacerbation, and / or reduces the severity of an exacerbation in a patient with an inflammatory respiratory disease, e.g., an agent that reduces COPD or asthma exacerbations.

[0555] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4, e.g., a level measured when the patient is not experiencing an exacerbation.

[0556] In some embodiments, one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4), such as LPA14:0, LPA16: The levels of one, two, three, four, five, six, seven, or all eight of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4, or one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4) are less than the reference levels.

[0557] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0558] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0559] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0560] In some embodiments, the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM, hi some embodiments, the reference level of LPA16:0 is about 0.14 μM.

[0561] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0562] In some embodiments, the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM, hi some embodiments, the reference level of LPA18:1 is about 0.12 μM.

[0563] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0564] In some embodiments, the reference level of LPA20:4 is between about 9 μM and about 13 μM, hi some embodiments, the reference level of LPA20:4 is about 10.9 μM.

[0565] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, or 50th percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population. ile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0566] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0567] In some embodiments, the reference level of LPA20:4 is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile of the level of LPA20:4 in a reference population. percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0568] In some embodiments, the reference level of LPA20:4 is the 67th percentile of LPA20:4 levels in a reference population.

[0569] B. Lipid Biomarkers for COPD and Asthma In some aspects, the disclosure features an exacerbation-reducing agent for use in treating a patient having an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma) and having a level of LPC in the sample that is below a reference level, and / or a level of one or both of sphingomyelin and ceramide in the sample that is above a reference level.

[0570] In some aspects, the disclosure features an exacerbation-reducing agent for use in treating a patient having an inflammatory respiratory disease, wherein the level of LPC in a sample from the patient has been determined to be below a reference level, and / or the level of one or both of sphingomyelin and ceramide in the sample from the patient has been determined to be above a reference level.

[0571] The sample may be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some embodiments, the sample is a bronchoalveolar lavage fluid (BALF) sample or a urine sample. The sample may be a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0572] The exacerbation may be an exacerbation as described in Section IIIF herein, e.g., any worsening of one or more symptoms of an inflammatory respiratory disease, e.g., an exacerbation of a disease that lasts for at least two consecutive days, requires treatment, and / or leads to hospitalization and / or treatment with systemic corticosteroids or antibiotics, e.g., an exacerbation of COPD or asthma.

[0573] The agent that reduces exacerbations can be an agent described in Section IIIG herein, for example, any agent that reduces the rate of exacerbations, increases the time to exacerbation (e.g., increases the time to the first exacerbation or increases the time between exacerbations, e.g., increases the time to the next exacerbation), shortens the duration of an exacerbation, and / or reduces the severity of an exacerbation in a patient with an inflammatory respiratory disease, for example, an agent that reduces COPD or asthma exacerbations.

[0574] In some embodiments, the level of one or more of LPC, sphingomyelin, and ceramide is a baseline level of one or more of LPC, sphingomyelin, and ceramide, e.g., a level measured when the patient is not experiencing an exacerbation.

[0575] In some embodiments, the reference level is a pre-assigned level of one or more of LPC, sphingomyelin, and ceramide.

[0576] In some embodiments, the reference level is the level of one or more of LPC, sphingomyelin, and ceramide in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD), IPF, or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0577] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is between about 227 nmol / mL and about 277 nmol / mL. In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is about 252 nmol / mL.

[0578] In some embodiments, the reference level of sphingomyelin is between about 448 nmol / mL and about 548 nmol / mL, hi some embodiments, the reference level of sphingomyelin is about 498 nmol / mL.

[0579] In some embodiments, the ceramide is hexosylceramide (HCER). In some embodiments, the reference level of HCER is between about 6.1 nmol / mL and about 7.5 nmol / mL. In some embodiments, the reference level of HCER is about 6.8 nmol / mL.

[0580] In some embodiments, the ceramide is lactosylceramide (LCER). In some embodiments, the reference level of LCER is between about 4.3 nmol / mL and about 5.3 nmol / mL. In some embodiments, the reference level of LCER is about 4.8 nmol / mL.

[0581] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0582] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 33rd percentile of LPC (e.g., LPC(16:0) or LPC(18:2)) levels in a reference population.

[0583] In some embodiments, the reference level of sphingomyelin or ceramide (e.g., HCER or LCER) is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, or 74th percentile of the level of sphingomyelin or ceramide, respectively, in a reference population. ile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0584] In some embodiments, the reference level of sphingomyelin or ceramide (eg, HCER and / or LCER) is the 67th percentile of the levels of sphingomyelin or ceramide, respectively, in a reference population.

[0585] In some embodiments, the level of LPC (e.g., LPC(16:0) or LPC(18:2)) (e.g., the baseline level of LPC (e.g., LPC(16:0) or LPC(18:2)) in the patient) is less than or equal to the 33rd percentile of the levels of LPC (e.g., LPC(16:0) or LPC(18:2)) in a reference population, e.g., less than or equal to the 32nd percentile, less than or equal to the 31st percentile, less than or equal to the 30th percentile, less than or equal to the 29th percentile, less than or equal to the 28th percentile, less than or equal to the 27th percentile, less than or equal to the 26th percentile, less than or equal to the 25th percentile of the levels of LPC (e.g., LPC(16:0) or LPC(18:2)) in a reference population. percentile or less, 24th percentile or less, 23rd percentile or less, 22nd percentile or less, 21st percentile or less, 20th percentile or less, 19th percentile or less, 18th percentile or less, 17th percentile or less, 16th percentile or less, 15th percentile or less, 14th percentile or less, 13th percentile or less, 12th percentile or less, 11th percentile or less, 10th percentile or less, 9th percentile or less, 8th percentile or less, 7th percentile or less, 6th percentile or less, 5th percentile or less, 4th percentile or less, 3rd percentile or less, 2nd percentile or less, or 1st percentile or less.

[0586] In some embodiments, the level of sphingomyelin or ceramide (e.g., HCER and / or LCER) (e.g., the patient's baseline level of sphingomyelin or ceramide) is greater than or equal to the 67th percentile of sphingomyelin or ceramide levels in a reference population, e.g., greater than or equal to the 68th percentile, greater than or equal to the 69th percentile, greater than or equal to the 70th percentile, greater than or equal to the 71st percentile, greater than or equal to the 72nd percentile, greater than or equal to the 73rd percentile, greater than or equal to the 74th percentile, greater than or equal to the 76th percentile, greater than or equal to the 77th percentile, greater than or equal to the 78th percentile, greater than or equal to the 79th percentile, greater than or equal to the 80th percentile, greater than or equal to the 81st percentile, greater than or equal to the 82nd percentile, greater than or equal to the 83rd percentile, greater than or equal to the 84th percentile, greater than or equal to the 85th percentile, greater than or equal to the 86th percentile, greater than or equal to the 87th percentile, greater than or equal to the 88th percentile, greater than or equal to the 89th percentile, greater than or equal to the 90th percentile, greater than or equal to the 91st percentile, greater than or equal to the 92nd percentile, greater than or equal to the 93rd percentile, greater than or equal to the 94th percentile, greater than or equal to the 95th percentile, greater than or equal to the 96th percentile, greater than or equal to the 97th percentile, greater than or equal to the 98th percentile, greater than or equal to the 99th percentile, greater than or equal to the 99th percentile, or above the 8th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0587] VI. Use of Drugs in the Manufacture of Medicines A. LPA Biomarkers for Use in the Manufacture of Medicaments for COPD or Asthma In some aspects, the disclosure features the use of an agent that reduces exacerbations in a patient having a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is below a reference level in the manufacture of a medicament for the treatment of an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma). In some aspects, the inflammatory respiratory disease is asthma, and the patient has a level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient that is below a reference level.

[0588] In some aspects, the disclosure features the use of an agent that reduces exacerbations in a patient having a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is below a reference level in the manufacture of a medicament for reducing an exacerbation of an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma). In some aspects, the inflammatory respiratory disease is asthma, and the patient has a level of one or more of LPA16:0, LPA18:0, and LPA18:2 in a sample from the patient that is below a reference level.

[0589] The sample may be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some embodiments, the sample is a bronchoalveolar lavage fluid (BALF) sample or a urine sample. The sample may be a preserved sample, a fresh sample, or a frozen sample. In some embodiments, the sample is a serum sample.

[0590] The exacerbation may be an exacerbation as described in Section IIIF herein, e.g., any worsening of one or more symptoms of an inflammatory respiratory disease, e.g., an exacerbation of a disease that lasts for at least two consecutive days, requires treatment, and / or leads to hospitalization and / or treatment with systemic corticosteroids or antibiotics, e.g., an exacerbation of COPD or asthma.

[0591] An agent that reduces exacerbations, e.g., a worsening of one or more symptoms of an inflammatory respiratory disease, can be an agent described in Section IIIG herein, e.g., any agent that reduces the rate of exacerbations, increases the time to exacerbation (e.g., increases the time to the first exacerbation, or increases the time between exacerbations, e.g., increases the time to the next exacerbation), shortens the duration of an exacerbation, and / or reduces the severity of an exacerbation in a patient with an inflammatory respiratory disease, e.g., an agent that reduces COPD or asthma exacerbations.

[0592] In some embodiments, the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4, e.g., a level measured when the patient is not experiencing an exacerbation.

[0593] In some embodiments, one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4 (e.g., one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4), such as LPA14:0, LPA16: The levels of one, two, three, four, five, six, seven, or all eight of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:4, or one, two, three, four, or all five of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4) are less than the reference levels.

[0594] In some embodiments, the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

[0595] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0596] In some embodiments, the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0597] In some embodiments, the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM, hi some embodiments, the reference level of LPA16:0 is about 0.14 μM.

[0598] In some embodiments, the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM, hi some embodiments, the reference level of LPA18:0 is about 0.025 μM.

[0599] In some embodiments, the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM, hi some embodiments, the reference level of LPA18:1 is about 0.12 μM.

[0600] In some embodiments, the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM, hi some embodiments, the reference level of LPA18:2 is about 0.48 μM.

[0601] In some embodiments, the reference level of LPA20:4 is between about 9 μM and about 13 μM, hi some embodiments, the reference level of LPA20:4 is about 10.9 μM.

[0602] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, or 50th percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population. ile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0603] In some embodiments, the reference level of LPA16:0, LPA18:0, LPA18:1, or LPA18:2 is the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

[0604] In some embodiments, the reference level of LPA20:4 is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile of the level of LPA20:4 in a reference population. percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0605] In some embodiments, the reference level of LPA20:4 is the 67th percentile of LPA20:4 levels in a reference population.

[0606] B. Lipid Biomarkers for Use in the Manufacture of Medicaments for COPD or Asthma In some aspects, the disclosure features the use of an agent that reduces an exacerbation in a patient having a level of LPC in a sample from the patient that is below a reference level, and / or a level of one or both of sphingomyelin and ceramide in a sample from the patient that is above a reference level, in the manufacture of a medicament for the treatment of an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE of the present specification, e.g., COPD or asthma).

[0607] In some aspects, the disclosure features the use of an agent that reduces an exacerbation in a patient having a level of LPC in the sample that is below a reference level and / or a level of one or both of sphingomyelin and ceramide in the sample that is above a reference level in the manufacture of a medicament for reducing an exacerbation of an inflammatory respiratory disease (e.g., a respiratory disease described in Section IIIE herein, e.g., COPD or asthma). The sample can be, for example, a whole blood sample, a plasma sample, a serum sample, or a combination thereof. In some aspects, the sample is a bronchoalveolar lavage fluid (BALF) sample or a urine sample. The sample can be an archived sample, a fresh sample, or a frozen sample. In some aspects, the sample is a serum sample.

[0608] The exacerbation may be an exacerbation as described in Section IIIF herein, e.g., any worsening of one or more symptoms of an inflammatory respiratory disease, e.g., an exacerbation of a disease that lasts for at least two consecutive days, requires treatment, and / or leads to hospitalization and / or treatment with systemic corticosteroids or antibiotics, e.g., an exacerbation of COPD or asthma.

[0609] An agent that reduces exacerbations, e.g., a worsening of one or more symptoms of an inflammatory respiratory disease, can be an agent described in Section IIIG herein, e.g., any agent that reduces the rate of exacerbations, increases the time to exacerbation (e.g., increases the time to the first exacerbation, or increases the time between exacerbations, e.g., increases the time to the next exacerbation), shortens the duration of an exacerbation, and / or reduces the severity of an exacerbation in a patient with an inflammatory respiratory disease, e.g., an agent that reduces COPD or asthma exacerbations.

[0610] In some embodiments, the level of one or more of LPC, sphingomyelin, and ceramide is a baseline level of one or more of LPC, sphingomyelin, and ceramide, e.g., a level measured when the patient is not experiencing an exacerbation.

[0611] In some embodiments, the reference level is a pre-assigned level of one or more of LPC, sphingomyelin, and ceramide.

[0612] In some embodiments, the reference level is the level of one or more of LPC, sphingomyelin, and ceramide in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0613] In some aspects, the levels of one or more of LPC, sphingomyelin, and ceramide (e.g., HCER or LCER) are baseline levels of one or more of LPC (e.g., LPC(16:0) or LPC(18:2)), sphingomyelin, and ceramide, e.g., levels measured when the patient is not experiencing an exacerbation.

[0614] In some aspects, the reference level is a pre-assigned level of one or more of LPC (eg, LPC(16:0) or LPC(18:2)), sphingomyelin, and ceramide.

[0615] In some embodiments, the reference level is the level of one or more of LPC (e.g., LPC(16:0) or LPC(18:2)), sphingomyelin, and ceramide (e.g., HCER or LCER) in a reference population, e.g., a reference population of patients with an inflammatory respiratory disease (e.g., COPD (e.g., Stage II, Stage III, or Stage IV COPD) or asthma). In some embodiments, the patient has experienced at least one exacerbation in the past 12 months.

[0616] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is between about 227 nmol / mL and about 277 nmol / mL. In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is about 252 nmol / mL.

[0617] In some embodiments, the reference level of sphingomyelin is between about 448 nmol / mL and about 548 nmol / mL, hi some embodiments, the reference level of sphingomyelin is about 498 nmol / mL.

[0618] In some embodiments, the ceramide is hexosylceramide (HCER). In some embodiments, the reference level of HCER is between about 6.1 nmol / mL and about 7.5 nmol / mL. In some embodiments, the reference level of HCER is about 6.8 nmol / mL.

[0619] In some embodiments, the ceramide is lactosylceramide (LCER). In some embodiments, the reference level of LCER is between about 4.3 nmol / mL and about 5.3 nmol / mL. In some embodiments, the reference level of LCER is about 4.8 nmol / mL.

[0620] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 25th percentile, 26th percentile, 27th percentile, 28th percentile, 29th percentile, 30th percentile, 31st percentile, 32nd percentile, 33rd percentile, 34th percentile, 35th percentile, 36th percentile, 37th percentile, 38th percentile, 39th percentile, 40th percentile, 41st percentile, 42nd percentile, 43rd percentile, 44th percentile, 45th percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile percentile, 46th percentile, 47th percentile, 48th percentile, 49th percentile, 50th percentile, 51st percentile, 52nd percentile, 53rd percentile, 54th percentile, 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, 74th percentile, or 75th percentile.

[0621] In some embodiments, the reference level of LPC (e.g., LPC(16:0) or LPC(18:2)) is the 33rd percentile of LPC (e.g., LPC(16:0) or LPC(18:2)) levels in a reference population.

[0622] In some embodiments, the reference level of sphingomyelin or ceramide (e.g., HCER or LCER) is the 55th percentile, 56th percentile, 57th percentile, 58th percentile, 59th percentile, 60th percentile, 61st percentile, 62nd percentile, 63rd percentile, 64th percentile, 65th percentile, 66th percentile, 67th percentile, 68th percentile, 69th percentile, 70th percentile, 71st percentile, 72nd percentile, 73rd percentile, or 74th percentile of the level of sphingomyelin or ceramide, respectively, in a reference population. ile, 74th percentile, 75th percentile, 76th percentile, 77th percentile, 78th percentile, 79th percentile, 80th percentile, 81st percentile, 82nd percentile, 83rd percentile, 84th percentile, 85th percentile, 86th percentile, 87th percentile, 88th percentile, 89th percentile, 90th percentile, 91st percentile, 92nd percentile, 93rd percentile, 94th percentile, 95th percentile, 96th percentile, 97th percentile, 98th percentile, or 99th percentile.

[0623] In some embodiments, the reference level of sphingomyelin or ceramide (eg, HCER and / or LCER) is the 67th percentile of the levels of sphingomyelin or ceramide, respectively, in a reference population.

[0624] In some embodiments, the level of LPC (e.g., LPC(16:0) or LPC(18:2)) (e.g., the baseline level of LPC (e.g., LPC(16:0) or LPC(18:2)) in the patient) is less than or equal to the 33rd percentile of the levels of LPC (e.g., LPC(16:0) or LPC(18:2)) in a reference population, e.g., less than or equal to the 32nd percentile, less than or equal to the 31st percentile, less than or equal to the 30th percentile, less than or equal to the 29th percentile, less than or equal to the 28th percentile, less than or equal to the 27th percentile, less than or equal to the 26th percentile, less than or equal to the 25th percentile of the levels of LPC (e.g., LPC(16:0) or LPC(18:2)) in a reference population. percentile or less, 24th percentile or less, 23rd percentile or less, 22nd percentile or less, 21st percentile or less, 20th percentile or less, 19th percentile or less, 18th percentile or less, 17th percentile or less, 16th percentile or less, 15th percentile or less, 14th percentile or less, 13th percentile or less, 12th percentile or less, 11th percentile or less, 10th percentile or less, 9th percentile or less, 8th percentile or less, 7th percentile or less, 6th percentile or less, 5th percentile or less, 4th percentile or less, 3rd percentile or less, 2nd percentile or less, or 1st percentile or less.

[0625] In some embodiments, the level of sphingomyelin or ceramide (e.g., HCER and / or LCER) (e.g., the patient's baseline level of sphingomyelin or ceramide) is greater than or equal to the 67th percentile of sphingomyelin or ceramide levels in a reference population, e.g., greater than or equ...

Claims

1. 1. A method for identifying, diagnosing, and / or predicting whether a patient having chronic obstructive pulmonary disease (COPD) may be at high risk for an exacerbation, comprising measuring a level of one or more of lysophosphatidic acid (LPA) 16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for an exacerbation.

2. 1. A method for identifying, diagnosing, and / or predicting whether a patient having COPD may benefit from a treatment comprising an agent that reduces exacerbations, comprising measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as a patient that may benefit from a treatment comprising an agent that reduces exacerbations.

3. A method of selecting a therapy for a patient having COPD, comprising measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as one who may benefit from a treatment including an agent that reduces exacerbations.

4. 4. The method of any one of claims 1 to 3, wherein the patient has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces an exacerbation.

5. 1. A method of treating a patient having COPD, comprising: (a) measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from a patient, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is less than a reference level; (b) administering to the patient an effective amount of an agent that reduces an exacerbation; A method comprising:

6. A method of treating a patient having COPD and having a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is below a reference level, the method comprising administering to the patient an effective amount of an agent that reduces exacerbations.

7. A method of treating a patient having COPD, comprising administering to the patient an effective amount of an agent that reduces exacerbations, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be less than a reference level.

8. 1. A method for reducing exacerbations in a patient with COPD, comprising: (a) measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from a patient, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is less than a reference level; (b) administering to the patient an effective amount of an agent that reduces an exacerbation; A method comprising:

9. A method for reducing exacerbations in a patient having COPD and having levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that are less than a reference level, the method comprising administering to the patient an effective amount of an agent that reduces an exacerbation.

10. A method for reducing exacerbations in a patient having COPD, comprising administering to the patient an effective amount of an agent that reduces an exacerbation, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be less than a reference level.

11. 1. A method for identifying a patient suitable for administration with an agent that treats COPD or reduces exacerbations of COPD, comprising measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2 and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2 and LPA20:4 in the sample that is less than a reference level identifies the patient as being suitable for administration with an agent that treats COPD or reduces exacerbations of COPD.

12. 1. A method for monitoring a response of a patient having COPD to a treatment comprising an agent that reduces exacerbations, comprising: (a) measuring a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample obtained from the patient at a time point after administration of a first dose of a treatment comprising an exacerbation reducing agent; (b) comparing the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample to a reference level, thereby monitoring the patient's response to treatment that includes an agent that reduces exacerbations; A method comprising:

13. The method of claim 12, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is greater than the reference level indicates that the patient is responding to the agent that reduces exacerbations.

14. The method of claim 13, further comprising administering at least a second dose of an exacerbation-reducing agent to a patient whose sample has a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 above a reference level.

15. 1. A method for enrolling a patient suitable for a clinical study, comprising measuring levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is less than a reference level identifies the patient as suitable for the clinical study.

16. 16. The method of claim 15, further comprising enrolling patients identified as suitable for the clinical study in the clinical study.

17. The method of any one of claims 1 to 16, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

18. The method of any one of claims 1 to 16, wherein the sample is a bronchoalveolar lavage fluid (BALF) sample.

19. 19. The method of claim 17 or 18, wherein the sample is a preserved sample, a fresh sample, or a frozen sample.

20. 20. The method of claim 17 or 19, wherein the sample is a serum sample.

21. 21. The method of any one of claims 1 to 20, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:

4.

22. 22. The method of any one of claims 1 to 21, wherein the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:

4.

23. The method of any one of claims 1 to 22, wherein the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM.

24. 24. The method of claim 23, wherein the reference level of LPA16:0 is about 0.14 μM.

25. The method of any one of claims 1 to 24, wherein the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM.

26. 26. The method of claim 25, wherein the reference level of LPA18:0 is about 0.025 μM.

27. The method of any one of claims 1 to 26, wherein the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM.

28. 28. The method of claim 27, wherein the reference level of LPA18:1 is about 0.12 μM.

29. The method of any one of claims 1 to 28, wherein the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM.

30. 30. The method of claim 29, wherein the reference level of LPA18:2 is about 0.48 μM.

31. The method of any one of claims 1 to 30, wherein the reference level of LPA20:4 is between about 9 μM and about 13 μM.

32. 32. The method of claim 31, wherein the reference level of LPA20:4 is about 10.9 μM.

33. 33. The method of any one of claims 1 to 32, wherein the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population.

34. The method of claim 33, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, and LPA18:2 in the sample is less than or equal to the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

35. 35. The method of claim 33 or 34, wherein the level of LPA20:4 in the sample is below the 67th percentile of the level of LPA20:4 in a reference population.

36. The method according to any one of claims 33 to 35, wherein the reference population is a population of patients with COPD.

37. 37. The method of any one of claims 1 to 36, wherein the COPD is stage II, stage III, or stage IV COPD.

38. 38. The method of claim 36 or 37, wherein the patient has experienced at least one exacerbation in the past 12 months.

39. 40. The method of any one of claims 2-4 and 17-38, wherein the benefit comprises an increase in the patient's time to exacerbation compared to treatment without the agent that reduces exacerbations.

40. 40. The method of any one of claims 1 to 39, wherein the exacerbation is an increase in one or more of the following: dyspnea, cough, sputum volume, sputum purulence, fatigue, sleep disturbance, morning headache, confusion, and hypoxemia.

41. The method of any one of claims 1 to 40, wherein the exacerbation is a severe exacerbation.

42. Medications that reduce exacerbations include influenza vaccination, pneumococcal vaccination, supplemental oxygen, short-acting bronchodilators (SABDs), long-acting bronchodilators, dual-acting bronchodilators, short-acting anticholinergics, long-acting anticholinergics, short-acting antimuscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), and short-acting beta-blockers. 2 Agonist (SABA), long-acting beta 2 42. The method of any one of claims 2-14 and 17-41, wherein the therapeutic agent is a LABA, a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulatory agent, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

43. 43. The method of claim 42, wherein the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

44. Drugs that reduce exacerbations are included in the Global Initiative for Chronic Obstructive Lung Disease. TM The method according to any one of claims 1 to 43, wherein the agent is a drug disclosed in the (GOLD) Pocket Guide to COPD Diagnosis, Management, and Prevention (2020 edition).

45. 45. The method of any one of claims 1 to 44, wherein the exacerbation reducing agent is approved by a regulatory health authority for reducing, controlling or maintaining an exacerbation.

46. 46. ​​The method of claim 45, wherein the regulatory health authority is the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

47. The method of any one of claims 1 to 46, wherein the patient is male.

48. Use of an agent that reduces exacerbations in patients having levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that are below a reference level, in the manufacture of a medicament for the treatment of COPD.

49. Use of an agent that reduces exacerbations in patients having levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that are below a reference level, in the manufacture of a medicament for reducing exacerbations of COPD.

50. 50. The use according to claim 48 or 49, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

51. 50. The use according to claim 48 or 49, wherein the sample is a BALF sample.

52. 52. The use according to claim 50 or 51, wherein the sample is a preserved sample, a fresh sample or a frozen sample.

53. 53. The use according to claim 50 or 52, wherein the sample is a serum sample.

54. 54. The use of any one of claims 48 to 53, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:

4.

55. 55. The use according to any one of claims 48 to 54, wherein the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2 and LPA20:

4.

56. The use according to any one of claims 48 to 55, wherein the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM.

57. 57. The use of claim 56, wherein the reference level of LPA16:0 is about 0.14 μM.

58. The use according to any one of claims 48 to 57, wherein the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM.

59. 59. The use of claim 58, wherein the reference level of LPA18:0 is about 0.025 μM.

60. 60. The use according to any one of claims 48 to 59, wherein the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM.

61. 61. The use of claim 60, wherein the reference level of LPA18:1 is about 0.12 μM.

62. The use according to any one of claims 48 to 61, wherein the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM.

63. 63. The use of claim 62, wherein the reference level of LPA18:2 is about 0.48 μM.

64. The use according to any one of claims 48 to 63, wherein the reference level of LPA20:4 is between about 9 μM and about 13 μM.

65. 65. The use of claim 64, wherein the reference level of LPA20:4 is about 10.9 μM.

66. 66. The use according to any one of claims 48 to 65, wherein the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2 and LPA20:4 in a reference population.

67. The use of claim 66, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, and LPA18:2 in the sample is less than or equal to the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

68. 68. The use of claim 66 or 67, wherein the level of LPA20:4 in the sample is below the 67th percentile of the level of LPA20:4 in a reference population.

69. The use according to any one of claims 55 to 68, wherein the reference population is a population of patients with COPD.

70. The use according to any one of claims 48 to 69, wherein the patient has COPD.

71. 71. The use of claim 70, wherein the COPD is stage II, stage III, or stage IV COPD.

72. 72. The use of claim 70 or 71, wherein the patient has experienced at least one exacerbation in the past 12 months.

73. 73. The use according to any one of claims 48 to 72, wherein the exacerbation is an increase in one or more of the following: dyspnea, cough, sputum volume, sputum purulence, fatigue, sleep disturbance, morning headache, confusion, and hypoxemia.

74. 74. The use according to claim 72 or 73, wherein the exacerbation is a severe exacerbation.

75. Medications that reduce exacerbations include influenza vaccination, pneumococcal vaccination, supplemental oxygen, short-acting bronchodilators (SABDs), long-acting bronchodilators, dual-acting bronchodilators, short-acting anticholinergics, long-acting anticholinergics, short-acting antimuscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), and short-acting beta-blockers. 2 Agonist (SABA), long-acting beta 2 75. The use of any one of claims 48 to 74, wherein the agonist is a LABA, a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

76. 76. The use according to claim 75, wherein the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

77. Drugs that reduce exacerbations are included in the Global Initiative for Chronic Obstructive Lung Disease. TM The use according to any one of claims 48 to 76, which is a drug disclosed in the (GOLD) Pocket Guide to COPD Diagnosis, Management, and Prevention (2020 edition).

78. 78. The use of any one of claims 48 to 77, wherein the exacerbation reducing agent is approved by a regulatory health authority for reducing, controlling or maintaining an exacerbation.

79. 79. The use of claim 78, wherein the regulatory health authority is the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

80. The use according to any one of claims 48 to 78, wherein the patient is male.

81. An agent that reduces exacerbations for use in treating a patient having COPD and having levels of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that are below reference levels.

82. An agent that reduces exacerbations for use in treating a patient having COPD, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be less than a reference level.

83. 83. The method for use according to claim 81 or 82, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

84. The method for use according to any one of claims 81 to 83, wherein the sample is a BALF sample.

85. 85. The method of claim 83 or 84, wherein the sample is a preserved sample, a fresh sample, or a frozen sample.

86. 86. The method for use according to claim 83 or 85, wherein the sample is a serum sample.

87. 87. The medicament for use according to any one of claims 81 to 86, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2 and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2 and LPA20:

4.

88. 88. The method of claim 81, wherein the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:

4.

89. The method for use according to any one of claims 81 to 88, wherein the reference level of LPA16:0 is between about 0.12 μM and about 0.16 μM.

90. 90. The agent for use according to claim 89, wherein the reference level of LPA16:0 is about 0.14 μM.

91. The method for use according to any one of claims 81 to 90, wherein the reference level of LPA18:0 is between about 0.01 μM and about 0.035 μM.

92. 92. The agent for use according to claim 91, wherein the reference level of LPA18:0 is about 0.025 μM.

93. The method for use according to any one of claims 81 to 92, wherein the reference level of LPA18:1 is between about 0.10 μM and about 0.14 μM.

94. 94. The agent for use according to claim 93, wherein the reference level of LPA18:1 is about 0.12 μM.

95. The method for use according to any one of claims 81 to 94, wherein the reference level of LPA18:2 is between about 0.42 μM and about 0.53 μM.

96. 96. The agent for use according to claim 95, wherein the reference level of LPA18:2 is about 0.48 μM.

97. The method for use according to any one of claims 81 to 96, wherein the reference level of LPA20:4 is between about 9 μM and about 13 μM.

98. The agent for use according to claim 97, wherein the reference level of LPA20:4 is about 10.9 μM.

99. The method of any one of claims 81 to 98, wherein the reference level is the level of one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population.

100. The agent for use according to claim 99, wherein the level of one or more of LPA16:0, LPA18:0, LPA18:1, and LPA18:2 in the sample is less than or equal to the 33rd percentile of the levels of LPA16:0, LPA18:0, LPA18:1, or LPA18:2, respectively, in a reference population.

101. 101. The method of claim 99 or 100, wherein the level of LPA20:4 in the sample is below the 67th percentile of the level of LPA20:4 in a reference population.

102. Medicament for use according to any one of claims 99 to 101, wherein the reference population is a population of patients with COPD.

103. The method according to any one of claims 81 to 102, wherein the COPD is stage II, stage III or stage IV COPD.

104. The method of any one of claims 81 to 103, wherein the patient has experienced at least one exacerbation in the past 12 months.

105. 105. The medicament for use according to any one of claims 81 to 104, wherein the exacerbation is an increase in one or more of the following: dyspnea, cough, sputum volume, sputum purulence, fatigue, sleep disturbance, morning headache, confusion, and hypoxemia.

106. The method of any one of claims 81 to 105, wherein the exacerbation is a severe exacerbation.

107. Medications that reduce exacerbations include influenza vaccination, pneumococcal vaccination, supplemental oxygen, short-acting bronchodilators (SABDs), long-acting bronchodilators, dual-acting bronchodilators, short-acting anticholinergics, long-acting anticholinergics, short-acting antimuscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), and short-acting beta-blockers. 2 Agonist (SABA), long-acting beta 2 107. The agent for use according to any one of claims 81 to 106, which is a LABA, a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

108. 108. The method of claim 107, wherein the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

109. Drugs that reduce exacerbations are included in the Global Initiative for Chronic Obstructive Lung Disease. TM The drug for use according to any one of claims 81 to 108, which is a drug disclosed in the (GOLD) Pocket Guide to COPD Diagnosis, Management, and Prevention (2020 edition).

110. 110. The method of claim 81, wherein the exacerbation reducing agent is approved by a regulatory health authority for reducing, controlling or maintaining an exacerbation.

111. 111. The method for use according to claim 110, wherein the regulatory health authority is the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

112. The method for use according to any one of claims 81 to 111, wherein the patient is male.

113. 1. A method for identifying, diagnosing, and / or predicting whether a patient having COPD may be at high risk of exacerbation, comprising measuring the levels of one or more of LPC, sphingomyelin, and ceramide in a sample from the patient, wherein a level of LPC in the sample that is less than a reference level, and / or a level of one or both of sphingomyelin and ceramide in the sample that is greater than a reference level, identifies, diagnoses, and / or predicts the patient as being at high risk of exacerbation.

114. 114. The method of claim 113, wherein the LPC is LPC(16:0) or LPC(18:2).

115. The method of claim 113 or 114, wherein the patient has a level of LPC in the sample that is below a reference level and / or a level of one or both of sphingomyelin and ceramide in the sample that is above the reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces the exacerbation.

116. The method of any one of claims 113 to 115, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

117. The method of any one of claims 113 to 115, wherein the sample is a BALF sample.

118. 118. The method of claim 116 or 117, wherein the sample is a preserved sample, a fresh sample, or a frozen sample.

119. The method of claim 116 or 118, wherein the sample is a serum sample.

120. 120. The method of any one of claims 113-119, wherein the levels of one or more of LPC, sphingomyelin, and ceramide are baseline levels of one or more of LPC, sphingomyelin, and ceramide.

121. 121. The method of any one of claims 113 to 120, wherein the reference level is a pre-assigned level of one or more of LPC, sphingomyelin, and ceramide.

122. The method of any one of claims 113 to 121, wherein the reference level of LPC is between about 227 nmol / mL and about 277 nmol / mL.

123. 123. The method of claim 122, wherein the reference level of LPC is about 252 nmol / mL.

124. The method of any one of claims 113 to 123, wherein the reference level of sphingomyelin is between about 448 nmol / mL and about 548 nmol / mL.

125. 125. The method of claim 124, wherein the reference level of sphingomyelin is about 498 nmol / mL.

126. The method of any one of claims 113 to 125, wherein the ceramide is hexosylceramide (HCER).

127. 127. The method of claim 126, wherein the reference level of HCER is between about 6.1 nmol / mL and about 7.5 nmol / mL.

128. 128. The method of claim 127, wherein the reference level of HCER is about 6.8 nmol / mL.

129. The method according to any one of claims 113 to 128, wherein the ceramide is lactosylceramide (LCER).

130. 130. The method of claim 129, wherein the reference level of LCER is between about 4.3 nmol / mL and about 5.3 nmol / mL.

131. 131. The method of claim 130, wherein the reference level of LCER is about 4.8 nmol / mL.

132. The method of any one of claims 113 to 131, wherein the reference level is the level of one or more of LPC, sphingomyelin, and ceramide in a reference population.

133. 133. The method of claim 132, wherein the ceramide is LCER or HCER.

134. The method of claim 133, wherein the level of LPC in the sample is below the 33 percentile of the levels of LPC in a reference population, and / or the level of sphingomyelin, LCER, and / or HCER is above the 67 percentile of the levels of sphingomyelin, LCER, or HCER, respectively, in a reference population.

135. 135. The method of claim 133 or 134, wherein the reference population is a population of patients with COPD.

136. A method for predicting the time to next exacerbation in a patient with COPD who has experienced at least one exacerbation in the past 12 months, comprising measuring levels of one or both of LPA18:0 and LPA18:2 in a sample from the patient, wherein a level of one or both of LPA18:0 and LPA18:2 in the sample that is greater than a reference level identifies the patient as one who is likely to have an increased time to next exacerbation.

137. The method of claim 136, wherein the patient has a level of one or both of LPA18:0 and LPA18:2 in the sample that is above a reference level, and the method further comprises maintaining the patient's treatment regimen and / or reducing monitoring of the patient.

138. 138. The method of claim 136 or 137, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

139. The method of claim 136 or 137, wherein the sample is a BALF sample.

140. 140. The method of claim 138 or 139, wherein the sample is a preserved sample, a fresh sample, or a frozen sample.

141. The method of claim 138 or 140, wherein the sample is a serum sample.

142. 142. The method of any one of claims 136 to 141, wherein the level of one or both of LPA18:0 and LPA18:2 is a baseline level of one or both of LPA18:0 and LPA18:

2.

143. 143. The method of any one of claims 136 to 142, wherein the reference level is a pre-assigned level of one or both of LPA18:0 and LPA18:

2.

144. The method of any one of claims 136 to 143, wherein the reference level of LPA18:0 is between about 0.03 μM and about 0.05 μM.

145. The method of claim 144, wherein the reference level of LPA18:0 is about 0.04 μM.

146. The method of any one of claims 136 to 145, wherein the reference level of LPA18:2 is between about 0.68 μM and about 0.84 μM.

147. The method of claim 146, wherein the reference level of LPA18:2 is about 0.76 μM.

148. The method of any one of claims 136 to 147, wherein the reference level is the level of one or both of LPA18:0 and LPA18:2 in a reference population.

149. The method of claim 148, wherein the level of one or both of LPA18:0 and LPA18:2 in the sample is greater than or equal to the 67th percentile of the levels of LPA18:0 or LPA18:2, respectively, in a reference population.

150. 150. The method of any one of claims 136-149, wherein the increase in time to next exacerbation is an increase of at least 100 days.

151. 151. The method of any one of claims 136 to 150, wherein the COPD is stage II, stage III, or stage IV COPD.

152. 152. The method of any one of claims 136-151, wherein the exacerbation is an increase in one or more of the following: dyspnea, cough, sputum volume, sputum purulence, fatigue, sleep disturbance, morning headache, confusion, and hypoxemia.

153. The method of any one of claims 136 to 152, wherein the patient is male.

154. A method for identifying, diagnosing, and / or predicting whether a patient may be at high risk for COPD, comprising measuring levels of one or both of LPA18:0 and LPA18:1 in a sample from the patient, wherein a level of one or both of LPA18:0 and LPA18:1 in the sample that is greater than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for inflammatory respiratory disease.

155. 155. The method of claim 154, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

156. The method of claim 154, wherein the sample is a BALF sample.

157. 157. The method of claim 155 or 156, wherein the sample is a preserved sample, a fresh sample, or a frozen sample.

158. The method of claim 155 or 157, wherein the sample is a serum sample.

159. The method of any one of claims 154 to 158, wherein the level of one or both of LPA18:0 and LPA18:1 is a baseline level of one or both of LPA18:0 and LPA18:

1.

160. 160. The method of any one of claims 154 to 159, wherein the reference level is a pre-assigned level of one or both of LPA18:0 and LPA18:

1.

161. The method of any one of claims 154 to 160, wherein the reference level is the level of one or both of LPA18:0 and LPA18:1 in a reference population.

162. The method of claim 161, wherein the reference population is a population of patients not having an inflammatory respiratory disease.

163. The method of claim 162, wherein the level of one or both of LPA18:0 and LPA18:1 in the sample is at least 4.6 times the average level of one or both of LPA18:0 and LPA18:1, respectively, in a reference population.

164. The method of any one of claims 154 to 163, wherein the reference level of LPA18:0 is between about 0.01 nmol / mL and about 0.035 nmol / mL.

165. The method of claim 164, wherein the reference level of LPA18:0 is 0.025 nmol / mL.

166. The method of any one of claims 154 to 165, wherein the reference level of LPA18:1 is between about 0.05 nmol / mL and about 0.017 nmol / mL.

167. The method of claim 166, wherein the reference level of LPA18:1 is 0.11 nmol / mL.

168. 168. The method of any one of claims 154 to 167, wherein the COPD is stage II, stage III, or stage IV COPD.

169. The method of any one of claims 1 to 168, wherein the sample is from a fasting patient.

170. 1. A method for identifying, diagnosing, and / or predicting whether a patient having idiopathic pulmonary fibrosis (IPF) may be at high risk for exacerbation or respiratory hospitalization, comprising measuring a level of one or more of lysophosphatidic acid (LPA) 16:0, LPA 18:1, LPA 18:2, and LPA 20:4 in a sample from the patient, wherein a level of one or more of LPA 16:0, LPA 18:1, LPA 18:2, and LPA 20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for exacerbation or respiratory hospitalization.

171. 1. A method for identifying, diagnosing, and / or predicting whether a patient having IPF may benefit from a treatment comprising an agent that reduces exacerbations, comprising measuring a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as a patient that may benefit from a treatment comprising an agent that reduces exacerbations.

172. 1. A method of selecting a therapy for a patient having IPF, comprising measuring a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies the patient as one who may benefit from a treatment that includes an agent that reduces exacerbations.

173. 173. The method of any one of claims 170-172, wherein the patient has a level of one or more of LPA16:0, LPA18:0, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces an exacerbation.

174. 1. A method of treating a patient having IPF, comprising: (a) measuring a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from a patient, wherein the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is equal to or greater than a reference level; (b) administering to the patient an effective amount of an agent that reduces an exacerbation; A method comprising:

175. A method of treating a patient having IPF and having a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient that is equal to or greater than a reference level, comprising administering to the patient an effective amount of an agent that reduces exacerbations.

176. A method of treating a patient having IPF, comprising administering to the patient an effective amount of an agent that reduces exacerbations, wherein a level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient has been determined to be equal to or greater than a reference level.

177. 177. The method of any one of claims 170 to 176, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

178. 178. The method of claim 177, wherein the sample is a preserved sample, a fresh sample, or a frozen sample.

179. The method of claim 177 or 178, wherein the sample is a serum sample.

180. 180. The method of any one of claims 170-179, wherein the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 is a baseline level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:

4.

181. 181. The method of any one of claims 170 to 180, wherein the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:

4.

182. The method of any one of claims 170 to 181, wherein: (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM.

183. The method of claim 182, wherein: (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

184. The method of any one of claims 170 to 183, wherein: (a) the patient is female and the reference level of LPA 18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA 18:1 is between about 0.078 μM and about 0.118 μM.

185. The method of claim 184, wherein: (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

186. The method of any one of claims 170 to 185, wherein: (a) the patient is female and the reference level of LPA18:2 is between about 0.388 μM and about 0.428 μM; or (b) the patient is male and the reference level of LPA18:2 is between about 0.339 μM and about 0.379 μM.

187. The method of claim 186, wherein: (a) the patient is female and the reference level of LPA18:2 is about 0.408 μM; or (b) the patient is male and the reference level of LPA18:2 is about 0.359 μM.

188. The method of any one of claims 170 to 187, wherein: (a) the patient is female and the reference level of LPA 20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA 20:4 is between about 0.110 μM and about 0.150 μM.

189. The method of claim 188, wherein: (a) the patient is female and the reference level of LPA 20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA 20:4 is about 0.130 μM.

190. 190. The method of any one of claims 170 to 189, wherein the reference level is the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in a reference population.

191. The method of claim 190, wherein the level of one or more of LPA16:0, LPA18:1, and LPA18:2 in the sample is equal to or greater than the median level of LPA16:0, LPA18:1, or LPA18:2, respectively, in a reference population.

192. 192. The method of claim 190 or 191, wherein the reference population is a population of patients with IPF.

193. 192. The method of claim 190 or 191, wherein the reference population is a population of patients not having IPF.

194. The method of claim 193, wherein the level of one or more of LPA16:0, LPA18:1, LPA18:2, and LPA20:4 in the sample is at least twice the reference level.

195. 174. The method of any one of claims 171 to 173, wherein the benefit comprises an increase in the patient's time to exacerbation compared to treatment without the agent that reduces exacerbations.

196. The method of any one of claims 170 to 195, wherein the exacerbation is an acute respiratory exacerbation.

197. The method of claim 196, wherein the acute respiratory deterioration is dyspnea.

198. 198. The method of claim 196 or 197, wherein the acute respiratory compromise is not caused by pneumothorax, cancer, heart failure, fluid overload, or pulmonary embolism.

199. 200. The method of any one of claims 196 to 198, wherein the acute respiratory deterioration is associated with new radiological abnormalities.

200. 200. The method of claim 199, wherein the radiological abnormality is bilateral ground-glass opacities / consolidations.

201. The method of any one of claims 170 to 200, wherein the exacerbation is a severe exacerbation.

202. Medications that reduce exacerbations include influenza vaccination, pneumococcal vaccination, supplemental oxygen, short-acting bronchodilators (SABDs), long-acting bronchodilators, dual-acting bronchodilators, short-acting anticholinergics, long-acting anticholinergics, short-acting antimuscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), and short-acting beta-blockers. 2 Agonist (SABA), long-acting beta 2 202. The method of any one of claims 171-201, wherein the agonist is a LABA, a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

203. The method of claim 202, wherein the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

204. The method of any one of claims 171 to 203, wherein the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, anti-acid therapy, corticosteroids, cyclophosphamide or a combination thereof.

205. The method of claim 204, wherein the agent that reduces exacerbations is nintedanib or pirfenidone.

206. 206. The method of any one of claims 171 to 205, wherein the exacerbation reducing agent is approved by a regulatory health authority for reducing, controlling or maintaining an exacerbation.

207. The method of claim 206, wherein the regulatory health authority is the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

208. 1. A method for identifying, diagnosing, and / or predicting whether a patient having idiopathic pulmonary fibrosis (IPF) may be at high risk of death, comprising measuring a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk of death.

209. 1. A method for identifying, diagnosing, and / or predicting whether a patient having IPF may benefit from a treatment comprising an agent that reduces exacerbations, comprising measuring a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies, diagnoses, and / or predicts the patient as one who may benefit from a treatment comprising an agent that reduces exacerbations.

210. A method of selecting a therapy for a patient having IPF, comprising measuring a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient, wherein a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level identifies the patient as one who may benefit from a treatment that includes an agent that reduces exacerbations.

211. 211. The method of any one of claims 208 to 210, wherein the patient has a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces an exacerbation.

212. 1. A method of treating a patient having IPF, comprising: (a) measuring the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from a patient, wherein the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample is less than a reference level; (b) administering to the patient an effective amount of an agent that reduces an exacerbation; A method comprising:

213. A method of treating a patient having IPF and having a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient that is below a reference level, the method comprising administering to the patient an effective amount of an agent that reduces exacerbations.

214. A method of treating a patient having IPF, comprising administering to the patient an effective amount of an agent that reduces exacerbations, wherein the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a sample from the patient has been determined to be less than a reference level.

215. The method of any one of claims 208 to 214, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

216. 216. The method of claim 215, wherein the sample is a preserved sample, a fresh sample, or a frozen sample.

217. The method of claim 215 or 216, wherein the sample is a serum sample.

218. The method of any one of claims 208 to 217, wherein the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 is a baseline level of one or both of TG48:4-FA12:0 and TG48:4-FA18:

2.

219. The method of any one of claims 208 to 218, wherein the reference level is a pre-assigned level of one or both of TG48:4-FA12:0 and TG48:4-FA18:

2.

220. The method of any one of claims 208 to 219, wherein: (a) the patient is female and the reference level of TG48:4-FA12:0 is between about 0.800 μM and about 0.840 μM; or (b) the patient is male and the reference level of TG48:4-FA12:0 is between about 1.166 μM and about 1.206 μM.

221. The method of claim 220, wherein: (a) the patient is female and the reference level of TG48:4-FA12:0 is about 0.820 μM; or (b) the patient is male and the reference level of TG48:4-FA12:0 is about 1.186 μM.

222. The method of any one of claims 208 to 221, wherein: (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is between about 1.587 μM and about 1.627 μM; or (b) the patient is male and the reference level (μM) of TG48:4-FA18:2 is between about 2.153 μM and about 2.193 μM.

223. The method of claim 222, wherein: (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is about 1.607 μM; or (b) the patient is male and the reference level of TG48:4-FA18:2 is about 2.173 μM.

224. The method of any one of claims 208 to 223, wherein the reference level is the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in a reference population.

225. 225. The method of claim 224, wherein one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample are less than the median levels of TG48:4-FA12:0 and TG48:4-FA18:2, respectively, in a reference population.

226. 226. The method of claim 224 or 225, wherein the reference population is a population of patients with IPF.

227. 226. The method of claim 224 or 225, wherein the reference population is a population of patients not having IPF.

228. 228. The method of claim 227, wherein the level of one or both of TG48:4-FA12:0 or TG48:4-FA18:2 in the sample is at least half the reference level.

229. 229. The method of any one of claims 224 to 228, wherein the benefit comprises an increase in the time to patient death compared to treatment without the agent that reduces progression.

230. Medications that reduce exacerbations include influenza vaccination, pneumococcal vaccination, supplemental oxygen, short-acting bronchodilators (SABDs), long-acting bronchodilators, dual-acting bronchodilators, short-acting anticholinergics, long-acting anticholinergics, short-acting antimuscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), and short-acting beta-blockers. 2 Agonist (SABA), long-acting beta 2 230. The method of any one of claims 209-229, wherein the agonist is a LABA, a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

231. The method of claim 230, wherein the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

232. The method of any one of claims 209 to 231, wherein the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, anti-acid therapy, corticosteroids, cyclophosphamide or a combination thereof.

233. The method of claim 232, wherein the agent that reduces exacerbations is nintedanib or pirfenidone.

234. 234. The method of any one of claims 209-233, wherein the exacerbation reducing agent is approved by a regulatory health authority for reducing, controlling or maintaining an exacerbation.

235. The method of claim 234, wherein the regulatory health authority is the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

236. 1. A method for predicting time to exacerbation or respiratory hospitalization in a patient having IPF, comprising measuring a level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 in a sample from the patient, wherein (a) a level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample that is equal to or greater than a reference level, or (b) a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level, identifies the patient as one who is likely to have a reduced time to exacerbation or respiratory hospitalization.

237. The method of claim 236, wherein the patient has (a) a level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample that is equal to or greater than a reference level, or (b) a level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample that is less than a reference level, and the method further comprises administering to the patient an effective amount of an agent that reduces an exacerbation.

238. The method of claim 236 or 237, wherein the sample is a whole blood sample, a plasma sample, a serum sample, or a combination thereof.

239. 239. The method of claim 238, wherein the sample is a preserved sample, a fresh sample, or a frozen sample.

240. The method of claim 238 or 239, wherein the sample is a serum sample.

241. 241. The method of any one of claims 236-240, wherein the level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 is a baseline level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:

2.

242. 242. The method of any one of claims 236 to 241, wherein the reference level is a pre-assigned level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:

2.

243. The method of any one of claims 236 to 242, wherein: (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM.

244. The method of claim 243, wherein: (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

245. The method of any one of claims 236 to 244, wherein: (a) the patient is female and the reference level of LPA 18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA 18:1 is between about 0.078 μM and about 0.118 μM.

246. The method of claim 245, wherein (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

247. The method of any one of claims 236 to 246, wherein: (a) the patient is female and the reference level of LPA 20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA 20:4 is between about 0.110 μM and about 0.150 μM.

248. The method of claim 247, wherein (a) the patient is female and the reference level of LPA 20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA 20:4 is about 0.130 μM.

249. The method of any one of claims 236 to 248, wherein: (a) the patient is female and the reference level of LPA22:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA22:4 is between about 0.110 μM and about 0.150 μM.

250. The method of claim 249, wherein (a) the patient is female and the reference level of LPA22:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA22:4 is about 0.130 μM.

251. The method of any one of claims 236 to 250, wherein: (a) the patient is female and the reference level of TG48:4-FA12:0 is between about 0.800 μM and about 0.840 μM; or (b) the patient is male and the reference level of TG48:4-FA12:0 is between about 1.166 μM and about 1.206 μM.

252. The method of claim 251, wherein: (a) the patient is female and the reference level of TG48:4-FA12:0 is about 0.820 μM; or (b) the patient is male and the reference level of TG48:4-FA12:0 is about 1.186 μM.

253. The method of any one of claims 236 to 252, wherein: (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is between about 1.587 μM and about 1.627 μM; or (b) the patient is male and the reference level (μM) of TG48:4-FA18:2 is between about 2.153 μM and about 2.193 μM.

254. The method of claim 253, wherein: (a) the patient is female and the reference level (μM) of TG48:4-FA18:2 is about 1.607 μM; or (b) the patient is male and the reference level of TG48:4-FA18:2 is about 2.173 μM.

255. 255. The method of any one of claims 236 to 254, wherein the reference level is the level of one or more of LPA16:0, LPA18:1, LPA20:4, LPA22:4, TG48:4-FA12:0, and TG48:4-FA18:2 in a reference population.

256. The method of claim 255, wherein (a) the level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample is greater than or equal to the median level of LPA16:0, LPA18:1, LPA20:4, or LPA22:4, respectively, in a reference population; or (b) the level of one or both of TG48:4-FA12:0 and TG48:4-FA18:2 in the sample is less than or equal to the median level of TG48:4-FA12:0 or TG48:4-FA18:2, respectively, in a reference population.

257. The method of claim 255 or 256, wherein the reference population is a population of patients with IPF.

258. The method of claim 255 or 256, wherein the reference population is a population of patients not having IPF.

259. The method of claim 258, wherein (a) the level of one or more of LPA16:0, LPA18:1, LPA20:4, and LPA22:4 in the sample is at least twice the reference level, or (b) the level of one or both of TG48:4-FA12:0 or TG48:4-FA18:2 in the sample is at least half the reference level.

260. The method of any one of claims 236 to 259, wherein the exacerbation is an acute respiratory exacerbation.

261. The method of claim 260, wherein the acute respiratory deterioration is dyspnea.

262. 262. The method of claim 260 or 261, wherein the acute respiratory compromise is not caused by pneumothorax, cancer, heart failure, fluid overload, or pulmonary embolism.

263. 263. The method of any one of claims 260 to 262, wherein the acute respiratory deterioration is associated with new radiological abnormalities.

264. The method of claim 261, wherein the radiological abnormality is bilateral ground-glass opacities / consolidations.

265. The method of any one of claims 236 to 264, wherein the exacerbation is a severe exacerbation.

266. Medications that reduce exacerbations include influenza vaccination, pneumococcal vaccination, supplemental oxygen, short-acting bronchodilators (SABDs), long-acting bronchodilators, dual-acting bronchodilators, short-acting anticholinergics, long-acting anticholinergics, short-acting antimuscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), and short-acting beta-blockers. 2 Agonist (SABA), long-acting beta 2 266. The method of any one of claims 237 to 265, wherein the agonist is a LABA, a PDE4 inhibitor, a methylxanthine, a phosphodiesterase-4 inhibitor, a mucolytic agent, a mucomodulator, an antioxidant, an anti-inflammatory agent, a corticosteroid, an antibiotic, alpha-1 antitrypsin augmentation therapy, mepolizumab, benralizumab, or a combination thereof.

267. The method of claim 266, wherein the corticosteroid is an inhaled corticosteroid (ICS) or an oral corticosteroid (OCS).

268. The method of any one of claims 237 to 267, wherein the agent that reduces exacerbations is nintedanib, pirfenidone, procalcitonin, cyclosporine, rituximab in combination with plasma exchange and intravenous immunoglobulin, tacrolimus, thrombomodulin, anti-acid therapy, corticosteroids, cyclophosphamide or a combination thereof.

269. The method of claim 268, wherein the agent that reduces exacerbations is nintedanib or pirfenidone.

270. 270. The method of any one of claims 237-269, wherein the exacerbation reducing agent is approved by a regulatory health authority for reducing, controlling or maintaining an exacerbation.

271. The method of claim 270, wherein the regulatory health authority is the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA), or the China National Medical Products Administration (NMPA).

272. 1. A method for identifying, diagnosing, and / or predicting whether a patient with idiopathic pulmonary fibrosis (IPF) may be at increased risk for deterioration in a measure of lung health, comprising: (a) measuring a level of one or more of LPA16:0, LPA16:1, LPA18:1, LPA18:2, and LPA20:4 in a sample from a patient, where the measure of lung health is diffusing capacity for carbon monoxide (DLCO), and a level of one or more of LPA16:0, LPA16:1, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for worsening DLCO; (b) measuring a level of LPA22:4 in a sample from the patient, where the measure of lung health is global ground-glass opacity and where the level of LPA22:4 in the sample is equal to or greater than a reference level, the level identifying, diagnosing, and / or predicting the patient as being at high risk for increased global ground-glass opacity; or (c) measuring a level of one or more of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in a sample from the patient, where the measure of lung health is sub-segmental lung fibrosis, and a level of one or more of LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, and LPA20:4 in the sample that is equal to or greater than a reference level identifies, diagnoses, and / or predicts the patient as being at high risk for sub-segmental lung fibrosis. A method comprising:

273. The method of claim 272, wherein: (a) the patient is female and the reference level of LPA16:0 is between about 0.207 μM and about 0.247 μM; or (b) the patient is male and the reference level of LPA16:0 is between about 0.153 μM and about 0.193 μM.

274. The method of claim 273, wherein: (a) the patient is female and the reference level of LPA16:0 is about 0.227 μM; or (b) the patient is male and the reference level of LPA16:0 is about 0.173 μM.

275. The method of any one of claims 272 to 274, wherein (a) the patient is female and the reference level of LPA 16:1 is between about a ratio to normal (rts) of 0.101 and about 0.141rts; or (b) the patient is male and the reference level of LPA 16:1 is between about 0.058rts and about 0.098rts.

276. The method of claim 275, wherein (a) the patient is female and the reference level of LPA16:1 is about 0.121 rts; or (b) the patient is male and the reference level of LPA16:1 is about 0.078 rts.

277. The method of any one of claims 272 to 276, wherein: (a) the patient is female and the reference level of LPA18:0 is between about 0.007 μM and about 0.047 μM; or (b) the patient is male and the reference level of LPA18:0 is between about 0.003 μM and about 0.043 μM.

278. The method of claim 277, wherein: (a) the patient is female and the reference level of LPA18:0 is about 0.027 μM; or (b) the patient is male and the reference level of LPA18:0 is about 0.023 μM.

279. The method of any one of claims 272 to 278, wherein: (a) the patient is female and the reference level of LPA 18:1 is between about 0.082 μM and about 0.122 μM; or (b) the patient is male and the reference level of LPA 18:1 is between about 0.078 μM and about 0.118 μM.

280. The method of claim 279, wherein (a) the patient is female and the reference level of LPA18:1 is about 0.102 μM; or (b) the patient is male and the reference level of LPA18:1 is about 0.098 μM.

281. The method of any one of claims 272 to 280, wherein: (a) the patient is female and the reference level of LPA18:2 is between about 0.388 μM and about 0.428 μM; or (b) the patient is male and the reference level of LPA18:2 is between about 0.339 μM and about 0.379 μM.

282. The method of claim 281, wherein (a) the patient is female and the reference level of LPA18:2 is about 0.408 μM; or (b) the patient is male and the reference level of LPA18:2 is about 0.359 μM.

283. The method of any one of claims 272 to 282, wherein: (a) the patient is female and the reference level of LPA 20:4 is between about 0.100 μM and about 0.140 μM; or (b) the patient is male and the reference level of LPA 20:4 is between about 0.110 μM and about 0.150 μM.

284. The method of claim 283, wherein: (a) the patient is female and the reference level of LPA 20:4 is about 0.120 μM; or (b) the patient is male and the reference level of LPA 20:4 is about 0.130 μM.

285. The method of any one of claims 272 to 284, wherein: (a) the patient is female and the reference level of LPA22:4 is between about 0.009rts and about 0.049rts; or (b) the patient is male and the reference level of LPA22:4 is between about 0.011rts and about 0.051rts.

286. The method of claim 285, wherein (a) the patient is female and the reference level of LPA22:4 is about 0.029 rts; or (b) the patient is male and the reference level of LPA22:4 is about 0.031 rts.

287. 1. A method for preparing an LPA fraction from a patient, useful for analyzing LPA species involved in inflammatory respiratory diseases, comprising: (a) providing a serum or BALF sample from a patient, wherein the sample has a volume of between about 5 μL and about 20 μL; (b) extracting LPA from the sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, where the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the sample; A method comprising:

288. 288. The method of claim 287, further comprising (c) separating LPA species from the fraction of LPA extracted in (b).

289. 289. The method of claim 287 or 288, wherein the extraction buffer comprises between about 27-33 mM citric acid and between about 36-44 mM disodium phosphate.

290. 290. The method of claim 289, wherein the extraction buffer comprises about 30 mM citric acid and 40 mM disodium phosphate.

291. 291. The method of any one of claims 287 to 290, wherein the extraction buffer does not contain hydrochloric acid.

292. 292. The method of any one of claims 288 to 291, wherein the separating in (c) is by liquid chromatography.

293. 293. The method of claim 292, wherein the liquid chromatography is high performance liquid chromatography (HPLC).

294. 294. The method of claim 293, wherein HPLC is performed using a reverse phase column.

295. The method of claim 294, wherein the reverse phase column is a C18 column.

296. (a) providing a serum sample from a patient, wherein the serum sample has a volume of between about 5 μL and about 20 μL; (b) extracting LPA from the serum sample of (a) using an extraction buffer containing citric acid and disodium phosphate, where the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample. An LPA fraction from a patient, produced by a method comprising:

297. (a) providing a serum sample from a patient, wherein the serum sample has a volume of between about 5 μL and about 20 μL; (b) extracting LPA from the serum sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, where the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample; (c) separating LPA species from the fraction of LPA extracted in (b); and 2. A purified LPA species produced by a method comprising:

298. 300. A method for analyzing an LPA fraction according to claim 296, comprising separating LPA species from the LPA fraction.

299. 300. The method of claim 298, further comprising analyzing the separated LPA species.

300. 1. A method for analyzing LPA species in a serum sample from a patient, comprising: (a) providing a serum sample from a patient, wherein the serum sample has a volume of between about 5 μL and about 20 μL; (b) extracting LPA from the serum sample of (a) using an extraction buffer comprising citric acid and disodium phosphate, where the extraction buffer does not result in hydrolysis of choline groups from other lysophospholipids in the serum sample; (c) separating LPA species from the fraction of LPA extracted in (b); (d) analyzing the separated LPA species produced in (c); and The method includes:

301. 301. The method of claim 299 or 300, wherein the analysis is by mass spectrometry.

302. 302. The method of claim 301, wherein mass spectrometry is performed using negative ionization mode.

303. The method of claim 301 or 302, wherein the limit of detection (LOD) of the LPA species is less than 0.008 pmol / μL serum.

304. The method of claim 303, wherein the LOD of the LPA species is between 0.002 pmol / μL serum and 0.008 pmol / μL serum.

305. The method of claim 304, wherein the LOD of the LPA species is less than 0.002 pmol / μL serum.

306. A method according to any one of claims 299 to 305, wherein the absolute recovery of the LPA species from the sample is between 82% and 110%.

307. 307. The method of any one of claims 287-295 and 299-306, wherein the LPA species is one or more of LPA14:0, LPA16:0, LPA16:1, LPA18:0, LPA18:1, LPA18:2, LPA20:4, and LPA22:

4.

308. 308. The method of claim 307, wherein the LPA species is one or more of LPA16:0, LPA18:0, LPA18:1, LPA18:2, and LPA20:4.

Citation Information

Patent Citations

  • Treatments to improve lung function

    JP2013544235A

  • Prognosis prediction, diagnosis, and treatment methods for idiopathic pulmonary fibrosis

    JP2015522246A

  • Autotaxin inhibitors and uses thereof

    WO2019228403A1

  • Novel 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same

    WO2020022470A1

Cited By

  • Herbicidal compounds

    US12540120B2